Preeclampsia and the Development and Programming of Maternal and Newborn Tissues : Clinical and Epigenetic Studies by Herzog, E.M. (Emilie)
EMILIE M. HERZOG
CLINICAL AND EPIGENETIC STUDIES
AND THE DEVELOPMENT AND 
PROGRAMMING OF MATERNAL 
AND NEWBORN TISSUES
PREECLAMPSIA  
AND THE DEVELOPMENT AND  
PROGRAMMING OF MATERNAL  
AND NEWBORN TISSUES
CLINICAL AND EPIGENETIC STUDIES
Emilie M. Herzog
ISBN: 978-94-028-0849-0
Cover photography: M. Vidovic - www.magdalenavidovic.de
Cover and graphic design: A. Spindler - www.annaspindler.com 
Printing: Ipskamp printing, Amsterdam, the Netherlands
Financial support by the Dutch Heart Foundation for the publication of  this thesis is gratefully 
acknowledged. The printing of  this thesis was additionally supported by the HELLP Foundation, 
Herzog Medical, the department of  Obstetrics and Gynaecology of  the Erasmus MC, University 
Medical Centre Rotterdam and the Erasmus University Rotterdam, the Netherlands.
Copyright © 2017 by E.M. Herzog. All right reserved. No part of  this publication may be reproduced, 
stored in a retrieval system of  any nature, or transmitted in any form or by any means, without prior 
written permission of  the author, or when appropriate, of  the scientific journal in which parts of  the 
thesis have been published.
PREECLAMPSIA AND THE DEVELOPMENT  
AND PROGRAMMING OF MATERNAL  
AND NEWBORN TISSUES
CLINICAL AND EPIGENETIC STUDIES
Preeclampsie en de ontwikkeling en programmering  
van maternale en neonatale weefsels 
Klinische en epigenetische studies
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de Rector Magnificus
Prof. dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
vrijdag 8 december 2017 om 09.30 uur
door
Emilie Marjolein Herzog
geboren te Amersfoort

PROMOTIECOMMISSIE
Promotor  Prof. dr. R.P.M. Steegers-Theunissen
Copromotor  Dr. A.J. Eggink
Overige leden  Prof. dr. A.H.J. Danser
  Prof. dr. A. Franx
  Prof. dr. C.M. van Duijn
Paranimfen Dr. M.H. van Coevorden - Hameete
  M.E. Herzog
CHAPTER 1  General introduction
        
PART I  CLINICAL STUDIES 
CHAPTER 2  The impact of  early- and late-onset preeclampsia on 
umbilical cord blood cell populations 
Journal of  Reproductive Immunology, 2016 Aug. 116: p. 81-85
CHAPTER 3 Impact of  early- and late-onset preeclampsia on fea-
tures of  placental and newborn vascular health 
Placenta, 2017 Jan. 49: p. 72-79
CHAPTER 4 Microcirculation in women with severe preeclampsia 
and HELLP syndrome: a case-control study 
British Journal of  Obstetrics and Gynaecology, 2014. 121: p. 363–370
PART II  EPIGENETIC STUDIES 
CHAPTER 5  Tissue-specific DNA methylation profiles in newborns 
Clinical Epigenetics, 2013. 5: p. 8-12
CHAPTER 6 The tissue-specific aspect of  genome-wide DNA-methy- 
lation in newborn and placental tissues: implications for 
epigenetic epidemiologic studies 
 Submitted
009
017
019
033
049
063
065
073
TABLE OF CONTENTS
CHAPTER 7 Early- and late-onset preeclampsia and the tissue- 
specific epigenome of  the placenta and newborn 
Placenta, 2017. 58: p. 122-132
CHAPTER 8 DNA hypomethylation of  placental growth factor 
and decreased SAM:SAH ratio in placental tissue of  
preeclampsia-complicated pregnancies 
 Submitted
PART III
CHAPTER 9 General discussion
CHAPTER 10  Summary / Samenvatting 
De dans van DNA: een aanvulling op de Nederlandse 
samenvatting
ADDENDUM
  References
  Authors and affiliations
  List of  abbreviations
  List of  publications 
  About the author
  PhD Portfolio
  Acknowledgements
107
137
149
151
167
179
180
192
194
196
198
199
203

General introduction
CHAPTER 1
010
GENERAL INTRODUCTION
In line with the Developmental Origins of  Health and Disease (DOHaD) 
paradigm, epidemiological and experimental animal studies have associated 
adverse intrauterine conditions with increased susceptibility to cardiovascular 
disease throughout the offspring's lifespan 1, 2. For instance, offspring exposed to 
pregnancies complicated by preeclampsia (PE) have enhanced risks of  increased 
blood pressure and body mass index in childhood and early adolescence and 
nearly a double risk of  stroke in adulthood 3-7. Moreover, the American Heart 
Association has recently added PE to the list of  risk factors for developing 
cardiovascular disease, as women who experienced PE have a fourfold increased 
risk of  developing hypertension and a more than twofold increased risk of  dying 
from cardiovascular diseases 3, 8, 9. 
PREECLAMPSIA 
PE affects 2-8% of  all pregnancies and is considered a major obstetric problem 
due to the high prevalence of  maternal and perinatal morbidity and mortality 3. 
This complex disorder is characterised by gestational hypertension of  at least 
140/90 mmHg accompanied by an urine protein/creatinine ratio of  ≥ 30 mg/
mmol arising de novo at or after 20 weeks of  pregnancy, although the new clinical 
definition also includes gestational hypertension with one or more of  the following 
new-onset conditions: proteinuria, thrombocytopenia, impaired liver function, 
renal insufficiency, pulmonary oedema or cerebral or visual disturbances 3, 10. Two 
main disease entities have been identified with early-onset PE (EOPE) as the 
more severe phenotype, diagnosed before 34 weeks of  gestation, and late-onset 
PE (LOPE) diagnosed at or after 34 weeks of  gestation 3, 11. 
 Although the pathophysiology of  both phenotypes is not yet fully 
understood, there is extensive evidence that EOPE originates from poor first 
trimester placentation, characterised by early unplugging of  spiral arteries, 
superficial trophoblast invasion and insufficient remodelling of  spiral arteries 
in the myometrium, causing episodes of  placental hypoxia and reperfusion 12. 
The poor and restricted placental development in EOPE is associated with small 
placental volume and often fetal growth restriction (Figure 1A). Whereas LOPE 
is considered a more maternal disorder originating from underlying maternal 
cardiovascular- and metabolic risk factors, with potential trophoblast dysfunction 
at the end of  gestation due to villous overcrowding in large, term placentas 
without prior pathology and typically well-grown fetuses 13. Both phenotypes are 
characterised by an excessive production of  placental induced reactive oxygen 
species (ROS) which induce a hyperoxidative state to which the developing 
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embryo and fetus are exposed. In LOPE this occurs more towards the end of  
gestation than in EOPE (Figure 1B) 11. As a result, pro-inflammatory cytokines 
and (anti)angiogenic factors are released into the maternal circulation inducing 
maternal endothelial dysfunction, leading to the clinical symptoms of  PE 14. 
EPIGENETICS 
The adverse prenatal PE environment can disturb the development and 
programming of  placental and newborn tissues 15-17. This development and 
programming is subject to complex interactions between genes and environmental 
conditions. The process of  developmental programming is strongly mediated 
by various epigenetic mechanisms 18, 19, that can be defined as ‘chromosome-based 
mechanisms that change the phenotypic plasticity in a cell or organism’ 20. This allows for the 
generation of  diverse cell phenotypes and functions of  an organism from a single 
genome, and for the regulation of  gene-expression in response to a range of  
environmental exposures 21. Epigenetic processes generally involve the regulation 
of  gene-expression without changing the underlying DNA sequence 18. 
 DNA methylation is the best-characterised epigenetic modification, 
involving the attachment of  a methyl group on predominantly cytosine 
nucleotides that precede a guanosine nucleotide in the DNA sequence (so-called 
CpG dinucleotides) 22. DNA methylation is established in a tissue-specific manner 
and takes place at various positions on the genome, relative to genes and CpG-
density. The function of  DNA methylation seems to vary within this context 
affecting the relationship between DNA methylation and transcription 23-26. 
Disturbed epigenetic programming of  specific tissues such as the placenta, is 
suggested to be involved as cause or consequence, in the development of  PE 18.
HYPOTHESIS
From this background we hypothesize that prenatal PE exposure is associated 
with a disturbed development (1) and epigenetic programming (2) of  placental 
and newborn cardiovascular tissues, resulting in a cardiovascular phenotype of  
the newborn that is more susceptible to develop cardiovascular diseases later in 
life 22 (Figure 1).
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PLACENTAL AND NEWBORN TISSUES 
Since it is not feasible to study our hypotheses in the cardiovascular tissues of  
the human embryo and fetus directly, we aimed to examine human umbilical 
cord vein endothelial cells (HUVEC), umbilical cord blood, and placental tissue 
in clinical and epigenetic studies. It is known that these tissues are essential for 
normal embryonic and fetal development and involved in the pathophysiology 
of  PE. They may therefore provide novel insights into the potential development 
and programming of  long-term cardiovascular disease susceptibility, and unravel 
underlying mechanisms. 
 The umbilical cord vasculature, originating from the intra- and extra-
embryonic mesodermal layers, is the best accessible representative tissue of  
the newborn vasculature, and its development is highly influenced by local 
haemodynamic conditions of  pregnancy, such as blood flow, oxygen tension and 
oxidative stress 20, 21, 27. The umbilical cord vessels are responsible for transport 
of  oxygen- and nutrient-rich blood and deoxygenated blood and metabolic waste 
between mother and child 28, 29. Umbilical cord blood (UCB) originates from 
the same embryonic mesodermal layers as HUVEC and provides information 
on the prenatal inflammatory- and haematopoietic systemic conditions and as 
such represents a widely-studied, easily-accessible newborn tissue 27. The main 
regulatory organ of  the intrauterine environment is the placenta, serving as a 
metabolic, immunologic and endocrine organ of  extra-embryonic origin. By 
monitoring fetal demands and intrauterine adaptations, the placenta regulates 
fetal growth and development. Due to its involvement in the pathophysiology of  
PE, the investigation of  placental tissue is crucial in this context 30, 31.
OBJECTIVES OF THE THESIS
The main objectives of  this thesis are to investigate:
1.  The development of  placental and newborn cardiovascular tissues in 
 association with EOPE and LOPE (a), and of  the maternal microcirculation 
 in association with PE (b) (Part I)
2.  The tissue-specific DNA methylation in placental and newborn cardiovascu- 
 lar tissues in association with EOPE and LOPE (Part II)
METHODOLOGY 
Data for the studies in this thesis was obtained from a nested case-control 
study embedded in the Rotterdam Periconceptional Cohort (Predict Study), a 
prospective tertiary hospital-based cohort study conducted at the Department 
of  Obstetrics and Gynaecology of  the Erasmus MC, University Medical Centre 
GENERAL INTRODUCTION
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Rotterdam, the Netherlands 32. Pregnant women and their newborns were recruited 
between June 2011 and June 2013. Enrolment was aimed early in the first trimester 
of  pregnancy, but was also possible if  patients were admitted to our hospital 
after the first trimester, meeting the inclusion criteria. Maternal and newborn 
characteristics were obtained from hospital medical records. Umbilical cord tissue 
(including HUVEC), umbilical cord blood and placental tissue were collected and 
subjected to flow-cytometric, histological and (genome-wide) epigenetic analysis. 
 Cases comprised of  women with pregnancies that were complicated by 
EOPE or LOPE. PE is known to be complicated by fetal growth restriction 
(FGR) in 12% and iatrogenic preterm birth (PTB) in 20% 33. These conditions 
can independently influence the intrauterine development and epigenetic 
programming of  placental and newborn tissues 34-36. In order to examine 
associations with EOPE and LOPE independent of  FGR and PTB, control 
pregnancies comprised of  both uncomplicated and complicated normotensive 
FGR and PTB pregnancies.
 To investigate associations with the maternal microcirculation, women with 
severe PE with or without HELLP syndrome (haemolysis, elevated liver enzymes 
and low platelets), and healthy controls were included between November 2009 
and September 2012 for the study described in chapter 4. Both study populations 
were recruited and conducted at the same hospital department.
THESIS OUTLINE
The first objective is addressed in Part I of  this thesis by performing three 
clinical studies. Chapter 2 describes the associations between EOPE, LOPE 
and umbilical cord blood cell populations. In chapter 3 we address whether 
EOPE and LOPE are associated with placental and umbilical cord (vascular) 
(histo-) morphological alterations. The associations between the maternal 
microcirculatory perfusion and severe PE are studied in chapter 4.
 Part II describes both gene-specific and epigenome-wide DNA 
methylation studies. The first two chapters (chapter 5 and 6) address the 
tissue-specific characteristics of  DNA methylation in newborn tissues, 
on a genome-wide level and of  the imprinted Insulin-like growth factor 2 
(IGF2)/H19 genes. This is followed by chapter 7 and 8 that evaluate the 
associations between EOPE, LOPE and variations in tissue-specific DNA 
methylation, both genome-wide and in placental-specific angiogenic genes. 
 Chapter 9 covers the general discussion of  the main findings, 
methodological considerations, clinical implications and recommendations 
for future research.
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CHAPTER 2  
The impact of early- and late-onset preeclampsia on umbilical 
cord blood cell populations (Journal of Reproductive Immu-
nology, 2016 Aug. 116: p. 81-85)
CHAPTER 3 
Impact of early- and late-onset preeclampsia on features of 
placental and newborn vascular health (Placenta, 2017 Jan. 
49: p. 72-79) 
CHAPTER 4 
Microcirculation in women with severe preeclampsia and 
HELLP syndrome: a case-control study (British Journal of 
Obstetrics and Gynaecology, 2014. 121: p. 363–370)
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The impact of early- and late-onset preeclampsia on  
umbilical cord blood cell populations
CHAPTER 2
E.M. Herzog, A.J. Eggink, M. van der Zee, J. Lagendijk, S.P. Willemsen, R. de Jonge, 
E.A.P. Steegers, R.P.M. Steegers-Theunissen
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020
THE IMPACT OF EARLY- AND LATE-ONSET PREECLAMPSIA ON UMBILICAL CORD BLOOD CELL POPULATIONS
ABSTRACT
Pregnancies complicated by preeclampsia (PE) are characterised by an enhanced 
maternal and fetal inflammatory response with increased numbers of  leukocytes 
in maternal peripheral blood. The impact of  PE on newborn umbilical cord blood 
cell (UCBC) populations however, has been scarcely studied. We hypothesise 
that PE deranges fetal haematopoiesis and subsequently UCBC populations. 
Therefore, the objective of  this study was to investigate newborn umbilical cord 
blood cell populations in early- (EOPE) and late-onset PE (LOPE).
 A secondary cohort analysis in the Rotterdam Periconceptional cohort 
was conducted comprising 23 PE cases, including 11 EOPE and 12 LOPE, and 
195 controls, including 153 uncomplicated and 23 fetal growth restriction and 
19 preterm birth complicated controls. UCBC counts and differentials were 
quantified by flow cytometry and analysed as main outcome measures.
 Multivariable regression analysis revealed associations of  EOPE 
with decreased leucocytes (monocytes, neutrophils , eosinophils , immature 
granulocytes) and thrombocyte counts and increased NRBC counts (all p <0.05). 
EOPE remained associated with neutrophils (β-0.92, 95%CI -1.27,-0.57, p 
<0.001) and NRBC counts (β1.11, 95%CI 0.27,1.95, p = 0.010) after adjustment 
for gestational age and birth weight. LOPE did not reveal any significant 
association.
 We conclude that derangements of  fetal haematopoiesis, in particular of  
neutrophils and NRBC counts, are associated with EOPE only, with a potential 
impact for future health of  the offspring. This heterogeneity in UCBC should be 
considered as confounder in epigenetic association studies examining EOPE. 
021
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INTRODUCTION
Preeclampsia (PE) is a heterogeneous disease with early-onset (EOPE) and 
late-onset (LOPE) PE as the main phenotypes. Due to inadequate spiral artery 
remodelling with suboptimal placental perfusion, excessive amounts of  oxidative 
stress can lead to an enhanced release of  syncytiotrophoblast microparticles 
and cytokines, which particularly contributes to the pathogenesis of  the more 
severe EOPE phenotype 11. In contrast, LOPE shows a relatively normal initial 
placentation and is associated with conditions that enhance excessive oxidative 
stress and placental inflammation later in pregnancy, such as obesity and pre-
existing hypertension 3, 14. Circulating syncytiotrophoblast microparticles can 
induce an increased maternal systemic inflammatory response with increased 
numbers of  neutrophils and total leukocytes in maternal peripheral blood 37, 38. 
The impact of  PE on newborn umbilical cord blood cell (UCBC) populations, 
however, has been scarcely studied. 
 During pregnancy, haematopoiesis takes place in the yolk sac, liver, bone 
marrow as well as in the placenta, generating all blood cell types from a small 
population of  pluripotent hematopoietic stem cells as pregnancy advances 39-42. We 
hypothesise that PE, in particular EOPE, deranges fetal haematopoiesis resulting 
in heterogeneity of  UCBC populations 43, and investigated the associations 
between UCBC counts and differentials in early- and late-onset PE.
MATERIALS AND METHODS 
Study design. Between June 2011 and June 2013 we included pregnant women 
in a prospective hospital based periconception birth cohort: The Rotterdam 
Predict Study, at the Erasmus MC, University Medical Centre Rotterdam, the 
Netherlands 32. For the current secondary cohort analysis, we selected EOPE 
and LOPE as cases and uncomplicated pregnancies as controls. To adjust for the 
often accompanied fetal growth restriction (FGR) and iatrogenic preterm birth 
(PTB) in PE, we oversampled the uncomplicated control group with FGR and 
PTB as complicated controls. Pregnancies were included in the cohort during the 
first trimester (early cohort inclusions) or after the first trimester when they were 
referred to our hospital (late cohort inclusions).
  PE was defined according to the International Society for the Study of  
Hypertension in Pregnancy as gestational hypertension of  at least 140/90 mmHg 
accompanied by an urine protein/creatinine ratio of  ≥ 30 mg/mmol, arising de 
novo after the 20th week of  gestation 44. EOPE was defined when PE was diagnosed 
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before 34 weeks of  gestation, LOPE when diagnosed after 34 weeks of  gestation 
45. Uncomplicated control pregnancies were defined as pregnancies without the 
presence of  PE, gestational hypertension, FGR or PTB. FGR inclusion was based 
on an estimated fetal weight below the 10th percentile for gestational age based on 
ultrasound measurements performed between 20 and 38 weeks gestational age 46. 
Birth weight percentiles were calculated using the reference curves of  the Dutch 
Perinatal Registry to validate birth weight ≤ 10th percentile and exclude those 
newborns with birth weight > 10th percentile 47. Spontaneous preterm deliveries 
between 22 and 37 weeks of  gestation were defined as PTB 48. Women with HIV 
infection, age < 18 years and insufficient knowledge of  the Dutch language could 
not participate and pregnancies complicated with a fetal congenital malformation 
and twins were excluded for the current study. Maternal comorbidity was defined 
by any concurrent cardiovascular-, hematologic-, endocrine-, metabolic-, auto-
immune- or renal disease. Maternal and fetal characteristics were obtained from 
hospital medical records. All women gave written informed consent before 
participation and written parental informed consent was obtained for the child. 
Ethical approval was given by the Erasmus MC, University Medical Centre 
Research Ethics Board (MEC-2004-227).
Collection and handling of  blood samples. UCB samples from the umbilical 
vein were obtained in vacutainer tubes (Ethylenediaminetetraacetic acid as 
anticoagulant), immediately after delivery and clamping of  the umbilical cord. 
Samples were transported at room temperature and subjected to flow cytometric 
analysis within 48 hours after delivery (Sysmex XE-5000, Sysmex XN-3000 and 
XS-800i, Etten-Leur, the Netherlands) to quantify erythrocyte, thrombocyte 
and leucocyte differentials. Between arrival at the Clinical Chemistry Laboratory 
and time of  analysis, samples were stored at four to eight °C. Quality of  the 
blood cell counts was guaranteed by a manual check whereby flow cytometric 
data of  suspect plots or reported system errors were excluded for further analysis.
Statistical analysis. We used cell numbers/L for the analysis of  leucocyte 
differentials and NRBC, which is preferable to the widely used percentages 
of  total leucocyte count, since the largely variable total leucocyte count could 
result in misleading percentages 49. The normal distributed maternal and 
newborn characteristics were tested using Analysis of  Variance (ANOVA) to 
detect overall differences between the groups, followed by the posthoc Dunnett 
t-test for pairwise comparisons of  EOPE and LOPE with uncomplicated 
controls and FGR and PTB complicated controls. The Dunnett t-test limits 
the multiple testing problem by comparing each group to one reference group 
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only. The Kruskall-Wallis-test was applied to all non-parametric maternal and 
newborn characteristics, followed by pairwise Mann-Whitney tests for posthoc 
comparisons. 
 Log-transformation was applied to the non-parametric UCBC to 
achieve normal distributions of  neutrophils, monocytes, eosinophils, basophils, 
nucleated red blood cells (NRBC) and immature granulocytes. We converted 
zero values of  neutrophils and NRBC into half  of  the lowest detectable 
value of  the Sysmex haematology system, prior to log-transformation. Linear 
regression analysis was performed to investigate the association between UCBC 
counts and differentials and EOPE/LOPE versus the pooled group of  (un)
complicated controls. In the crude linear regression analyses, UCBC counts 
were estimated with group (case-control) as the only predictive variable. In the 
adjusted multivariable analyses, gestational age and birth weight were additionally 
entered to the model as covariates, in formula: [UCBC]= β0 + β1group + β2GA 
+ β3BW + ε. Here group is an indicator variable that is 1 for EOPE or LOPE 
and 0 for the pooled group of  (un)complicated controls. [UCBC] represents 
the concentration of  a certain UCBC population. All measurements were 
performed with IBM SPSS Statistics version 21.0 (SPSS Inc, Chicago, IL, USA).
RESULTS
From the Predict Study we included all eligible women for this secondary 
cohort analysis that met the inclusion criteria as described earlier (n=412). After 
exclusion of  194 pregnancies due to missing blood samples (n=117) or poor 
quality of  blood cell counts (n=77), 218 pregnancies were included for analysis. 
Patients with missing data were characterised by a shorter gestational age (38.2 
versus 39.1 weeks, p <0.001) and lower birth weight (3065 versus 3363 grams, 
p <0.001) as compared to the final study population, and contained twice as 
much EOPE- (10.3% versus 5.0%) and LOPE pregnancies (9.3% versus 5.5%, 
p = 0.076), as depicted in Supplementary table 1. The final study population 
comprised 23 cases of  PE including 11 EOPE and 12 LOPE, and 195 controls, 
including 153 uncomplicated controls and 23 FGR and 19 PTB complicated 
controls (Supplementary figure 1). 
 Maternal and newborn characteristics are shown in Table 1. In 
addition to the case specific parameters blood pressure, proteinuria, gestational 
age and birth weight, a significant lower mean maternal age in EOPE versus 
LOPE and uncomplicated controls was shown (27.1 year, versus 34.1 and 32.2 
year respectively, overall p = 0.002). EOPE pregnancies ended more often in a 
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TABLE 1.  Maternal and newborn characteristics
Uncomplicated    Complicated controls
EOPE LOPE controls FGR PTB Overall
Maternal characteristics (n=11) (n=12) (n=153) (n=23) (n=19) p-value
Age (years) 27.1 (5.2) 34.1* (3.8) 32.2* (5.1) 29.3# (5.8) 30.6 (5.2) 0.002
Nulliparous, n (%) 8 (72.7) 7 (58.3) 66 (43.1) 11 (47.8) 6 (31.3) 0.204
Ethnicity, n (%)                          
Western 
Non-Western 
9 (81.8)
1 (18.2)
7 (58.3)
5 (41.7)
122 (80.3)
30 (19.7)
14 (60.9)
9 (39.1)
15 (83.3)
3 (16.7)
0.152
Preconception BMIa (kg/m2) 26.8 (9.3) 26.4 (2.8) 24.1 (7.1) 23.6 (5.6) 24.1 (7.1) 0.785
Smoking during pregnancy 
(yes), n (%)
1 (12.5) 0 (0.0) 8 (5.4) 2 (9.1) 1 (6.3)
0.813
Co-morbidity (yes), n (%) 1 (9.1) 3 (25.0) 61 (39.9) 4 (17.4) 3 (15.8) 0.022
Newborn characteristics
Male gender, n (%) 9 (81.8) 7 (58.3) 77 (50.3) 14 (60.9) 9 (47.4) 0.210
Gestational age at birtha 
(weeks) 
31.0 (3.7) 37.4* (1.9) 39.6*# (1.7) 39.0*# (2.6) 35.9*# (4.9) <0.001
Birth weighta (grams) 1155 (353) 3238* (1689) 3515* (563) 2625*# (600) 2650*# (1455) <0.001
Birth weight  
<10th percentile, n (%)
2 (18.2) 2 (16.7) 0*# (0.0) 23*# (100.0) 0 (0.0) <0.001
Data are presented as mean (standard deviation) with corresponding ANOVA testing to examine overall differences 
between the groups, followed by the post hoc Dunnett t-test for pairwise comparisons of  EOPE and LOPE with (un)
complicated controls. 
Data are presented as number (%) with corresponding Chi2/Fischer’s exact testing. 
a Non-parametric data are presented as median (interquartile range) with corresponding Kruskall-Wallis testing and post-
hoc Mann-Whitney testing. * p <0.05 versus EOPE pregnancies. # p <0.05 versus LOPE pregnancies. 
ANOVA analysis of  variance; BMI body mass index; EOPE early onset preeclampsia; LOPE late onset preeclampsia; 
FGR fetal growth restriction; PTB preterm birth.
caesarean section compared to LOPE and (un)complicated controls (90%, versus 
25% and up to 35% respectively, overall p = 0.003). Comorbidity was significantly 
different between the groups and highest in uncomplicated controls, but no 
significant differences were observed in the posthoc analysis. Neonatal temperature 
at birth was similar for each group.
 We observed significantly lower cell counts for all UCBC populations and a 
significantly higher NRBC count in EOPE versus (un)complicated controls. In LOPE 
only significantly higher neutrophil and erythrocyte counts and lower reticulocyte 
counts compared to PTB complicated controls were observed (Supplementary table 2).
 In Table 2 we show the results of  the linear regression analyses of  the 
UCBC counts and differentials of  both EOPE and LOPE versus the pooled (un)
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complicated controls. The crude estimates revealed that EOPE was associated 
with the decreased counts of  total leucocytes (β -7.6, 95% CI -10.53, -4.76, p 
<0.001); monocytes (β -0.88, 95% CI -1.26, -0.51, p <0.001); neutrophils (β 
-1.92, 95% CI -2.25, -1.60, p <0.001); eosinophils (β -0.67, 95% CI -1.16, -0.18, 
p = 0.007); immature granulocytes (β -1.82, 95% CI -2.60, -1.03, p <0.001) and 
thrombocytes (β -80.19, 95% CI -126.7, -33.7, p = 0.001). EOPE was associated 
with increased NRBC count (β 1.20, 95% CI 0.57, 1.84, p <0.001). After 
adjustment for gestational age and birth weight, EOPE remained associated with 
decreased neutrophil count (β -0.92, 95% CI -1.27, -0.57, p <0.001) and increased 
NRBC count (β 1.11, 95% CI 0.27, 1.95, p = 0.010). The linear regression analyses 
did not reveal any significant association with LOPE versus the (un)complicated 
control group.
DISCUSSION 
In this study we observed that pregnancies complicated by EOPE are associated 
with decreased leucocyte (monocytes, neutrophils, eosinophils, immature 
granulocytes) and thrombocyte counts and with increased NRBC counts in 
umbilical cord blood. After adjustment for gestational age and birth weight, 
EOPE remained associated with decreased neutrophil and increased NRBC 
counts.
 Our findings demonstrate that the associations of  most UCBC counts 
(total leucocyte, monocyte, eosinophil, immature granulocyte and thrombocyte 
counts) with EOPE are confounded by gestational age and birth weight, which 
is in agreement with previous studies 39, 42. It revealed that LOPE compared to 
EOPE has a marginally impact on UCBC populations, which may be explained 
by its milder phenotype as well as the absence of  FGR and PTB in this group. 
The four to sevenfold decrease of  neutrophil count and fivefold increase 
of  NRBC count in association with EOPE however, were independent of  
gestational age and birth weight. Because the innate immune-system matures 
during pregnancy, this system of  the newborn is prepared to be fully functional 
at birth by a sudden neutrophil rise during the late third trimester 39. The 
excessive oxidative stress from early pregnancy onwards might have affected 
UCB neutrophil counts in EOPE by generating enhanced inflammation in 
the fetal circulation, as demonstrated earlier by higher activated neutrophils 
and monocytes as well as increased CRP, α-1-antitrypsin and plasma chemokine 
levels 50, 51. As a consequence, fetal endothelial cell dysfunction might occur, 
by which the maturation and development of  fetal haematopoiesis can be 
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EOPE (n=11) LOPE (n=12)
Crude β
Adjusted β 
(GA+BW)
Crude β
Adjusted β 
(GA+BW)
  Haemoglobin (mmol/L) -0.51 (-1.22, 0.21) 0.37 (-0.54, 1.29) 0.36 (-0.28, 1.01) 0.48 (-0.15, 1.12)
Haematocrit (L/L) 0.00 (-0.03, 0.04) 0.05* (0.00, 0.09) 0.02 (-0.01, 0.05) 0.03 (-0.01, 0.06)
Leucocytes
Total leucocytes (x109/L) -7.6* (-10.53, -4.76) 0.32 (-3.14, 3.78) -0.75 (-3.66, 2.16) -0.07 (-2.68, 2.55)
Lymphocytes (109/L) -0.62 (-1.68, 0.44) 0.98 (-0.32, 2.28) -0.40 (-1.29, 0.50) -0.19 (-1.05, 0.66)
Monocytesa (109/L) -0.88* (-1.26, -0.51) -0.05 (-0.49, 0.39) -0.10 (-0.41, 0.22) -0.05 (-0.33, 0.23)
Granulocytes
Neutrophilsa (109/L) -1.92* (-2.25, -1.60) -0.92* (-1.27, -0.57) 0.05 (-0.22, 0.32) 0.14 (-0.08, 0.36)
Eosinophilsa (109/L) -0.67* (-1.16, -0.18) -0.37 (-1.01, 0.26) -0.08 (-0.49, 0.34) -0.10 (-0.51, 0.31)
Basophilsa (109/L) -0.51 (-1.12, 0.09) 0.59 (-0.15, 1.32) -0.05 (-0.56, 0.45) 0.04 (-0.44, 0.52)
Immature gran.a (109/L) -1.82* (-2.60, -1.03) -0.15 (-0.78, 1.07) -0.26 (-0.90, 0.37) -0.16 (-0.73, 0.41)
Erythroid cells
NRBCa (109/L) 1.20* (0.57, 1.84) 1.11* (0.27, 1.95) 0.07 (-0.54, 0.68) 0.08 (-0.53, 0.70)
Reticulocytes (x109/L) 18.93 (-9.72, 47.58) -24.25 (-60.40, 11.91) 1.12 (-25.36, 27.60) -5.34 (-30.48, 19.80)
Erythrocytes (x1012/L) -0.63* (-0.96, -0.30) 0.04 (-0.37, 0.44) 0.12 (-0.17, 0.42) 0.21 (-0.07, 0.49)
Thrombocytes
Thrombocytes (x109/L) -80.19* (-126.7, -33.7) -40.4 (-11.6, 19.8) -32.05 (-72.25, 8.16) -28.93 (-69.12, 11.27)
TABLE 2. Linear regression analysis of UCBC count and differentials in EOPE 
and LOPE versus the (un)complicated control group (n=195)
Data are presented as β (95% Confidence Interval) with corresponding multivariable linear regression analysis of  
EOPE and LOPE versus the (un)complicated controls, crude and with adjustment for gestational age and birth 
weight. The regression coefficient (β) indicates the increase or decrease (-) change per unit. 
a Log-transformed data. * p <0.05. GA gestational age; BW birth weight; NRBC nucleated red blood cells; UCB 
umbilical cord blood; EOPE early onset preeclampsia; LOPE late onset preeclampsia; Immature gran. Immature 
granulocytes.
affected. Fetal haematopoiesis originates from endothelial cells in the ventral 
aorta of  the developing embryo and is thus extremely sensitive to endothelial 
damage 52. It has been suggested that the maternal endothelial cell damage is 
of  more importance in EOPE than LOPE and that the excessive oxidative 
stress develops only towards the end of  gestation in LOPE 11. This is in line 
with the observed difference in leucocyte counts between EOPE and LOPE. 
The association between PE and decreased UCB leucocyte count has been 
described before and is in agreement with our findings 39, 53. Low neutrophil 
counts might result in a temporarily reduced immune capacity of  the newborn, 
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especially if  the child is also born preterm. This might increase the vulnerability 
for infections.  
 The observed increase of  UCB NRBC in EOPE pregnancies is in line 
with earlier studies 53-57. However, Akercan- and Catarino et al. did not observe 
this increase independent of  gestational age, which can be explained by the lack 
of  separate analysis for EOPE and LOPE. High numbers of  circulating NRBC 
can reflect an activation of  erythropoiesis as a response to the placental ischemia-
reperfusion phenomenon resulting from diminished and intermittent perfusion 
of  the intervillous space or a compensation of  the erythrocyte-damage, both 
more profoundly present in EOPE than in LOPE 11, 53, 55, 58. The suboptimal 
placental perfusion results in a relatively hypoxic placental environment, which 
is beneficial for early invasion of  the cytotrophoblast into the maternal decidua. 
However a prolonged hypoxic placental state may lead to an over-expression 
of  hypoxia-inducible factor 1α (HIF-1α), regulating several processes such as 
erythropoiesis 59. Placental over-expression of  HIF-1α has been described in 
PE pregnancies, which may explain our finding of  enhanced NRBC counts in 
umbilical cord blood, being a result of  HIF-1α-induced erythropoietin-release 59, 60. 
Strengths and limitations. A strength of  the study is that we investigated 
associations between PE and UCBC counts and differentials in EOPE and 
LOPE separately which revealed a much stronger association between UCBC 
counts and EOPE, and is relevant concerning the different aetiologies of  both. 
Moreover, associations were investigated independent of  gestational age and 
birth weight. 
 Pregnancies complicated by EOPE in our study population ended 
more often in a Caesarean section. This unfortunately resulted in more missing 
blood samples (n=25, 59.5%) compared to LOPE (n=7, 26.9%, p = 0.009) due 
to the emergency of  the Caesarean sections. Due to the sample size we were not 
able to adjust for many confounders and therefore inherent to an observational 
study residual confounding cannot be excluded. The wide confidence intervals 
demonstrate that the sample size also resulted in a limited power of  the study. 
This implies that certain UCBC values with seemingly clinical relevant UCBC 
differences between groups might have failed to achieve statistical significance 
because of  lack of  power. Additionally, a selection bias due to the relatively 
high percentage of  EOPE and LOPE pregnancies with missing data might 
be present, but this is an often occurring problem in high-risk patients where 
medical care is a priority. Another limitation of  our study is the tertiary 
university hospital-setting, in which uncomplicated pregnancies presented 
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with a relatively high percentage of  concurrent comorbidity (40%), for which 
they were referred. These patients were mostly included in the cohort study in 
the first trimester of  pregnancy. Complicated PE, FGR and PTB pregnancies 
were more often included as late cohort inclusions after the first trimester. 
They presented with less additional comorbidity, as visualised in Supplementary 
figure 1. Two neonates only in EOPE and LOPE were complicated by FGR. 
Therefore, future studies may address differences in UCBC populations in a 
subgroup of  early- and late-onset PE complicated by FGR.
CONCLUSION
Derangements of  fetal haematopoiesis, in particular of  neutrophils and NRBC 
counts, are associated with EOPE only. These findings imply potential impact 
on the future health of  offspring and that heterogeneity in UCBC should be 
considered as confounder in epigenetic association studies examining EOPE. 
Further investigation is needed to establish the potential impact for future 
health of  offspring.
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SUPPLEMENTARY DATA 
SUPPLEMENTARY FIGURE 1. Flowchart of  the study population. UCB umbilical 
cord blood; EOPE early onset preeclampsia; LOPE late onset preeclampsia; Unc. 
controls uncomplicated controls; FGR fetal growth restriction; PTB preterm birth.
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Patients with  
missing data
Final study  
population
p-value
Maternal characteristics (n=194) (n=218)
Age (years) 31.5 (4.9) 31.6 (5.3) 0.818
Nulliparous, n (%) 95 (49.0) 98 (45.0) 0.415
Caesarean section, n (%) 78 (402) 80 (36.7) 0.465
Ethnicity, n (%)                         Western
                  Non-Western 
23 (20.7)
88 (79.3)
49 (22.7)
167 (77.3)
0.685
Preconception BMIa (kg/m2) 23.3 (4.8) 24.2 (7.0) 0.113
Smoking during pregnancy (yes), n (%) 6 (5.9) 12 (5.8) 0.968
Co-morbidity (yes), n (%) 43 (35.8) 72 (33.0) 0.602
Case-control status, n (%)                  EOPE
LOPE
FGR
PTB
Uncomplicated controls
11 (10.3)
10 (9.3)
13 (12.1)
14 (13.1)
59 (55.1)
11 (5.0)
12 (5.5)
23 (10.6)
19 (8.7)
153 (70.2)
0.076
Newborn characteristics
Male gender, n (%) 96 (49.7) 107 (49.1) 0.894
Gestational age at birtha (weeks) 38.2 (4.7) 39.1 (2.4) <0.001
Birth weighta (grams) 3065 (1488) 3363 (814) <0.001
Birth weight <10th percentile, n (%) 37 (19.5) 27 (12.4) 0.050
SUPPLEMENTARY TABLE 1. Sensitivity analysis of maternal and newborn 
characteristics between patients with missing data and the final study population.
Data are presented as mean (standard deviation) with corresponding independent t-testing to examine differences 
between the groups. 
Data are presented as number (%) with corresponding Chi2/Fischer’s exact testing. 
a Non-parametric data are presented as median (interquartile range) with corresponding Mann-Whitney testing. BMI 
body mass index; EOPE early onset preeclampsia; LOPE late onset preeclampsia; FGR fetal growth restriction; PTB 
preterm birth.
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Data are presented as mean (standard deviation) with corresponding ANOVA testing to examine overall differences 
between the groups, followed by the post hoc Dunnett t-test for pairwise comparisons of  EOPE and LOPE with 
(un)complicated controls.
a Log-transformed data are presented as back-transformed mean (standard deviation). 
* p <0.05 versus EOPE pregnancies. # p <0.05 versus LOPE pregnancies. ANOVA analysis of  variance; UCB 
umbilical cord blood; NRBC nucleated red blood cells; Immature gran. Immature granulocytes; EOPE early onset 
preeclampsia; LOPE late onset preeclampsia; FGR fetal growth restriction; PTB preterm birth.
Complicated controls
EOPE LOPE
Uncom-
plicated 
controls
FGR PTB
 
Overall
(n=11) (n=12) (n=153) (n=23) (n=19) p-value
Haemoglobin (mmol/L)
Missings
9.24 (1.41) 
1
10.11 (1.08) 
0
9.78 (0.96) 
2
9.82 (1.32) 
0
9.39 (1.71) 
1
0.254
Haematocrit (L/L) 
Missings
0.47 (0.07) 
1
0.49 (0.05) 
0
0.47 (0.05) 
2
0.47 (0.07) 
0
0.45 (0.09) 
1
0.387
Leucocytes
Total leucocytes (x109/L) 
Missings
6.22 (1.97) 
0
13.11*(3.29) 
1
14.61* (4.62) 
8
12.42* (3.74) 
2
9.53 (5.01) 
1
<0.001
Lymphocytes (109/L) 
Missings
3.99 (1.10) 
4
4.21 (1.02) 
2
4.70 (1.39) 
29
4.76 (1.44) 
4
3.60 (1.18) 
5
0.034
Monocytesa (109/L) 
Missings
0.55 (0.25) 
4
1.16* (0.42) 
2
1.41* (0.57) 
29
1.05* (0.48) 
4
0.90 (0.44) 
5
<0.001
Granulocytes
Neutrophilsa (109/L)
Missings
1.04 (0.61) 
4
6.90* (2.21) 
2
7.21* (2.49) 
30
5.71* (2.03) 
4
4.16*# (2.89) 
6
<0.001
Eosinophilsa (109/L)
Missings
0.19 (0.10) 
4
0.36 (0.17) 
2
0.42* (0.24) 
29
0.30 (0.17) 
4
0.37 (0.26) 
6
0.008
Basophilsa (109/L) 
Missings
0.07 (0.06) 
4
0.10 (0.08) 
2
0.14 (0.14) 
30
0.07 (0.04) 
4
0.08 (0.07) 
5
0.027
Immature gran.a (109/L) 
Missings
0.06 (0.07) 
5
0.41* (0.51) 
2
0.45* (0.44) 
30
0.19* (0.15) 
4
0.31* (0.56) 
7
<0.001
Erythroid cells
NRBCa (109/L) 
Missings
5.44 (6.64) 
0
0.99* (0.63) 
1
1.18* (1.24) 
12
1.01* (0.53) 
2
1.68* (2.82) 
1
<0.001
Reticulocytes (x109/L) 
Missings
201.83 (61.83) 
1
184.02 (34.39) 
1
178.36 (35.04) 
12
175.17 (42.86) 
2
227.43# (73.92) 
1
<0.001
Erythrocytes (x1012/L)
Missings
3.79 (0.60) 
1
4.54* (0.40) 
0
4.47* (0.42) 
2
4.37* (0.56) 
0
4.08# (0.89) 
1
<0.001
Thrombocytes
Thrombocytes (x109/L) 
Missings
182.11 (83.19) 
2
230.25 (68.23) 
0
266.57* (66.83) 
2
254.61* (72.83) 
0
236.28 (74.48) 
1
0.002
SUPPLEMENTARY TABLE 2. UCB cell counts and differentials

The impact of early- and late-onset preeclampsia on  
features of placental and newborn vascular health
CHAPTER 3
E.M. Herzog, A.J. Eggink, A. Reijnierse, M.A.M. Kerkhof, R.R. de Krijger, A.J.M. Roks, 
I.K.M. Reiss, A.L. Nigg, P.H.C. Eilers, E.A.P. Steegers, R.P.M. Steegers-Theunissen
Placenta, 2017 Jan. 49: p. 72-79 
IMPACT OF EARLY- AND LATE-ONSET PREECLAMPSIA ON FEATURES OF PLACENTAL AND NEWBORN VASCULAR HEALTH
034
ABSTRACT 
Introduction. Offspring exposed to preeclampsia (PE) show an increased risk 
of  cardiovascular disease in adulthood. We hypothesize that this is mediated 
by a disturbed vascular development of  the placenta, umbilical cord and fetus. 
Therefore, we investigated associations between early-onset PE (EOPE), late-
onset PE (LOPE) and features of  placental and newborn vascular health.
Methods. We performed a nested case-control study in The Rotterdam 
Periconceptional Cohort, including 30 PE pregnancies (15 EOPE, 15 LOPE) and 
218 control pregnancies (164 uncomplicated controls, 54 complicated controls 
including 28 fetal growth restriction, 26 preterm birth) and assessed macroscopic 
and histomorphometric outcomes of  the placenta and umbilical cord.
Results. A significant association was observed between PE and a smaller 
umbilical vein area and wall thickness, independent of  gestational age and birth 
weight. In EOPE we observed significant associations with a lower weight, 
length and width of  the placenta, length of  the umbilical cord, and thickness 
and wall area of  the umbilical vein and artery. These associations attenuated after 
gestational age and birth weight adjustment. In LOPE a significant association 
with a larger placental width and smaller umbilical vein wall thickness was shown, 
independent of  gestational age and birth weight. 
Discussion. Our study suggests that PE is associated with a smaller umbilical 
cord vein area and wall thickness, independent of  gestational age and birth 
weight, which may serve as a proxy of  disturbed cardiovascular development in 
the newborn. Follow-up studies are needed to ultimately predict and lower the 
risk of  cardiovascular disease in offspring exposed to PE.
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INTRODUCTION
In line with the developmental origins of  health and disease paradigm, 
epidemiological studies substantiated by animal studies strongly suggest that 
adverse prenatal exposures increase the risk of  cardiovascular diseases in 
child- and adulthood 1, 2. Preeclampsia (PE) occurs in approximately 2-8% of  
all pregnancies and accounts for one of  the major placental-related pregnancy 
complications. PE is a complex disease characterised by increased maternal 
blood pressure and proteinuria during pregnancy and increased risks of  fetal 
growth restriction (FGR) in 12% and preterm birth (PTB) in 20% 33. Evidence 
is accumulating that offspring exposed to PE have enhanced risks of  increased 
blood pressure and body mass index in childhood and nearly a double risk of  
stroke in adulthood 3-6. Early-onset PE (EOPE) is often more severe than late-
onset PE (LOPE) and largely originates from poor first trimester placentation. 
LOPE seems to be exaggerated by predisposing cardiovascular and metabolic 
risks for endothelial dysfunction in the second half  of  pregnancy 3. It was recently 
suggested that also LOPE may be associated with trophoblast dysfunction due 
to villous overcrowding in term placentas, leading to diminished intervillous 
perfusion and increased hypoxia 13. Both PE phenotypes show enhanced systemic 
inflammatory responses resulting in exposure of  vessels and tissues to excessive 
oxidative stress 11. 
 Impaired placentation is a result of  inadequate invasion of  the maternal 
spiral arteries by the trophoblast, and has been suggested to affect placental and 
fetal growth. A lower placental weight at birth has been shown to predict the 
risk of  hypertension in later life, suggesting an association between placental 
morphological features and offspring vascular health 61. The umbilical- cord and 
fetal vasculature share the same embryonic origin and are derived from intra- 
and extra-embryonic mesodermal layers 28, 29. Therefore umbilical cord vessels 
are often used as a model for the investigation of  non-accessible fetal vessels 
to reflect newborn vascular health 62-66. These vessels are essential for prenatal 
transport of  oxygen, nutrient-rich and deoxygenated blood and metabolic waste 
28, 29. The development of  the umbilical cord is highly influenced by systemic and 
local haemodynamic conditions of  pregnancy, such as blood flow, oxygen tension 
and oxidative stress 20, 21, 27.
 Here we hypothesize that a poor placental development particularly 
in severe EOPE induces excessive inflammatory responses and changes in the 
intrauterine haemodynamics, contributing to the remodelling of  the umbilical 
cord and fetal vasculature and resulting in a vascular phenotype of  the newborn at 
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risk for cardiovascular disease in later life. Therefore, the objective of  our study was 
to investigate associations between PE and the phenotypes EOPE and LOPE, 
and placental and umbilical cord vessel morphology as features of  placental and 
newborn vascular health, in which gestational age and birth weight are taken into 
account. 
METHODS
Study design. Between June 2011 and June 2013 mother-child pairs were 
recruited before delivery and included in a nested case-control study embedded 
in the Rotterdam periconception cohort (Predict study), an ongoing prospective 
hospital-based cohort conducted at the Erasmus MC, University Medical Centre 
Rotterdam, the Netherlands 32. We selected EOPE and LOPE as cases and 
uncomplicated pregnancies as controls. In order to reduce confounding by FGR 
and iatrogenic PTB, we also included FGR and PTB as complicated control 
groups. 
Maternal characteristics. PE was defined according to the International Society 
for the Study of  Hypertension in Pregnancy as gestational hypertension of  at 
least 140/90 mmHg accompanied by an urine protein/creatinine ratio of  ≥ 
30 mg/mmol arising de novo after the 20th week of  gestation 44. EOPE and 
LOPE were defined as being diagnosed before and after 34 weeks of  gestation, 
respectively 45. Uncomplicated control pregnancies were defined as pregnancies 
without PE, gestational hypertension, FGR or PTB. FGR was defined as an 
estimated fetal weight below the 10th percentile for gestational age based on 
ultrasound measurements performed between 20 and 38 weeks gestational age 
46. Birth weight percentiles were calculated using the reference curves of  the 
Dutch Perinatal Registry to validate birth weight < 10th percentile 47. PTB was 
defined as a spontaneous delivery between 22 and 37 weeks of  gestation 48. 
Maternal comorbidity was defined by any concurrent presence of  cardiovascular-, 
endocrine-, metabolic-, auto-immune- and/or renal disease. Women with HIV 
infection, aged < 18 years, not able to read and understand the Dutch language, 
multiple birth pregnancies or women with pregnancies complicated by fetal 
congenital malformations were excluded. 
 Maternal and neonatal characteristics were obtained from hospital 
medical records. All women gave written informed consent before participation 
and parental informed consent was obtained for the child. The research has been 
carried out in accordance with the Declaration of  Helsinki (2013) of  the World 
Medical Association. 
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Data collection. Macroscopic morphological outcomes including weight, length 
and width of  the placenta and length, diameter, number of  vessels and number 
of  coils of  the umbilical cord, were performed immediately after delivery. The 
umbilical coiling index was calculated as the total number of  coils divided by the 
total length of  the cord in centimetres. After clamping of  the umbilical cord, 
samples of  two centimetres for microscopic morphological examination were 
obtained next to the clamping site within one hour after delivery and immediately 
fixed in a 4% formaldehyde solution for paraffin sections. All samples and 
measurements were obtained by trained researchers according to protocol. 
Between 00:00h and 07.00h and during weekends, placental measurements were 
not performed due to logistic constraints. 
Umbilical cord sample processing. Formalin-fixed umbilical cord samples 
were cut in transversal slices of  four millimetres, perpendicular to the umbilical 
cord vessels. The slices were dehydrated in graded ethanol series, cleaned in xylene 
and embedded in paraffin. Paraffin samples were sectioned at 4 micrometre. 
Sections were deparaffinised and hydrated, before Haematoxylin/eosin (HE) 
staining and Elastica Von Gieson (EVG) staining was performed. Sections were 
digitally scanned using a digital slide scanner (NanoZoomer 2.0-HT, C9600-13, 
Hamamatsu Photonics, Japan) and analysed using the software NDP.view2, U12388-
01 (Hamamatsu Photonics, Japan), IMAGE J version 2.0 (National Institutes of  
Health, US) and KS400 version 3.0 (Carl Zeiss Vision GmbH, Aalen, Germany). 
 The following parameters of  the umbilical cord were measured in 
digitised HE stained sections; umbilical cord area, Wharton jelly area, vessel 
area, vessel lumen area and vessel wall thickness. Every individual area was 
measured manually with Image J 67. Vessel wall thickness was measured manually 
in NDP viewer, as the mean of  the smallest and largest wall diameter. Artery 
wall measurements were performed for both the internal and external muscular 
layer. EVG stained sections were used for the measurement of  the percentage of  
elastin content in the wall of  the umbilical artery and umbilical vein and internal 
elastic lamina (IEL) of  the umbilical vein with KS400. The area of  elastic fibres 
in the vessels was digitally marked and divided by the total vessel area to calculate 
the percentage of  elastin content in the vein and in one artery separately.
 All measurements were performed blinded by one researcher. Only 
sections without artefacts were used for analysis. Accuracy of  the digital slices 
and measurements were checked by an experienced pathologist at the Erasmus 
MC, University Medical Centre in Rotterdam.
Statistical analysis. For normal distributed maternal and neonatal characteristics 
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and outcomes of  the umbilical cord and placenta Analysis of  Variance (ANOVA) 
was applied to assess overall differences between the groups, followed by the 
post hoc Dunnett t-test for pairwise comparisons between EOPE, LOPE and 
uncomplicated and complicated control groups. Kruskall-Wallis was applied 
to skewed variables, followed by pairwise Mann-Whitney tests for posthoc 
comparisons. 
 In the comparisons between PE and the total control group, multivariable 
linear regression analysis with adjustment for gestational age and birth weight 
was applied. We additionally applied the multivariable linear regression model to 
compare EOPE and LOPE with the total control group. 
 Differences were considered statistically significant at p <0.05. All 
analyses were performed with Statistical Package for Social Sciences (SPSS, version 
21.0, SPSS Inc, Chicago, IL, USA) and logistic regression with SAS version 9.3 
(SAS Campus Drive, Cary, NC, USA 27513).
RESULTS 
298 women met the inclusion criteria and after exclusion of  50 pregnancies because 
of  missing umbilical cord samples or macroscopic outcomes, 248 pregnancies 
FIGURE 1. Flowchart of the study groups
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remained for further analysis (Figure 1). PE cases comprised 15 EOPE and 15 
LOPE, and controls included 164 uncomplicated and 54 complicated pregnancies 
(28 FGR, 26 PTB). Microscopic outcomes were assessed in all EOPE, 14 
LOPE, a random selection of  24 uncomplicated- and in 52 complicated control 
pregnancies.
 Maternal and neonatal characteristics are depicted in Table 1. Except 
for the case specific parameters, such as blood pressure, proteinuria, gestational 
age and birth weight, we observed a higher frequency of  nulliparous women in 
EOPE (80.0%) and LOPE (86.7%) versus uncomplicated controls (40.9%) and 
PTB (46.2%, overall p <0.001). The frequency of  caesarean section was higher 
in EOPE (80%) compared to LOPE and (un)complicated controls (23.1-37.5%, 
overall p = 0.004). In EOPE, one pregnancy was complicated by FGR (6.7%) 
versus two in LOPE (13.3%, p = 1.000) and all pregnancies were complicated by 
PTB (100%) versus two in LOPE (13.3%, p <0.001).
 Table 2 depicts the results of  the multivariable linear regression analyses 
with gestational age and birth weight adjustments for the associations between 
the macroscopic morphological placental and umbilical cord outcomes and total 
PE, EOPE and LOPE versus the total control group. A negative association with 
placental weight, length and width and umbilical cord length was observed in total 
PE and EOPE, which attenuated after adjustment for birth weight and gestational 
age. LOPE was only positively associated with placental width, which remained 
statistically significant after adjustment for birth weight and gestational age (p = 
0.009). 
 Macroscopic morphological outcomes of  the placenta and umbilical 
cord are also depicted in Supplementary table 1. In EOPE we observed negative 
associations with placental weight, length and width and umbilical cord length 
versus (un)complicated controls (overall p <0.001). In LOPE Dunnett t-testing 
revealed a significantly higher placental weight compared to FGR, and a higher 
placental width compared to FGR and PTB complicated controls. 
 The multivariable linear regression analyses for the microscopic 
umbilical cord outcomes are depicted in Table 3. Since there were no 
significant differences between the two individual artery measurements, the 
mean of  both measurements was used for further analysis. In PE we revealed 
a negative association with umbilical cord length, total vessel area, vein area 
and wall thickness, total artery area, outer artery wall area and artery wall 
thickness (all p <0.05). After adjustment for gestational age and birth weight, 
PE remained inversely associated with the vein area (β -1.05, 95% CI -2.05, 
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Cases Uncomplicated Complicated controls
EOPE LOPE controls
Normotensive 
FGR
Normotensive 
 PTB
Overall
Maternal characteristics (n=15) (n=15) (n=164) (n=28) (n=26) p-value
Age (years) 30.4 (5.2) 33.3 (4.7) 32.3 (4.9) 29.7 (5.9) 30.9 (5.1) 0.051
Nulliparous, n (%) 12 (80.0) 13 (86.7) 67*† (40.9) 17 (60.7) 12*† (46.2) <0.001
Geographical origin, n (%)
Western
Non-Western
 
13 (86.7)
2 (13.3)
 
8 (53.3)
7 (46.7)
 
130 (79.8)
33 (20.2)
 
18 (64.3)
10 (35.7)
 
22 (84.6)
4 (15.4)
 
0.172
Preconception BMI‡ (kg/m2) 24.1 (9.1) 24.2 (4.3) 24.1 (7.1) 22.5 (6.2) 23.9 (6.4) 0.620
Smoking in pregnancy (yes), n (%) 2 (15.4) 0 (0.0) 9 (5.7) 2 (7.7) 2 (8.7) 0.549
Co-morbidity (yes), n (%) 1 (6.7) 7 (46.7) 49 (30.1) 7 (25.0) 5 (19.2) 0.115
Neonatal characteristics
Gender (male), n (%) 5 (33.3) 6 (40.0) 85 (51.8) 15 (53.6) 13 (50.0) 0.622
Gestational age at birth‡ (weeks) 30.7 (3.4) 37.4* (1.9) 39.6*† (1.7) 38.9* (2.6) 35.1*† (6.6)  <0.001
Birth weight‡ (grams) 1185 (435) 3200* (1250) 3560*† (565) 2628*† (593) 2568*† (1674) <0.001
Birth weight <10th percentile, n (%) 1 (6.7) 2 (13.3) 0† (0.0) 28*† (100.0) 0 (0.0) <0.001
TABLE 1. Maternal and newborn characteristics
Data are presented as mean (standard deviation) with corresponding ANOVA testing to examine overall differences between the 
groups, followed by the post hoc Dunnett t-test for pairwise comparisons between EOPE, LOPE and the uncomplicated and 
complicated control groups. 
Data are presented as number (%) with corresponding Chi2/Fischer’s exact testing. ‡ Skewed data are presented as median 
(interquartile range) with corresponding Kruskall-Wallis testing and posthoc Mann-Whitney testing. * p <0.05 versus EOPE 
pregnancies. † p <0.05 versus LOPE pregnancies. ANOVA analysis of variance; BP blood pressure; BMI body mass index; 
EOPE early onset preeclampsia; LOPE late onset preeclampsia; FGR fetal growth restriction; PTB preterm birth.
Data are presented as β (95% Confidence Interval) with corresponding multivariate linear regression analysis of both EOPE (on 
the left) and LOPE (on the right) versus the total control group (n=218), crude and with adjustment for gestational age and birth 
weight. The regression coefficient (β) indicates the increase or decrease (-) change per unit. 
* p <0.05. GA gestational age; BW birth weight; PE preeclampsia; EOPE early-onset preeclampsia; LOPE late-onset preeclampsia. 
Missings are depicted in Supplementary table 1.
PE (n=30) EOPE (n=15) LOPE (n=15)
Crude β Adjusted β 
(GA+BW)
Crude β Adjusted β 
(GA+BW)
Crude β Adjusted β 
(GA+BW)
Macroscopy of the placenta
Weight (gr) -148.0 (-236, -60)* 34.0 (-31, 98) -300.1(-408.7,-191.5)* 6.7 (-86.6, 100.1) 41.9 (-81.7, 165.5) 55.5 (-28.8, 139.8)
Length (cm) -2.38 (-3.84, -0.92)* -0.52 (-1.99, 0.95) -3.9 (-5.8, -2.0)* -0.2 (-2.4, 2.1) -0.7 (-2.7, 1.3) -0.8 (-2.6, 1.0)
Width (cm) -1.51 (-2.85, -0.18)* 0.99 (-0.22, 2.21) -4.8 (-6.4, -3.2)* -0.8 (-2.6, 1.0) 2.1 (0.3, 3.8)* 2.0 (0.5, 3.6)*
Macroscopy of the umbilical cord
Length (cm) -6.92 (-11.75, -2.08)* -0.33 (-5.50, 4.84) -15.6 (-22.1, -9.2)* -5.2 (-13.4, 3.0) 1.8 (-4.7, 8.4) -2.4 (-4.0, 8.7)
Diameter (mm) 0.69 (-0.71, 2.09) 1.02 (-0.54, 2.58) 0.2 (-1.8, 2.1) 1.1 (-1.4, 3.6) 1.2 (-0.7, 3.1) 1.1 (-0.7, 3.0)
Coiling index (coils/cm) -0.01 (-0.04, 0.03) -0.02 (-0.06, 0.02) 0.0 (-0.0, 0.1) 0.0 (-0.0, 0.1) -0.0 (-0.1, 0.0) -0.0 (-0.1, 0.0)
TABLE 2. Multivariable linear regression analysis of the macroscopic morphology of the 
placenta and umbilical cord in EOPE and LOPE versus the total control group
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0.04, p = 0.041) and vein wall thickness (β -0.15, 95% CI -0.26, -0.04, p = 
0.006). EOPE was negatively associated with total umbilical cord vessel area, 
vein area, wall thickness and artery areas and wall thickness, which attenuated 
after adjustment for gestational age and birth weight. 
A negative association was observed between LOPE and vein wall thickness, 
only after adjustment for gestational age and birth weight. 
 In Figure 2, 3 and Supplementary table 2, the microscopic 
morphological outcomes of  the umbilical cord are depicted per group. In EOPE 
we observed smaller total umbilical cord areas, vein area, wall thickness, external 
artery wall area and vein elastin content compared to uncomplicated controls. 
In EOPE vein total area and vein wall thickness were also significantly smaller 
compared to FGR and PTB (overall p = 0.001 and p = 0.004 respectively). In 
LOPE we only observed a smaller Wharton jelly area versus uncomplicated 
controls (p = 0.030). 
DISCUSSION
Main findings. This study shows a negative association between the umbilical 
Microscopic morphological outcomes of  the umbilical cord are presented as mean (+/- standard deviation) with 
corresponding ANOVA testing to examine overall differences between the groups, followed by the post hoc Dun-
nett t-test for pairwise comparisons of  EOPE and LOPE with the (un)complicated control groups. ‡ Skewed data 
are analysed by Kruskall-Wallis testing.
* p <0.05 versus EOPE pregnancies. † p <0.05 versus LOPE pregnancies. ANOVA analysis of  variance; EOPE 
early onset preeclampsia; LOPE late onset preeclampsia; FGR fetal growth restriction; PTB preterm birth.
 FIGURE 2. Microscopic morphological outcomes of the umbilical cord
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 FIGURE 3. Microscopic Transversal sections of the umbilical cord in an uncom-
plicated control (A) and EOPE (B).
Umbilical cord paraffin section with Haematoxylin Eosin staining. Veins consist of  a single layer circular smooth 
muscle cells and an internal elastic lamina (IEL). The umbilical arteries have a double-layered muscular wall divided 
in an internal layer of  longitudinal smooth muscle cells and an external layer of  crossing spiralled smooth muscle 
cells. Umbilical arteries do not contain an IEL. 
A and B. Umbilical cord transversal section of  an uncomplicated control (A) and EOPE (B) with a smaller vein area 
versus (un)complicated pregnancies. 
C and D. Umbilical cord transversal paraffin sections with Elastic Van Gieson staining in an uncomplicated control 
(C) and EOPE (D) with a lower total vein elastin content versus uncomplicated pregnancies (x5).
W Wharton jelly; V vein; A artery; i internal muscular layer; e external muscular layer; IEL internal elastic lamina.
vein area and vein wall thickness in the total group of  PE pregnancies, 
independent of  gestational age and birth weight. In EOPE, the negative 
associations with placental weight, length and width and umbilical cord length, 
vein and artery wall area and wall thickness are largely explained by a shorter 
gestational age and lower birth weight. This is in contrast to LOPE showing 
a positive association with placental width and a negative association with 
umbilical vein wall thickness independent of  gestational age and birth weight. 
Strengths and limitations. Strengths of  our study are that we established 
different associations between EOPE and LOPE and microscopic 
morphological outcomes in umbilical cord vessels and independent of  FGR 
and PTB. The digital qualitative elastin measurement-technique is novel and 
accurate and seems feasible for future examinations. 
Interpretation. The different associations observed in EOPE and LOPE with 
IMPACT OF EARLY- AND LATE-ONSET PREECLAMPSIA ON FEATURES OF PLACENTAL AND NEWBORN VASCULAR HEALTH
044
placental and umbilical cord morphology can partly be explained by a shorter 
gestational age and lower birth weight in the more severe EOPE phenotype. In 
addition, the positive association between LOPE and placental width is even 
opposite to the association with EOPE, as observed by others 68. Kajantie et al. 
described an association between a smaller placental width and the risk of  PE 
severity, which is in line with our observation in EOPE suggesting that placental 
width is a marker of  placental development 61. The discrepancy of  placental 
measurements in EOPE and LOPE may be explained by the concept of  
initial poor and restricted placental development in EOPE versus microvillous 
overcrowding in term placentas without prior pathology in LOPE 13.  
 The association of  an approximately twofold smaller vein area 
and approximately one-and-a-half-fold smaller vein wall thickness in EOPE 
compared to the total control group was much stronger than in LOPE, but 
appeared only independent of  gestational age and birth weight in LOPE. This 
may be due to the exposure to maternal cardiovascular and metabolic risk 
factors associated with LOPE (47% in LOPE versus 7% in EOPE pregnancies). 
However, in the total PE group we also demonstrated that the EOPE and 
LOPE subgroups may in fact be underpowered, by revealing a strong significant 
association with a smaller vein area and wall thickness in PE, independent of  
gestational age and birth weight. Moreover, the low rate of  FGR cases within 
the EOPE pregnancies indicates that a relatively small number of  pregnancies 
complicated with severe placental dysfunction leading to FGR were included, 
which cannot exclude that the observed association is underestimated. 
 We do believe that the significantly smaller vein wall thickness is 
related to the adverse influences originating from PE itself  and possibly 
the additional complications of  PTB and FGR. Both gestational age and 
birthweight are highly related to the severity and moment of  onset of  PE, 
suggesting that the most evident findings are appearing in the most severe 
EOPE cases, who suffered from excessive oxidative stress from the beginning 
of  pregnancy. PTB and FGR have indeed been associated with alterations of  
cardiovascular risk factors in offspring 69, 70. However, as suggested by our data 
and that of  others, the intrauterine PE environment seems to be unique and 
exacerbates or acts in synergy with any risks inferred by PTB or FGR 7. During 
normal fetal development, the morphology of  the vessel walls changes due 
to a thickening of  the elastic lamellae of  the media 71. PE however deranges 
the haemodynamic characteristics of  the materno-fetal circulation with 
fluctuations in shear stress, which affects the fetal vascular development 72, 73. It 
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has been shown that umbilical perfusion and elastin content of  the umbilical 
veins are decreased in neonates born after PE 62, 65. Additionally, episodes of  
placental hypoxia or reperfusion result in excessive oxidative stress and the 
production of  inflammatory cytokines in both maternal and fetal circulation 
51. A disbalance between angiogenic factors and pro-inflammatory chemokines 
is associated with maternal endothelial cell dysfunction as pregnancy advances 
with possible consequences for the structure and content of  the vessel walls 3. 
In PE pregnancies a reduced prostacyclin production in endothelial cells of  the 
umbilical cord vessels resulting in decreased placental perfusion and umbilical 
cord blood flow has been observed 74. This substantiates our finding of  the 
smaller umbilical cord vein wall thickness and tendency of  decreased elastin 
content being related to the haemodynamic fluctuations and excessive oxidative 
stress.
 An overexpression of  type III and down regulation of  type I collagen 
has been described in umbilical cord veins, arteries and Wharton jelly of  
neonates exposed to PE, which decreases solubility (water-binding capacity) 
and may explain the smaller vessel wall thickness and also the decreased elastin 
content of  the umbilical vein walls 64, 65.
 Our findings are consistent with Inan et al., who reported a significant 
reduction in the umbilical vein and artery wall areas of  70 neonates exposed to 
PE 63. In contrast, two smaller studies reported an increased umbilical artery 
wall thickness, which may be due to differences in the definition of  PE and 
umbilical cord sampling methods (at the placental side instead of  next to the 
umbilical cord clamping site) and sample sizes 62, 66. 
Conclusion. Our study suggests that PE is associated with a smaller umbilical 
cord vein area and wall thickness, independent of  gestational age and birth 
weight, which may be considered as a proxy for early features of  disturbed 
cardiovascular development in the newborn.
 Periconceptional follow-up studies are needed to ultimately predict 
the risk of  cardiovascular disease in offspring exposed to PE which may create 
opportunities for early prediction, prevention and treatment in the future.
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SUPPLEMENTARY DATA
SUPPLEMENTARY TABLE 1. Macroscopic morphological outcomes of  the placenta and 
umbilical cord vasculature
Data are presented as mean (standard deviation) with corresponding ANOVA testing to examine overall differences 
between the groups, followed by the post hoc Dunnett t-test for pairwise comparisons of  EOPE and LOPE with the 
uncomplicated and complicated control groups. 
* p <0.05 versus EOPE pregnancies. † p <0.05 versus LOPE pregnancies. ANOVA analysis of  variance; EOPE ear-
ly-onset preeclampsia; LOPE late-onset preeclampsia; FGR fetal growth restriction; PTB preterm birth.
Cases Uncomplicated Complicated controls
EOPE LOPE controls
Normotensive 
FGR
Normotensive 
PTB
Overall
(n=15) (n=15) (n=164) (n=28) (n=26) p-value
Macroscopy of the placenta
Placental weight (gr) 309 (95.5) 650* (184) 656* (153) 452*† (97) 494* (198) <0.001
Placental length (cm) 16.4 (4.0) 19.7* (3.9) 20.9* (2.9) 18.1 (2.1) 19.5* (3.7) <0.001
Placental width (cm) 12.3 (1.8) 19.2* (4.2) 17.7* (2.4) 15.2*† (2.2) 15.8*† (2.5) <0.001
Macroscopy of the umbilical cord
Length (cm) 34.8 (8.2) 52.2* (12.0) 51.2* (12.3) 49.9* (12.5) 45.1* (12.9) <0.001
Diameter (mm) 12.8 (4.0) 13.9 (2.9) 12.8 (3.5) 11.3 (3.8) 13.3 (4.4) 0.197
Coiling index (coils/cm) 0.23(0.12) 0.15 (0.06) 0.20 (0.08) 0.18 (0.01) 0.20 (0.10) 0.149
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Cases Uncomplicated Complicated controls
EOPE LOPE controls
Normotensive 
FGR
Normotensive 
 PTB
Overall
(n=15) (n=14) (n=24) (n=26) (n=26)
p-value
Total cord area (mm2)
Missings
71.7 (20.1)
1
78.0 (26.9)
0
99.8* (35.1)
1
68.3 (21.9)
0
85.0 (24.1)
1
0.001
Wharton jelly area (mm2)
Missings
65.5 (21.3)
4
67.7 (27.4)
1
91.0*† (34.3)
5
51.7 (11.9)
5
66.1 (18.7)
12
<0.001
Total vessel area (mm2)
Missings
6.7 (1.8)
3
9.1 (1.7)
1
11.6* (3.3)
5
8.8 (2.9)
5
9.3 (3.7)
11
<0.001
Total lumen area (mm2)‡
Missings
0.8 (0.5)
3
1.5 (1.2)
1
1.3 (1.1)
5
0.8 (1.1)
5
1.4 (1.7)
11
0.192
Umbilical Vein
Vein total area (mm2)
Missings
2.9 (1.3)
1
4.8 (1.4)
0
6.4* (2.5)
2
4.9* (2.4)
1
5.4* (2.7)
0
0.001
Wall thickness (mm)
Missings
0.47 (0.17)
0
0.60 (0.12)
0
0.76* (0.20)
1
0.68* (0.24)
1
0.73* (0.32)
0
0.004
Lumen area (mm2)‡
Missings
0.61 (0.58)
1
1.30 (0.93)
0
1.13 (1.01)
2
0.65 (0.95)
1
0.90 (1.05)
0
0.086
Elastin content (%)
Missings
5.8 (2.1)
0
5.9 (1.6)
0
9.0* (2.5)
0
7.4 (1.9)
1
7.5 (2.7)
1
0.033
Umbilical Artery
Artery total area (mm2)
Missings
2.2 (0.5)
0
2.7 (0.8)
0
3.1 (0.9)
1
2.8 (1.0)
1
2.8 (1.2)
0
0.059
External wall layer area (mm2)
Missings
1.4 (0.3)
0
1.9 (0.5)
0
2.2* (0.6)
1
2.0* (0.9)
1
1.9 (0.8)
0
0.018
Internal wall layer area (mm2)‡
Missings
0.62 (0.25)
0
0.79 (0.29)
0
0.85 (0.59)
1
0.71 (0.40)
1
0.69 (0.64)
0
0.068
Wall thickness (mm)
Missings
0.68 (0.11)
0
0.74 (0.10)
0
0.80 (0.13)
1
0.77 (0.17)
1
0.76 (0.18)
0
0.206
Lumen area (mm2)‡
Missings
0.03 (0.08)
0
0.02 (0.08)
0
0.03 (0.05)
1
0.02 (0.07)
1
0.03 (0.13)
0
0.437
Elastin content (%)
Missings
6.7 (1.8)
1
7.7 (2.2)
0
5.9 (2.3)
1
6.3 (1.8)
2
5.5 (1.6)
0
0.686
Data are presented as mean (standard deviation) with corresponding ANOVA testing to examine overall differences 
between the groups, followed by the post hoc Dunnett t-test for pairwise comparisons of  EOPE and LOPE with the 
uncomplicated and complicated control groups. 
‡ Skewed data are presented as median (interquartile range) with corresponding Kruskall-Wallis testing. 
* p <0.05 versus EOPE pregnancies. † p <0.05 versus LOPE pregnancies. ANOVA analysis of  variance; EOPE ear-
ly-onset preeclampsia; LOPE late-onset preeclampsia; FGR fetal growth restriction; PTB preterm birth.
SUPPLEMENTARY TABLE 2. Microscopic morphological outcomes of  the umbilical cord

Microcirculation in women with severe preeclampsia and 
HELLP syndrome: a case-control study
J.M.J. Cornette, E.M. Herzog, E.A.B. Buijs, J.J. Duvekot, D. Rizopoulos, W.C.J. Hop, 
D. Tibboel, E.A.P. Steegers
British Journal of Obstetrics and Gynaecology, 2014. 121: p. 363–370
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ABSTRACT
Objective. To compare microcirculatory perfusion in women with severe 
preeclampsia against that in healthy pregnant women, and secondly in women 
with severe preeclampsia with or without HELLP syndrome (haemolysis, elevated 
liver enzymes, and low platelets).
Design. Case–control study.
Setting. University Hospital Rotterdam, the Netherlands.
Population. Twenty-three women with severe preeclampsia and 23 healthy 
pregnant controls, matched for maternal and gestational age. Out of  the 23 
women with severe preeclampsia, ten presented with HELLP syndrome.
Methods. Microcirculation was analysed sublingually by a non-invasive sidestream 
dark-field imaging device (SDF).
Main outcome measures. Perfused vessel density (PVD), microcirculatory flow 
index (MFI), and heterogeneity index (HI) were calculated for both small vessels 
(∅ < 20 μm; capillaries) and non-small vessels (∅ > 20 μm; venules and arterioles).
Results. There were no significant differences between women with severe 
preeclampsia and healthy controls. Women with preeclampsia and HELLP 
syndrome showed a reduced PVD (p =  0.045), MFI (p = 0.008), and increased 
HI (p = 0.002) for small vessels, as compared with women with preeclampsia but 
without HELLP syndrome.
Conclusions. Sidestream dark-field is a novel, promising technique in obstetrics 
that permits the non-invasive evaluation of  microcirculation. We did not observe 
major differences in sublingual microcirculatory perfusion between women 
with severe preeclampsia and healthy pregnant controls. In women with severe 
preeclampsia, the presence of  HELLP syndrome is characterised by impaired 
capillary perfusion.
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INTRODUCTION
The microcirculation is a vast network of  small vessels with a diameter below 
100 μm. It consists of  arterioles that regulate flow to the capillaries, which 
subsequently drain in venules 75. Exchange of  oxygen and nutrients occurs at the 
level of  the capillaries, which mainly consist of  a thin layer of  endothelium. With 
the availability of  new imaging modalities, the importance of  microcirculatory 
perfusion in the pathophysiology, prognosis, and treatment of  conditions with 
profound haemodynamic imbalance, like sepsis, shock, and cardiac disease, 
is emerging. Parameters of  microcirculatory perfusion seem independent of  
global haemodynamic status and appear to be strong predictors of  outcome 
75-80. Sidestream dark-field (SDF) imaging is a novel technique enabling direct, 
non-invasive visualisation of  microcirculatory perfusion at the bedside in adults, 
children, and newborns 75-77. Severe preeclampsia is characterised by a maternal 
haemodynamic instability caused by generalised endothelial dysfunction 3. 
Many of  its symptoms and complications strongly suggest microcirculatory 
dysfunction. A recent study indicates that capillary rarefaction precedes the 
clinical onset of  preeclampsia 81. HELLP syndrome (haemolysis, elevated liver 
enzymes, and low platelets) is considered an expression of  disease severity 
82, 83. Although its exact pathophysiology is not completely understood, the 
haemolysis, platelet consumption, and liver cell necrosis might reflect a more 
profound disturbance in microcirculatory function. Our aim was to explore 
the potential and reliability of  SDF in pregnant women, and to analyse 
microcirculatory perfusion in women with severe preeclampsia as compared 
with that in healthy pregnant women. Secondly, we investigated the influence 
of  HELLP syndrome on microcirculation in women with severe preeclampsia.
MATERIALS AND METHODS
Study setting. The study was conducted from November 2009 to September 
2012 at the department of  Obstetrics and Prenatal Medicine of  the Erasmus 
Medical Centre of  the University of  Rotterdam. Twenty-three women with 
severe preeclampsia were included. In ten of  these women, preeclampsia was 
complicated by HELLP syndrome. Four women with severe preeclampsia had 
a history of  systemic lupus erythematosus or chronic hypertension. Twenty-
three healthy pregnant women, matched for maternal and gestational age, were 
included as controls. Informed consent was obtained from all women and the 
study protocol was approved by the local medical ethical committee.
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 Severe preeclampsia was defined as preeclampsia (hypertension and 
significant proteinuria) with severe hypertension, and/or with symptoms, 
and/or with biochemical and/or haematological impairment 84. HELLP 
syndrome was defined as the presence of  at least two components of  
either haemolysis (lactate dehydrogenase, LDH ≥ 600 U/l), elevated liver 
enzymes (aspartate aminotransferase, AST ≥ 70 U/l), or thrombocytopenia 
(thrombocytes < 100 × 109/l) 83. All women with severe preeclampsia were 
categorised into severe preeclampsia either with or without HELLP syndrome 
according to previous definitions after expert agreement by three of  the authors 
(J.C., E.H., and J.D.). Women with severe preeclampsia were managed according 
to our local protocol, as described in Appendix S1.
 In women with severe preeclampsia we aimed to perform microcirculatory 
analysis at time points when disease activity was estimated to be maximal and 
when the interference from treatment was estimated to be as minimal as possible. 
Therefore, measurements were performed either before intravenous nicardipine, 
magnesium sulphate bolus, or when laboratory abnormalities consistent with 
HELLP syndrome occurred, irrespective of  other concomitant medication. Age, 
parity, body mass index (BMI), gestational age, and medical history were obtained 
for all women.
 All measurements were performed in a 15° left lateral tilt. Women were 
asked to refrain from eating or drinking for 30 minutes before measurements. 
Blood pressure was determined by manual sphygmomanometry. LDH, AST 
analysis, and thrombocyte count, as well as haematocrit and haemoglobin counts, 
FIGURE 1. Set-up for a sublingual micro-
circulatory perfusion measurement with 
SDF. A disposable sterile plastic cap covers 
the mouthpiece of the probe (A). A frozen 
video-clip image of sublingual microcircu-
lation as viewed with SDF (B).
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were performed as part of  the routine clinical procedure in women with severe 
preeclampsia on the day of  the measurements.
Sidestream dark-field imaging. The sublingual microcirculation was visualized 
using SDF (Figure 1A) 85. This hand-held video microscope (MicroScan; 
MicroVision Medical, Amsterdam, the Netherlands) emits stroboscopic green 
light (530 nm) from an outer ring of  light-emitting diodes (LEDs), which 
penetrates the tissue to a depth of  approximately 3 mm. The light is absorbed 
by the haemoglobin of  individual red blood cells in superficial vessels. A 
negative image is transmitted back, after 5× optical magnification, to an isolated 
synchronised charge-coupled device camera in the core of  the probe. This allows 
high-contrast video images of  circulating erythrocytes to be recorded with a 286× 
magnification from the microcirculation of  organs covered with a thin epithelial 
layer. (Figure 1B) 79. SDF imaging has been validated against and found to be 
superior to intravital videomicroscopy 75, 85.
 The consensus recommendations on how to best obtain and evaluate 
SDF measurements were followed 78, 86. After obtaining good image focus and 
contrast, with specific attention paid to avoiding pressure artefacts by assuring 
continuous venous perfusion, one investigator (E.H.) recorded three high-quality 
video clips per measurement, with a duration of  at least 20 seconds, each at a 
different sublingual site (using a high-definition videocassette recorder: GV-
HD700; Sony Instruments, Tokyo, Japan).These were digitalised, blinded, and 
stored on an external hard drive. After completion of  the data set, E.H. performed 
analysis of  the blinded recordings using ava 3.0 (Automated Vascular Analysis, 
MicroVision Medical, Amsterdam, the Netherlands).
Inter-observer variability was assessed though separate analysis of  the 45 
recordings of  15 randomly selected cases by a different investigator (E.B.).
 As described in the consensus recommendations, the perfused vessel 
density (PVD), microcirculatory flow index (MFI), and the heterogeneity index 
(HI) for MFI were calculated, each reflecting distinctive characteristics of  
microcirculatory perfusion 78, 86. Each parameter was determined separately for both 
small vessels (∅ < 20 μm, capillaries) and non-small vessels (20 μm ≤ ∅ ≤ 100 μm, 
mostly venules and arterioles) 86-88. A detailed description of  these parameters and 
respective methods of  calculation is available in Appendix S2.
Statistical analysis. Statistical analysis was performed with spss 20.0 (SPSS 
Inc., Chicago, IL, USA). Variables were tested for normality and compared with 
the Students' t-test or non-parametric Mann–Whitney U-test, as appropriate. 
The effect of  parameters with a known potential to influence haemodynamics 
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FIGURE 2. Bland–Altman plots showing interobserver agreement for PVD in 
small and non-small vessels.
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(gestational age, use of  oral antihypertensive medication), vascular structure 
(maternal age, BMI, race), or SDF measurements (haematocrit, haemoglobin) was 
assessed by analysis of  covariance (ancova) or by its non-parametric variant (the 
Quade test), as appropriate 89-93. The adjusted p-values, with P ≤ 0.05 (two-sided) as 
the limit of  significance, were used without correction for multiple comparisons.
 Inter-observer reliability was assessed by calculation of  the intraclass 
correlation coefficients from each parameter (PVD, MFI, and HI), separated for 
small- and non-small vessels in 15 cases. Inter-observer agreement for PVD was 
shown in Bland–Altman plots.
 In the absence of  SDF data on microcirculatory perfusion in pregnancy 
and severe preeclampsia, no power calculation was performed and this study was 
undertaken as an exploratory pilot.
RESULTS
Adequate recordings and measurements were obtained for all participants. 
Intraclass correlation coefficients were good for capillary measurements and were 
moderate for larger vessels (Table 1). Figure 2 shows the inter-observer agreement 
for PVD in small and non-small vessels. Twelve women with severe preeclampsia 
received concomitant oral antihypertensive medication. This included women 
with and without HELLP syndrome. All received methyldopa, nifedipine, or a 
combination of  both. One woman received additional oral labetalol. The baseline 
characteristics of  women with severe preeclampsia and healthy controls were 
similar (Table 2). As expected, blood pressure was significantly higher in women 
with severe preeclampsia. Preeclampsia was considered to be severe in all women 
either because of  the severity of  their hypertension (systolic blood pressure, 
SBP, ≥ 160 mmHg and/or diastolic blood pressure, DBP, ≥ 110 mmHg) or 
because of  the presence of  HELLP. Baseline characteristics between women with 
severe preeclampsia, with or without HELLP, were also comparable, except for 
the components of  HELLP syndrome (Table 2).
 Women with HELLP syndrome had significantly lower values of  PVD 
and MFI and significantly higher values of  HI for small vessels, as compared 
with women with severe preeclampsia without HELLP (Figure 3A, B). 
These differences remained significant after adjusting for haemoglobin count, 
haematocrit, BMI, medication use, pre-existent disease, maternal age, and 
gestational age.
MICROCIRCULATION IN WOMEN WITH SEVERE PREECLAMPSIA AND HELLP SYNDROME
056
TABLE 1. Intraclass correlation coefficients (ICCs) and 95% CIs for inter-observer 
reliability
TABLE 2. Population characteristics
ICC (95% CI) PVD MFI HI
Small vessels 0.87 (0.61–0.96) 0.94 (0.77–0.98) 0.96 (0.84–0.99)
Non-small vessels 0.66 (0.05–0.89) 0.88 (0.63–0.96) 0.73 (0.15–0.91)
Characteristics
Severe preeclampsia
(n = 23)
Controls 
(n = 23)
P 
Severe preeclampsia versus control pregnancies
Nulliparous 54.5% 45.5% ns
Gestational age (weeks) a 33 (21–37) 33 (20–38) nt
Age (years) 31 (±5) 31 (±5) nt
BMI a 28 (20–56) 26 (18–41) ns
Systolic blood pressure (mmHg) a 170 (130–2015) 110 (99–135) <0.001
Diastolic blood pressure (mmHg) a 102 (76–115) 68 (50–90) <0.001
Characteristics
With HELLP
(n = 10)
Without HELLP
(n = 13)
P 
Severe preeclampsia with or without HELLP syndrome
Nulliparous 50% 54% ns
Gestational age (weeks) a 30 (21–37) 33 (25–37) ns
Age (years) 31.1 (±3.9) 31.7 (±6.5) ns
BMI a 26 (20–32) 30 (20–56) ns
Systolic blood pressure (mmHg) 157 (±31) 174 (±20) ns
Diastolic blood pressure (mmHg) 96 (±12) 102 (±7) ns
Oral antihypertensive medication 40% 69% ns
LDH (U/l) a 850 (602–2964) 426 (265–575) <0.001
AST (U/l) a 221 (42–1593) 23 (14–52) <0.001
Thrombocytes (109/l) a 99 (41–289) 250 (134–375) <0.001
ns, not significant; nt, not tested (matching criterion). Values are expressed as means ± standard deviations or medi-
ans with ranges according to normality.
a Non-parametric test used.
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DISCUSSION
Main findings. In this study we explored microcirculatory perfusion in women 
with severe preeclampsia with SDF, a novel technique in obstetrics. Microcirculatory 
research has mainly been hampered by technological limitations. SDF allows the 
direct recording of  high-contrast images and assessment of  different aspects of  
microcirculatory perfusion. In our study, satisfactory images were obtained at 
the bedside and with minimal discomfort in all women. Inter-observer variability 
showed good reliability for capillary vessels, but is less evident in non-small 
vessels given the wide confidence intervals for PVD and HI, despite acceptable 
intraclass correlation coefficients. These findings are in line with previous results 
in non-pregnant populations 78, 88, 94, 95. Fortunately previous research and our 
results suggest that the capillary compartment is the main area of  interest in 
microcirculatory perfusion. Therefore, SDF seems a preferred method for 
microcirculatory analysis in obstetrics 75. Nevertheless, although image recording 
is relatively straightforwards, offline analysis still requires substantial human input 
and remains time consuming. Developments in the most recent version of  the 
SDF camera now permit automatic image analysis, which will further improve 
reliability, and holds promise for bedside recording and analysis in the future.
 Despite the increased blood pressure we did not observe any difference 
in microcirculatory parameters in women with severe preeclampsia, as compared 
with healthy pregnant controls. Apparently, the major macrocirculatory 
disturbances of  severe preeclampsia are not reflected in significant differences in 
sublingual microcirculatory perfusion. Interestingly, when comparing women with 
severe preeclampsia with or without HELLP syndrome, we observed significant 
differences in all aspects of  capillary perfusion, with a decrease in PVD and MFI 
and an increased HI in women with HELLP syndrome.
Interpretation and relation to other studies. Previous microcirculation 
studies described a decreased venular diameter and increased postcapillary 
(venular) resistance in women with preeclampsia using intravital microscopy 
and plethysmography 96, 97. Although we did not specifically asses changes in 
vessel diameters and used different techniques in different organ systems, we 
did not observe major changes in large vessels, which mostly consist of  venules 
and arterioles to a lesser extent. Hasan, using intravital capillaroscopy, reported 
a reduced capillary density in 11 women with preeclampsia, as compared with 
normal healthy pregnant and non-pregnant women 98. Houben, using a similar 
set-up, could not confirm these findings, and Vollebregt, using orthogonal 
polarisation spectral imaging (OPS), did not find any changes in nail fold capillary 
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FIGURE 3. Scatter plots (A) and box plots (B) depicting differences in PVD, MFI, and HI for 
small and non-small vessels between women with severe preeclampsia and controls, as well 
as between women with severe preeclampsia with and without HELLP syndrome.
Boxes denote interquartile ranges, bars in boxes represent median values, and error bars represent ranges. *Non-parametric 
test used. Adjusted P values are depicted for comparisons with statistical significant difference. PVD Perfused vessel density; 
MFI microcirculatory flow index; HI and heterogeneity index; HELLP, severe preeclampsia with HELLP syndrome; PE, 
severe preeclampsia without HELLP syndrome.  
A
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red blood cell velocity 97, 99. Neither did we observe any changes at a capillary 
level between women with severe preeclampsia and healthy pregnant women. 
This discrepancy may be explained by the use of  medication in women with 
preeclampsia, as Hasan performed the measurements before any intervention. 
Most women in our, Vollebregt's, and Houben's studies had already received 
some form of  antihypertensive therapy, magnesium sulphate, or steroids for fetal 
lung maturation. These drugs have the potential to influence capillary perfusion 
100. In further studies, attempts should be made to perform measurements before 
any treatment; however, this remains difficult, as the maternal condition often 
does not permit treatment delay in severe preeclampsia.
 The suggestion of  impaired capillary perfusion in women with 
both preeclampsia and HELLP syndrome might explain some aspects of  
the pathophysiology of  HELLP syndrome 83. The reduced PVD and MFI 
might be a reflection of  microvascular erythrocyte fragmentation and platelet 
adherence to the damaged endothelial surface in narrowed capillaries 101. The 
increased heterogeneity could explain the diffuse pattern of  liver cell necrosis in 
HELLP, where fibrin microthrombi and fibrinogen deposits are often observed 
both in intact hepatic sinusoids and in areas with hepatocellular necrosis upon 
histology 82. Heterogeneity of  flow is an important characteristic of  impaired 
microcirculation 75, 78. With heterogeneous flow, a reduced number of  capillaries 
are perfused. Cells close to the capillaries extract the normal quantity of  oxygen, 
but cells too far away become hypoxic. Although the total oxygen delivery is the 
same, heterogeneous perfusion probably affects tissue oxygenation more than a 
reduced but homogenous flow.
Future research. Sublingual microcirculation is easily accessible for SDF. It is 
representative in sepsis, probably because of  the embryological and metabolic 
similarities with the splanchnic mucosa 75, 78. Even so, preeclampsia is a complex 
syndrome that groups a broad clinical spectrum with variable degrees of  organ 
dysfunction. It is therefore questionable whether the endothelial dysfunction 
is always manifested equally in all vascular beds. Our results, both in women 
with and without HELLP, could be explained by the fact that the sublingual 
microcirculation may not be the most representative site in all pre-eclamptic 
women. SDF enables microvascular analysis in different areas (e.g. skin, 
conjunctiva, nail fold, vagina, cervix, etc.). Further research in obstetrics should 
explore microcirculatory perfusion at various sites during the haemodynamic 
adaptation of  normal pregnancy, and explore eventual representative areas in 
pathological conditions.
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 Besides facilitating (patho) physiological research in larger populations, 
future improved versions with rapid bedside analysis also offer perspectives 
for clinical implications. As in sepsis and cardiogenic shock, microcirculatory 
perfusion analysis has the potential to improve outcome prediction, and assist in 
the selection of  candidates for expectant management or monitoring of  medical 
treatment 80, 102.
Strengths and limitations. This is the largest population of  women with 
preeclampsia investigated for microcirculatory changes in a prospective, case-
controlled design. Our control group of  23 pregnant women is also one of  the 
largest investigated populations of  healthy subjects using SDF. The significant 
capillary differences in women with HELLP syndrome seem supported by a large 
effect size. Although it remains controversial whether this exploratory set-up 
allows for adjustment, significant differences remained, irrespective of  adjustment 
for confounding factors. The absence of  clinically relevant spread in the 95% 
confidence intervals of  most parameters suggest that the size of  our population 
was probably sufficient to exclude differences in sublingual microcirculation 
between healthy women and women with preeclampsia. Still, the populations 
remain small and this study should merely be viewed as an exploratory analysis. 
Our results certainly need further confirmation in a larger trial, separating women 
with and without HELLP syndrome, and preferably before any intervention.
Conclusion. Sidestream dark-field (SDF) imaging is a promising technique for 
the study of  microcirculatory perfusion in obstetrics. Our study indicates that 
there are no major differences in sublingual microcirculatory perfusion between 
women with severe preeclampsia and healthy pregnant controls; however, HELLP 
syndrome is associated with an impairment of  all aspects of  capillary perfusion.
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SUPPLEMENTARY DATA
Appendix S1. Description of  local clinical management protocol for severe pre-
eclampsia. 
Antihypertensive therapy with oral medication aimed at blood pressure control 
within safety limits. Intravenous nicardipine was started in case of  hypertensive 
emergency (systolic blood pressure (SBP) ≥ 160 mmHg or diastolic blood 
pressure (DBP) ≥ 110 mmHg). Magnesium sulphate was administered for seizure 
prophylaxis in women with hypertensive emergencies, with signs and symptoms of  
imminent eclampsia or with HELLP syndrome. Fetal lung maturation as induced 
with steroids before 34 weeks. No steroid treatment for HELLP syndrome or 
plasma volume expansion occurred. 
Appendix S2. Description of  microcirculatory perfusion parameters and 
respective methods of  calculation.
PVD was obtained by multiplying the vessel density by the proportion of  perfused 
vessels. The calculation is based on the principle that density is proportional to 
the number of  vessels crossing 3 horizontal and 3 vertical equidistant lines drawn 
on the screen. Vessel density was calculated as the number of  vessels crossing 
these lines divided by the length of  these lines. Perfusion at the crossings was 
visually scored: 0 = absent flow, 1 = intermittent flow or 2 = continuous flow. The
proportion of  perfused vessels was calculated as follows: 100 × (total number of  
vessels – (no flow + intermittent flow)) / total number of  vessels. PVD is a good 
reflection of  functional capillary density. For the calculation of  MFI an SDF clip 
was divided in 4 quadrants. The predominant type of  flow, characterised as absent, 
intermittent, sluggish, normal or hyperdynamic, was determined in each quadrant 
and averaged for all three measurements. The MFI describes the predominant 
flow pattern of  the microcirculatory perfusion. Finally, heterogeneity of  
microcirculatory perfusion was calculated from the MFI scores of  each quadrant 
of  all three sublingual recordings by subtracting the lowest score from the highest 
score divided by the mean score.
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ABSTRACT
Background. Epidemiological studies demonstrate that fetal growth restriction 
and low birth weight affect long-term health. Derangements in tissue-specific 
epigenetic programming of  fetal and placental tissues are a suggested underlying 
mechanism of  which DNA methylation is best understood. DNA methylation 
has been mostly investigated in DNA from white blood cells. To improve baseline 
understanding of  tissue-specific DNA methylation, we examined variation in 
DNA methylation profiles of  the imprinted fetal growth genes IGF2 and H19 in 
three different tissues from the same newborn obtained at the same time.
Findings. We obtained DNA from umbilical cord blood mononuclear cells 
(MNC), i.e., CD34+ and CD34- (n = 6), the fetal side of  the placenta (n = 5) and 
umbilical cord Wharton jelly (n = 5). DNA methylation of  IGF2 differentially 
methylation region (DMR) and H19 DMR was measured using quantitative mass 
spectrometry. ANOVA testing showed no statistical difference between total mean 
methylation of  CD34+ and CD34- MNC. Further comparisons were made with 
the pooled total MNC fraction. Mean IGF2 DMR methylation of  Wharton jelly 
(p-value 0.001) was 1.3 times higher than mean methylation of  the pooled MNC. 
Placental mean methylation was 0.8 times lower (p-value <0.001) and Wharton 
jelly 0.9 times lower (p-value <0.001) than the pooled MNC of  H19 DMR.
Conclusion. Our study shows that the total MNC fraction is a rather 
homogeneous cell population for methylation studies of  imprinted genes in 
umbilical cord blood white blood cells. However, these blood cells may not always 
reflect the methylation levels of  IGF2 and H19 in other organs.
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BACKGROUND
The prenatal period is critical for adverse pregnancy outcome and chronic diseases 
in adulthood 103. Epigenetic programming of  fetal and placental tissues is a suggested 
underlying mechanism, of  which DNA methylation is best understood 26, 104. 
 DNA methylation profiles are tissue-specific in somatic and germ line 
tissues 26, 105, 106. This is important in the tissue-specific regulation of  cellular 
differentiation and lineage maintenance 107-109. However, human methylation 
profiles are mostly performed in DNA from an easily accessible, heterogeneous 
white blood cell population. DNA methylation studies often select imprinted loci 
as candidate genes, because DNA methylation levels at these loci were assumed to 
be comparable in different tissues. Recent literature, however, has questioned this 
assumption 26, 110, 111. The imprinted IGF2-H19 gene complex, involved in placental, 
embryonic and fetal growth and development, has been described extensively in 
this context. Both genes are located near each other and are reciprocally imprinted 
112. It was demonstrated in mice that placental Igf2 knockout results in fetal growth 
restriction, whereas H19 silencing leads to fetal overgrowth 113, 114. In human, the 
phenotype related to the silencing of  IGF2 is Silver Russell Syndrome and H19 
silencing is related to Beckwith Wiedemann Syndrome 110. 
 From this background, we aimed to improve the baseline understanding 
of  tissue-specific variation in DNA methylation profiles of  the imprinted genes 
IGF2 and H19, and therefore examined umbilical cord blood mononuclear cells 
(MNC), placental tissue and Wharton jelly derived from the umbilical cord. 
The rationale for selecting these tissues is that they are easily accessible, MNC 
consist of  a rather homogeneous population of  white blood cells, and placental 
and umbilical cord tissues are involved in fetal programming and development. 
Moreover, morphological abnormalities in these tissues are related to pregnancy 
complications, in which epigenetic derangements might be involved 22, 62, 63, 66. 
To examine a possible methylation difference between MNC subpopulations, 
CD34+ and CD34- fractions were also analysed separately.
MATERIALS AND METHODS
Maternal, pregnancy and child characteristics. In this study we analysed 
samples of  6 pregnancies. Median maternal age was 30.5 years (range: 23.8-37.3) 
and median parity was 0.5 (0-2). All pregnancies were uncomplicated, except 1 
gestational hypertension (peak blood pressure: 140/90 mmHg). Deliveries were 
at term and spontaneously, median birth weight was 3,303 grams (2,795-3,975). 
2 Out of  6 newborns were male. Samples were collected after written informed 
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consent was obtained before delivery at the Erasmus MC, University Medical 
Centre Rotterdam, the Netherlands. Ethical approval was given by the Erasmus 
MC, University Medical Centre Research Ethics Board (MEC-2004-227). 
Sample collection. Immediately after delivery of  the newborn with the placenta 
still in situ, umbilical cord blood (n = 6) was collected in cord blood collection 
bags containing 21 mL anticoagulant Citrate Phosphate Dextrose-solution (CPD). 
Placenta (n=5) and umbilical cord (n=5) were collected within 10 minutes after 
delivery of  the placenta. Samples of  0.5 cm3 were taken from the fetal side of  
the placental villi at 4 different sites in a 3 cm radius around the umbilical cord 
insertion, after carefully removing the membranes and 2 mm of  the top placental 
layer. Wharton jelly from the umbilical cord was isolated in pieces of  0.5 cm2 
avoiding the umbilical cord vessels. Tissues were frozen immediately in liquid 
nitrogen and stored at -80°C until DNA extraction. All samples were collected 
by two researchers.
Blood cell separation. Umbilical cord blood was processed within 48 hours 
after collection. Using Ficoll gradient centrifugation, the MNC fraction was 
obtained and washed. CD34+ MNC were isolated from this pool by magnetic-
activated cell separation (MACS) using “Direct CD34 Progenitor Cell Isolation 
Kit” (MACS Miltenyi Biotec, 130-046-702) according to manufacturer’s protocols. 
The remaining cells were collected and further analysed as CD34- MNC. 
DNA extraction. Placental and Wharton jelly tissues were grinded on liquid 
nitrogen and lysed overnight at 55°C using cell lysis buffer. Subsequently, 
genomic DNA was extracted from all tissues using the Gentra Puregene Tissue 
Kit (Qiagen, Hilden, Germany), following manufacturer’s instructions. 
DNA methylation measurement. The amplicons for IGF2 and H19 were 
described previously 115. The amplicon for IGF2 is located in the IGF2 DMR, 
TABLE 1. Characteristics of  primers per gene
Forward Primer Reverse Primer Base pair length (bp) Position CpG sites (no.)
IGF2 
DMR 
aggaagagagTGGATAGG 
AGATTGAGGAGAAA
cagtaatacgactcactatagggagaa 
ggctAAACCCCAACAAAAA 
CCACT
338 Chr. 11: 
2169458-
2169796
7
H19 
DMR
aggaagagagGGGTTTGG 
GAGAGTTTGTGAGGT
cagtaatacg actcactatagggagaagg 
ctATACCT ACTACTCCCTA 
CCTACCAAC
413 Chr. 11: 
2019371-
2019784
20
NCBI build: 37. Tags in lower case
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upstream of  exon 1 of  IGF2. For H19, the amplicon partly overlaps a CpG island, 
which is part of  the H19 DMR, upstream of  exon 1 of  H19. Table 1 shows the 
location, length and primers of  the amplicons. Firstly, the amplicons were tested 
on a standard curve constructed from DNA with low and high methylation 
(EpigenDx, Worcester, MA, USA) at stages of  10% methylation difference. Only 
amplicons with a good distribution of  the methylation percentages were used for 
measurements of  the samples. 
 Isolated genomic DNA (500 ng) was treated with sodium bisulphite 
for 16 hours using the EZ-96 DNA methylation kit (Shallow) (Zymo Research, 
Irvine, CA, USA). This was followed by PCR amplification, reverse transcription, 
fragmentation and analysis on a mass spectrometer (Sequenom, Inc, San Diego, 
USA). This generated mass signal patterns that were translated into quantitative 
DNA methylation levels per CpG site by Mass ARRAY EpiTYPER Analyzer 
software (v1.0, build1.0.6.88 Sequenom, Inc, San Diego, USA) 116. Fragments 
containing one or more CpG sites were called CpG units. Measurements were done 
in triplicate on DNA from the same bisulphite-treatment batch on different PCR-
plates. On every bisulphite plate, standard DNA with low, 25%, 50%, 75% and high 
methylation was included. 
Data cleaning. During quality control (QC), CpG units with a very low mass or 
very high mass or CpG units with overlapping RNA fragments were excluded from 
further analysis. Two out of  three of  the replicate measurements per CpG unit had 
to be successful, and the standard deviation (SD) of  the duplicates or triplicates had 
to be ≤0.10 to be included in the statistical analysis. CpG units with interference 
of  single-nucleotide polymorphisms were also excluded (dbSNP134). After QC, 3 
CpG units for IGF2 DMR and 9 for H19 DMR remained for further analysis.
Statistical analysis. Possible batch-effects were ruled out by comparing means 
of  the standards per bisulphite-plate and PCR plate with ANOVA-testing. To 
analyse total methylation per gene and per individual CpG unit between tissues, 
ANOVA-testing was used, followed by pair-wise comparisons. We adjusted the 
total methylation per gene for the number of  CpG units. 
 We checked and confirmed the normal distribution by visual inspection 
of  the residuals. Several individual CpG sites showed significant differences in 
variance of  DNA methylation. We excluded one patient and 4 CpGs from further 
testing for H19 DMR to deal with this variation. ANOVA was finally performed on 
3 CpG units of  IGF2 DMR and 5 CpG units of  H19 DMR.
 Firstly, we analysed CD34+ and CD34- MNC separately, followed by a 
weighted pooled total MNC fraction after these 2 fractions appeared not statistically 
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differently methylated. The original CD34+ and CD34- data was pooled in a 
1:100 distribution, comparable to the biological appearance of  CD34+ cells in an 
umbilical cord blood MNC fraction. Bonferroni correction was applied to correct 
for multiple comparisons. All tests were performed using means of  the data in 
triplicate. Statistical analysis was performed in SPSS version 17.0.2. 
RESULTS
The mean methylation of  CpG sites of  the IGF2 DMR and the H19 DMR are 
depicted in Table 2. IGF2 DMR and H19 DMR methylation of  CD34+ and 
CD34- MNC were not statistically different, neither the total mean methylation 
per amplicon nor the individual CpG units. Therefore, further comparisons were 
made with the weighted pooled total MNC fraction as a reference group. The 
mean IGF2 DMR methylation of  Wharton jelly (p-value 0.001) was statistically 
significantly higher than the mean methylation of  MNC. This was similar in two 
out of  the three individual IGF2 DMR CpG units. 
 The mean H19 DMR methylation of  both placenta (p-value <0.001) and 
Wharton jelly (p-value <0.001) was statistically significantly lower than of  MNC. 
This was similar in one out of  five individual H19 DMR CpG units and only applied 
TABLE 2. Mean absolute methylation level (SD) of  the different tissues per gene 
and per CpG site
CD34+ 
MNC (SD)
CD34- MNC 
(SD)
Pooled MNC 
(SD)
placental 
tissue (SD)
Wharton 
jelly (SD)
IGF2 DMR (total) 0.55 (0.14) 0.50 (0.13) 0.50 (0.13) 0.54 (0.16) 0.65 (0.13)†*
IGF2 DMR CpG 3 0.59 (0.05) 0.52 (0.02) 0.52 (0.02) 0.59 (0.07) 0.66 (0.07)†
IGF2 DMR CpG 4 0.64 (0.18) 0.59 (0.18) 0.59 (0.18) 0.58 (0.25) 0.77 (0.11)
IGF2 DMR CpG 6.7 0.43 (0.06) 0.39 (0.03) 0.39 (0.03) 0.44 (0.03) 0.52 (0.06)†
H19 DMR (total) 0.30 (0.02) 0.31 (0.02) 0.31 (0.02) 0.25 (0.02)† 0.28 (0.03)†*
H19 DMR CpG 2 0.28 (0.01) 0.29 (0.01) 0.29 (0.01) 0.26 (0.01) 0.27 (0.04)
H19 DMR CpG 9.10 0.31 (0.01) 0.31 (0.02) 0.31 (0.02) 0.26 (0.03) 0.30 (0.04)
H19 DMR CpG 12 0.28 (0.02) 0.29 (0.01) 0.29 (0.01) 0.23 (0.02)† 0.26 (0.02)†
H19 DMR CpG 13 0.30 (0.01) 0.31 (0.01) 0.31 (0.01) 0.24 (0.01)† 0.28 (0.03)
H19 DMR CpG 17 0.34 (0.02) 0.35 (0.01) 0.35 (0.01) 0.25 (0.03)† 0.31 (0.03)*
ANOVA testing between the different tissue groups. Bonferroni correction was applied to all p-values to adjust for 
multiple comparisons. † p-value <0.05 versus pooled MNC (Pairwise comparisons), * p-value <0.05 versus placenta 
(Pairwise comparisons)
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to placenta in two other CpG units. Wharton jelly was statistically significantly higher 
methylated than placenta in IGF2 DMR (p-value 0.032) and H19 DMR (p-value 
<0.001), as well as one individual H19 CpG unit (Table 2, Figure 1).
CONCLUSION
This study provides a basic understanding of  tissue-specific variation in DNA 
methylation of  two imprinted genes in easily accessible tissues. The total 
MNC fraction of  CD34+ and CD34- appears rather homogeneous for DNA 
methylation analysis of  these genes in umbilical cord blood. The observed 
between-tissue methylation differences seem to be small and could be explained 
by either consistently higher and lower methylation, or by differences in sensitivity 
of  tissues to environmental exposures, fetal and maternal factors. This needs 
further investigation in a larger sample size and therefore only careful conclusions 
should be drawn from this data.
 Thus, umbilical cord blood MNC are useful and easily accessible to 
study associations between epigenetic programming and pregnancy course and 
outcome, but not always exactly reflect the methylation levels of  other organs.
FIGURE 1. Mean absolute DNA methylation levels per CpG site for IGF2 DMR 
and H19 DMR
Error Plots of  mean methylation levels (coloured dots) of  all individuals +/- 2 standard deviations (coloured bars) 
shown for each CpG unit for each of  the three tissues separately for (A) IGF2 DMR and (B) H19 DMR.


Early- and late-onset preeclampsia and the tissue-specific 
epigenome of the placenta and newborn
E.M. Herzog, A.J. Eggink, S.P. Willemsen, R.C. Slieker, K.P.J. Wijnands, J.F. Felix,
J. Chen, A.P. Stubbs, P.J. van der Spek, J.B. van Meurs, R.P.M. Steegers-Theunissen
Placenta, 2017. 58: p. 122-132
CHAPTER 7
EARLY- AND LATE-ONSET PREECLAMPSIA AND THE TISSUE-SPECIFIC EPIGENOME OF THE PLACENTA AND NEWBORN
108
ABSTRACT 
Introduction. Preeclampsia (PE) carries increased risks of  cardiovascular- and 
metabolic diseases in mothers and offspring during the life course. While the 
severe early-onset PE (EOPE) phenotype originates from impaired placentation 
in early pregnancy, late-onset PE (LOPE) is in particular associated with pre-
existing maternal cardiovascular- and metabolic risk factors. We hypothesize that 
PE is associated with altered epigenetic programming of  placental and fetal tissues 
and that these epigenetic changes might elucidate the increased cardiovascular- 
and metabolic disease susceptibility in PE offspring. 
Methods. A nested case-control study was conducted in The Rotterdam 
Periconceptional Cohort comprising 13 EOPE, 16 LOPE, and three control 
groups of  36 uncomplicated pregnancies, 27 normotensive fetal growth restricted 
and 20 normotensive preterm birth (PTB) complicated pregnancies. Placental 
tissue, newborn umbilical cord blood white blood cells (UC-WBC) and umbilical 
vein endothelial cells were collected and DNA methylation of  cytosine-guanine 
dinucleotides was measured by the Illumina HumanMethylation450K BeadChip. 
An epigenome-wide analysis was performed by using multiple linear regression 
models.
Results. Epigenome-wide tissue-specific analysis between EOPE and PTB 
controls revealed 5001 mostly hypermethylated differentially methylated positions 
(DMPs) in UC-WBC and 869 mostly hypomethylated DMPs in placental 
tissue, situated in or close to genes associated with cardiovascular-metabolic 
developmental pathways.
Discussion. This study shows differential methylation in UC-WBC and placental 
tissue in EOPE as compared to PTB, identifying DMPs that are associated 
with cardiovascular system pathways. Future studies should examine these loci 
and pathways in more detail to elucidate the associations between prenatal PE 
exposure and the cardiovascular disease risk in offspring.
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INTRODUCTION 
Preeclampsia (PE) is a major cause of  maternal and fetal morbidity and mortality 
and is suggested to be associated with the future risk of  cardiovascular- and 
metabolic diseases in mothers and offspring 7. Two main disease entities have 
been identified. Early-onset PE (EOPE) is the more severe phenotype originating 
from impaired placentation during the first trimester of  pregnancy; late-onset 
PE (LOPE) occurs in the third trimester mainly as a consequence of  exposure 
to pre-existing maternal cardiovascular- and metabolic risk factors 3, 11. The 
exact pathophysiology of  PE is not understood, but it is known that in EOPE 
inadequate spiral artery remodelling leads to ischaemia-reperfusion-type placental 
insults 14. This induces an excessive production of  oxidative radicals. As a result, 
pro-inflammatory cytokines are released into the maternal circulation inducing 
endothelial dysfunction that leads to the clinical symptoms of  PE 14. Excessive 
placental oxidative stressors are also produced in LOPE but more towards the 
end of  pregnancy 11. 
 PE is considered a complex disease induced by gene- and environmental 
interactions 18, 19. Altered epigenetic programming of  specific tissues, induced by 
excessive oxidative stress, has been suggested to be an underlying mechanism 
18. Impaired placental perfusion, excessive production of  oxidative radicals, 
endothelial dysfunction and immune modifications in PE may disturb epigenetic 
programming in offspring tissues as well, resulting in derangements of  the 
vascular epigenome and function in the offspring 15-17, 151. From this background 
we hypothesize that altered epigenetic programming of  especially placental tissues 
is associated with the pathogenesis of  PE (as cause or consequence) and with 
cardiovascular and metabolic risks in the offspring over the life course 22.
 Although PE has been associated with DNA methylation changes of  
candidate genes in placental and newborn tissue, only a few epigenome-wide 
association studies (EWAS) have found new loci of  interest and most of  these did 
not examine multiple tissues per patient 25, 152-156. In this study we examined tissue-
specific genome-wide DNA methylation of  umbilical cord white blood cells (UC-
WBC), placental tissue and human umbilical cord endothelial cells (HUVEC) in 
relation to EOPE and LOPE. 
 Considering that PE is complicated by fetal growth restriction (FGR) 
in 12 % of  cases and associated with iatrogenic preterm birth (PTB) in 20 %, 
which are conditions that can independently affect epigenetic programming, we 
examined the epigenome of  PE and uncomplicated controls but also that of  
controls complicated by FGR and PTB 34-36.
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MATERIALS AND METHODS 
Study design. Pregnant women and their newborn babies were recruited between 
June 2011 and June 2013 in a nested case-control study embedded in The Rotterdam 
Periconceptional Cohort (Predict study), at the Erasmus MC, University Medical 
Centre Rotterdam, the Netherlands 32. Cases comprised of  EOPE and LOPE, 
and unmatched controls comprised of  uncomplicated pregnancies and FGR and 
PTB complicated pregnancies. Patients were recruited for our case-control study 
by two different pathways. The first pathway contains subjects that were included 
in the Predict study in the first trimester and developed PE later in pregnancy. The 
second pathway contains subjects that were admitted to our hospital because of  
PE after the first trimester, and were specifically recruited in the Predict Study for 
our case-control study. This also applies to our (un)complicated control groups. 
Maternal and fetal characteristics. PE was defined according to the International 
Society for the Study of  Hypertension in Pregnancy as gestational hypertension 
of  at least 140/90 mmHg accompanied by a urine protein/creatinine ratio of  
≥ 30 mg/mmol arising de novo after the 20th week of  gestation 44. EOPE and 
LOPE were defined as being diagnosed before and after 34 weeks of  gestation, 
respectively 45. Uncomplicated pregnancies were defined as pregnancies without 
the following pregnancy-specific complications: PE, gestational hypertension, 
FGR or PTB. FGR was defined as an estimated fetal weight below the 10th 
percentile for gestational age based on ultrasound measurements performed 
between 20 and 38 weeks gestational age 46. Birth weight percentiles were 
calculated using the reference curves of  the Dutch Perinatal Registry to validate 
birth weight < 10th percentile 47. Spontaneous preterm deliveries between 22 
and 37 weeks of  gestation were defined as PTB 48. Women with HIV infection, 
aged < 18 years, not able to read and understand the Dutch language, multiple 
birth pregnancies or women with pregnancies complicated by fetal congenital 
malformations were excluded. 
 Maternal and newborn characteristics were obtained from hospital 
medical records. All women gave written informed consent before participation 
and parental informed consent was obtained for the child. The research has been 
carried out in accordance with the Declaration of  Helsinki (2013) of  the World 
Medical Association.
Data collection. UC-WBC samples from the umbilical vein were collected with 
the placenta still in situ. Thereafter, placental tissue was obtained and HUVEC 
were isolated and stored until DNA extraction. A detailed description of  the 
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data collection, UC-WBC processing, HUVEC isolation and DNA extraction is 
provided in Appendix 1.  
DNA methylation measurement. Isolated genomic DNA (500 ng) was 
treated with sodium bisulphite using the EZ-96 DNA methylation kit (Shallow) 
(Zymo Research, Irvine, CA, USA). Hybridization was performed following 
manufacturer’s instructions. DNA methylation of  CpGs was measured by the 
Illumina HumanMethylation450K BeadChip using the manufacturer’s protocol 
(Illumina, Inc., San Diego, CA, USA) 138-140. Data quality control and pre-
processing is described in Appendix 2. 
Differentially methylated position (DMP) identification. To improve 
statistical power, prior to further statistical analysis a selection of  probes containing 
at least ≥0.05 SD variability in methylation β-values across all samples was applied 
for each tissue separately 157. This resulted in a remaining total of  43,488 UC-
WBC probes, 134,700 placental probes and 42,352 HUVEC probes. Methylation 
β-values were converted to M-values using: M-value = log2 (β-value/(1-β-value)) 
143. A multiple linear regression model was used predicting methylation M-values 
by disease state for EOPE and LOPE versus (un)complicated controls, adjusted 
for bisulphite-plate batch and gestational age as covariates for each tissue 
separately (R package ‘CpGassoc’). Sensitivity analyses were performed for the 
following covariates: batch-effect of  the bisulphite-plate, gestational age, birth 
weight, fetal gender, comorbidity, mode of  delivery and moment of  inclusion 
for the study in or >1st trimester. Only gestational age and bisulphite-plate were 
thereafter included in our statistical model as potential confounders.
 UC-WBC analyses were performed with additional adjustment for total 
number of  UC-WBC leucocytes (x109/L), available from our flow-cytometric 
data (n=61, 70 %) or otherwise imputed (n=27, 30 %) 158. Missing leucocyte 
numbers were imputed by ‘Multiple Imputations with Chained Equations’ 
using other available UC-WBC variables and all contributing maternal and 
fetal characteristics with maternal age2 as the best predictive variable (package 
mice) 159. Additionally, Houseman-data was applied during imputation, further 
predicting proportions of  lymphocytes, monocytes and granulocytes based 
on a community cohort of  94 non-diseased, non-smoking, predominantly 
female individuals between 24 to 45 years old, which improved the Akaike 
Information Criterion by 11 124. Imputed leucocyte concentrations are given in 
Supplementary table 1. Due to sample size constraints we could not adjust for 
further differentiated white blood cell counts. 
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FIGURE 1. Overview of  the study population and sample distribution.
EOPE early-onset preeclampsia; LOPE late-onset preeclampsia; FGR fetal growth restriction; PTB preterm birth; 
UC-WBC umbilical cord white blood cells; HUVEC human umbilical vein endothelial cells; no. number of.
We used the following model: 
Mi = β0 + β1G + β2GA + β3PLATE2 + β4PLATE3 + (+5UC-WBC-leucocytes) + εi. 
where Mi is the (base 2) logit of  the methylation of  individual i. G is the group 
indicator variable (that is one if  the sample corresponds to EOPE or LOPE and 
zero otherwise), GA is gestational age and PLATE2 and PLATE3 are indicator 
variables for the sample plates. β5 is only applied for the UC-WBC analysis. εi is 
the residual error assumed to derive from a normal distribution.
 A False Discovery Rate (FDR) adjusted p-value below 0.05 was 
considered significant. CpG sites were classified as DMP if  statistically significant 
and presenting with a minimal effect-size ΔM of  0.8. We considered various 
M-value cut-off  values for further data analysis and applied the widely used 
robust cut-off  of  12.5 % ∆β (~ 0.8 on M-value scale) (Supplementary table 2, 
Supplementary figure 2) 145, 153. For the comparison with the smallest number of  
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samples (n=8 HUVEC samples in EOPE), we were able to measure methylation 
differences of  at least 10% ∆β or higher, with a power of  0.7 (sd of  0.05 and 
FDR<0.05). An arbitrary selection of  100 epigenome-wide significant hits was 
subjected to a critical assessment of  M-value plots to exclude potential outlier-
driven hits or residual single nucleotide polymorphism-interference.
 A detailed description of  the DMP CpG-density- and gene-centric 
enrichment analysis, Gene Ontology (GO) term enrichment analysis and 
Ingenuity Pathway Analysis (IPA) is provided in Appendix 3. 
RESULTS
All eligible pregnancies that met the inclusion criteria and provided sufficient 
tissues were included for the case-control analysis. After exclusion of  2 
misclassified pregnancies the final study population consisted of  112 pregnancies. 
The 29 PE pregnancies comprised of  13 EOPE and 16 LOPE pregnancies, and 
controls included 36 uncomplicated and 27 FGR- and 20 PTB complicated 
control pregnancies (Figure 1). This number of  patients is a result of  the initially 
aimed number of  25 samples per tissue per case-control group. Because we were 
unable to collect this exact amount of  samples and because we obtained often 
more samples from one patient, the number of  corresponding patients differs for 
each case-control group.
 Maternal and newborn characteristics are shown in Table 1. In 
addition to significantly different PE-specific parameters, such as blood pressure, 
proteinuria, gestational age and birth weight, nulliparity was more frequent in 
EOPE (84.6 %) and LOPE (81.3 %) than in uncomplicated controls (30.6 %, 
overall p = 0.001). Caesarean section was more frequent in EOPE (84.6 %) than 
in both LOPE (31.3 %) and (un)complicated controls (20.0-33.3 %, overall p = 
0.002). In the EOPE group, one pregnancy was complicated by FGR (7.7 %) and 
all by PTB; in the LOPE group, three pregnancies (18.8 %) were complicated by 
FGR (p = 0.606, in comparison to the EOPE group) and three (18.8 %) by PTB 
(p <0.001, in comparison to the EOPE group).
DMP identification. Genome-wide DNA methylation data revealed an overall 
bimodal distribution for UC-WBC and HUVEC (Figure 2). In these tissues, 
only a small amount of  cytosine-guanine dinucleotides (CpGs) demonstrated 
methylation levels around 50 %. In placental tissue however, more CpGs presented 
50 % methylation levels. Methylation levels in placental tissue and HUVEC were 
comparable in all groups, but in EOPE the methylation levels in UC-WBC clearly 
deviated from those in all other groups.
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TABLE 1. Maternal and newborn characteristics 
Complicated controls
EOPE LOPE
Uncomplicated 
controls
Normoten-
sive FGR
Normotensive
PTB Overall
Maternal characteristics (n=13) (n=16) (n=36) (n=27) (n=20) p-value
Age (years) 30.0 (4.7) 33.3 (4.5) 31.8 (5.1) 29.7 (6.0) 31.0 (5.1) 0.187
Nulliparous, n (%) 11 (84.6) 13 (81.3) 11*# (30.6) 17 (63.0) 10 (50.0) 0.001
Caesarean section, n (%) 11 (84.6) 5* (31.3) 10* (27.8) 9* (33.3) 4* (20.0) 0.002
Ethnicity, n (%)                  
Western geographic origin 12 (92.3) 9 (56.3) 30 (83.4) 17 (63.0) 18 (90.0) 0.074
Non-Western geographic origin 1 (7.7) 7 (43.8) 6 (16.7) 10 (37.0) 2 (10.0)
Preconception BMIa (kg/m2) 24.7 (10.1) 24.1 (4.4) 23.7 (4.8) 23.0 (6.5) 23.8 (6.1) 0.668
Smoking during pregnancy 
(yes), n (%)
2 (18.2) 0 (0.0) 0 (0.0) 2 (8.0) 2 (10.5) 0.132
Co-morbidity (yes), n (%) 1 (7.7) 7 (43.8) 8 (22.2) 7 (25.9) 4 (20.0) 0.260
Newborn characteristics
Male gender, n (%) 3 (23.1) 7 (43.8) 21 (58.3) 15 (55.6) 10 (50.0) 0.253
Gestational age at birtha 
(weeks) 
30.7 (3.4) 37.4* (1.9) 39.9*# (1.9) 38.9* (2.6) 35.4*# (7.9) <0.001
Birth weighta (grams) 1,185 (481) 3,183* (1244) 3,713*# (551) 2,630*# (595) 2,660*# (1805) <0.001
Birth weight <10th percen-
tile, n (%)
1 (7.7) 3 (18.8) 0# (0.0) 27*# (100.0) 0 (0.0) <0.001
Data are presented as mean (standard deviation) with corresponding ANOVA testing to examine overall differences 
between the groups, followed by the post hoc Dunnett t-test for pairwise comparisons of  EOPE and LOPE with 
(un)complicated controls. 
Data are presented as number (%) with corresponding Chi2/Fischer’s exact testing. 
a Non-parametric data are presented as median (interquartile range) with corresponding Kruskall-Wallis testing and 
posthoc Mann-Whitney testing. 
* p <0.05 versus EOPE pregnancies. # p <0.05 versus LOPE pregnancies. 
ANOVA analysis of  variance; BMI body mass index; EOPE early-onset preeclampsia; LOPE late-onset preeclamp-
sia; FGR fetal growth restriction; PTB preterm birth.
 A heatmap based on the clustering of  methylation according to CpG 
and sample depicts prominent clustering of  the three different tissues (Figure 
3A). We therefore also examined clustering per tissue, which demonstrated 
EOPE clustering in UC-WBC but no clustering in the placental- and HUVEC 
samples (Figure 3B-D). This was validated by a principal component analysis 
(PCA) (Supplementary figure 1).
 Differences between EOPE, LOPE and (un)complicated controls were 
examined in an epigenome-wide analysis. In the comparison of  EOPE and PTB we 
found 12,040 (28 %) differentially methylated CpGs in UC-WBC and 5,668 (0.5 %) 
differentially methylated CpGs in placenta. One differentially methylated CpG each 
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was found in the comparison of  EOPE and uncomplicated controls in placental 
tissue and in HUVEC, and in the comparison of  EOPE and FGR in placental tissue 
(all FDR-adjusted p <0.05). No epigenome-wide significant CpGs were found in 
the comparisons of  LOPE and (un)complicated controls. Differentially methylated 
CpGs with an effect size > 0.8 in M-value (logit2 of  the β-value), representing an 
approximate change in β-value of  12.5 %, were defined as differentially methylated 
positions (DMPs), which left 5,001 DMPs in UC-WBC and 869 DMPs in placenta 
in EOPE compared to PTB (Supplementary table 2). 25 DMPs are overlapping 
between UC-WBC and placenta, which corresponds to 152 shared genes between 
UC-WBC and placenta. In UC-WBC, 71 % of  DMPs were hypermethylated; in 
contrast, hypomethylation was seen in 67 % of  the placental DMPs. Of  the shared 
set of  DMPs, 13 (52%) share the same methylation direction in both tissues and 54 
(36%) genes are overlapping in methylation direction (Figure 4). All (overlapping) 
UC-WBC and placental DMP identifiers are listed in Supplementary table 3.
CpG-density- and gene-centric enrichment of  DMPs. To evaluate whether 
DMPs were enriched in certain genomic annotations, CpG island- and gene-
centric annotations of  UC-WBC- and placental DMPs were examined (Figure 5 
and Supplementary table 4). DMP enrichment analysis relative to CpG islands 
revealed exactly opposite patterns for UC-WBC and placental DMPs with the 
strongest enrichment in non-CpG island regions and strongest depletion in 
CpG islands in UC-WBC (ORUC-WBC 1.61, 95 % CI 1.52-1.71 and ORUC-WBC 0.23, 
95 % CI 0.20-0.26, respectively) versus strongest enrichment in CpG island 
regions and strongest depletion in non-CpG islands in placenta (ORPlacenta 1.33, 
95 % CI 1.15-1.54 and ORPlacenta 0.72, 95 % CI 0.62-0.83, respectively) (Figure 
5 and Supplementary table 4).
 The location of  DMPs relative to genes revealed the strongest enrichment 
in gene bodies with additional high enrichment in downstream regions of  the 
placenta. A strong depletion of  DMPs in intergenic regions was observed in both 
UC-WBC and placental tissue (ORUC-WBC 0.53, 95 % CI 0.49-0.58, ORPlacenta 0.63, 
95 % CI 0.53-0.75).
Gene-ontology (GO) term enrichment of  DMP genes. To gain more insight 
in functionality, the DMPs were mapped to the nearest gene. This yielded 
3,444 unique UC-WBC genes and 697 unique placental genes. The 3,444 UC-
WBC DMP genes mapped to 2,744 genes in The Database for Annotation, 
Visualization and Integrated Discovery (DAVID) after discarding the remaining 
DMP annotations as transcripts. These genes were enriched for involvement 
in cell signalling processes and regulation of  cell death, gene expression, 
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FIGURE 2. Density plot of  β-values per tissue and per group. 
Density plots show the β-value-densities for UC-WBC (A), placenta (B) and HUVEC (C). Genome-wide DNA 
methylation data revealed an overall bimodal distribution of  methylation levels. In addition, the placenta demon-
strated a larger amount of  CpGs with methylation levels around 50%, in contrast to the other tissues. In UC-WBC, 
EOPE deviates from LOPE and (un)complicated control pregnancies.
EOPE early-onset preeclampsia; LOPE late-onset preeclampsia; FGR fetal growth restriction; PTB preterm birth; 
UC-WBC umbilical cord white blood cells; HUVEC human umbilical vein endothelial cells; CpGs cytosine-guanine 
dinucleotides. 
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FIGURE 3. Heatmap based on clustering of  methylation (β-value) of  all differentially 
methylated CpGs.
Heatmap plots show 
the clustering results 
of  the EWAS using all 
significant CpGs in all 
tissues (A), UC-WBC 
samples (B), placental 
samples (C) and 
HUVEC samples (D). 
Samples are plotted on 
the horizontal axis and 
CpGs on the vertical 
axis. Samples cluster 
between the different 
tissues (A) and between 
EOPE and the (un)
complicated control 
groups in UC-WBC 
samples (B). β-values 
are depicted for a better 
biological understanding 
of  the figure.
EOPE early-onset 
preeclampsia; LOPE 
late-onset preeclampsia; 
FGR fetal growth 
restriction; PTB preterm 
birth; UC-WBC 
umbilical cord white 
blood cells; HUVEC 
human umbilical vein 
endothelial cells. 
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samples
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RAS-activity, inflammatory responses and erythrocyte development. After 
excluding those DMPs that were mapped to transcripts instead of  genes, DAVID 
mapped 536 placental DMP genes and revealed enriched GO term involvement 
in embryogenesis, regulation of  transcription and cellular differentiation. UC-
WBC and placental highest enriched GO terms are presented in Table 2.
Ingenuity Pathway Analysis (IPA) of  DMP genes. We applied IPA to validate 
the GO findings from DAVID. Ingenuity software mapped 3,011 UC-WBC DMP 
genes and a canonical pathway analysis identified enrichment of  top-ranked 
pathways all involved in cascade-signalling mechanisms. We further conducted 
network analyses, which revealed that the top networks were mainly associated 
with cardiovascular system development, cellular function and development, 
haematological system development and infectious diseases. 
 596 placental DMP genes were mapped by Ingenuity, of  which 
enriched canonical pathways did not reach statistical significance. The top ten 
enriched networks were mainly associated with embryonic development, cellular 
development, regulation of  gene expression, cardiovascular system development, 
Red circles display the number of  hypermethylated DMPs relative to PTB (+), green circles display the number of  
hypomethylated DMPs relative to PTB (-). UC-WBC umbilical cord white blood cells; DMPs differentially methylat-
ed positions; EOPE early-onset preeclampsia; PTB preterm birth; no. number of.
FIGURE 4. Venn diagram of  the number of  (overlapping) UC-WBC- and placental 
DMPs in EOPE compared with PTB complicated pregnancies.
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cell death and survival and haematological system development. The highest 
enriched pathways and networks are presented in Table 3.
DISCUSSION
In this study we demonstrate significant differences in genome-wide UC-WBC and 
placental DNA methylation between EOPE and PTB controls but not between 
EOPE and FGR controls or uncomplicated controls. Significant differences were 
also not found between LOPE and all other (un)complicated control pregnancies. 
EOPE differential methylation in comparison to PTB, in UC-WBC and 
placental tissue. Our most evident observation was the large difference in the 
level of  differential methylation observed in EOPE but not in LOPE. This may 
be best explained by the excessive oxidative stress exposure in EOPE and LOPE 
pregnancies, suggested to be highly involved in the disturbance of  epigenetic 
programming 15. In response to various forms of  stress, cells increase the production 
of  important protective proteins while reducing the translation of  other less 
relevant proteins to restore cellular homeostasis 12. We observed both hyper- and 
A. DMP annotation relative to CpG islands showed exactly opposite patterns for UC-WBC as compared to placental 
DMPs with the strongest enrichment in non-CpG island regions and strongest depletion in CpG islands in UC-WBC 
versus strongest enrichment in CpG island regions and strongest depletion in non-CpG islands in placenta.
B. DMP annotation relative to genes, revealed strongest enrichment in gene body regions, with additional high en-
richment in downstream regions of  the placenta. A strong depletion of  DMPs in intergenic regions was observed 
in both UC-WBC and placental tissue.
* p<0.05. UC-WBC umbilical cord white blood cells; EOPE early-onset preeclampsia; PTB preterm birth; non-CGI 
non-CpG island; DMP differentially methylated position. 
FIGURE 5. UC-WBC- and placental- DMP enrichment in the CpG-density (A) 
and gene-centric (B) annotation, in EOPE compared to PTB complicated preg-
nancies.
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TABLE 2. Top 10 DAVID GO Functional annotation clusters of  EOPE UC-WBC- 
and placental DMP nearest genes
UC-WBC- and placental DMPs in EOPE were mapped to the nearest gene using Ensembl annotations from UCSC 
database. Assigned Ensembl genes were uploaded to the DAVID tool to examine possible enrichment of  corre-
sponding GO terms using the GO_BP_FAT annotation category. Fisher Exact was applied to measure the gene-en-
richment of  annotated GO terms of  the uploaded gene list, against the whole human genome list as a background. 
To focus on the biology of  the annotated GO terms, clusters of  similar annotations were examined from the 
DAVID Functional annotation Clustering table tool. The clustering algorithm is based on the hypothesis that similar 
annotations have similar gene members, resulting in a Group Enrichment Score to rank their biological significance, 
which is based on the Fisher Exact p-values of  each GO term within the cluster. The higher the enrichment score, 
the more enriched.
DMPs differentially methylated positions; DAVID Database for Annotation, Visualization and Integrated Discovery; 
GO-term, gene-ontology term; HUVEC human umbilical vein endothelial cells.
UC-WBC Enrichment score
1. Phosphorylation 4.6
2. Programming of cell death 3.9
3. Cytoskeleton organization 3.9
4. Positive regulation of gene expression 3.6
5. Regulation of RAS (GTPase) activity 3.3
6. Endocytose 2.8
7. Regulation of phosphate metabolic process 2.7
8. Defence/inflammatory response 2.4
9. Erythrocyte differentiation and development 2.1
10. Regulation of endocytosis and phagocytosis 2.0
Placenta Enrichment score
1. Embryonic development 7.3
2. Regulation of transcription 7.2
3. Neuron development 6.3
4. Embryonic morphogenesis 5.7
5. Positive regulation of transcription 4.9
6. Negative regulation of transcription 4.2
7. Embryonic morphogenesis 4.1
8. Respiratory development 3.9
9. Regulation of cell differentiation and development 3.5
10. Embryonic development: dorsal/ventral pattern formation 3.4
hypomethylation in association with EOPE in UC-WBC and placenta tissue, and 
enrichment of  both positive and negative regulation of  transcription among the 
functional annotations of  DMP genes, in line with these cellular stress responses. 
Moreover, if  cellular stress responses fail or a sudden excessive stress event occurs, 
cellular death might occur, through apoptosis or necrosis 13. Also this cellular 
death- and survival pathway was identified among the DMP gene functional 
annotations, underlining the potential involvement of  excessive oxidative stress. 
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TABLE3. Top 10 Ingenuity networks and pathways of  EOPE UC-WBC- and 
placental DMP nearest genes
UC-WBC Canonical pathways                                                                                         -log p-value 
1. Molecular Mechanisms of Cancer 4,49
2. Tec Kinase Signalling 4,37
3. Relaxin Signalling 4,37
4. IL-1 Signalling 4,00
5. Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 3,87
6. PPAR Signalling 3,78
7. Renal Cell Carcinoma Signalling 3,74
8. G Beta Gamma Signalling 3,67
9. G-Protein Coupled Receptor Signalling 3,67
10. HGF Signalling 3,49
UC-WBC networks Score
1. Cardiovascular System Development and Function, Lymphoid Tissue Structure and De-
velopment, Cell Morphology
29/35
2. Cardiovascular System Development and Function, Tissue Morphology, Cellular Movement 26/34
3. Cell Cycle, Cellular Development, Haematological System Development and Function 24/33
4. Connective Tissue Disorders, Developmental Disorder, Skeletal and Muscular Disorders 24/33
5. Cancer, Organismal Injury and Abnormalities, RNA Post-Transcriptional Modification 24/33
6. Cardiovascular Disease, Cellular Compromise, Organismal Injury and Abnormalities 23/32
7. Infectious Diseases, Antigen Presentation, Protein Synthesis 23/32
8. RNA Damage and Repair, Post-Translational Modification, Cellular Development 23/32
9. Cell Morphology, Cellular Function and Maintenance, Infectious Diseases 23/32
10. Cancer, Organismal Injury and Abnormalities, Reproductive System Disease 23/32
placental networks Score
1. Embryonic Development, Hereditary Disorder, Neurological Disease 45/32
2. Cellular Development, Cellular Growth and Proliferation, Organismal Development 36/28
3. Gene Expression, Cancer, Organismal Injury and Abnormalities 36/28
4. Cell Cycle, Cellular Movement, Developmental Disorder 30/25
5. Cardiovascular System Development and Function, Cellular Movement, Carbohydrate Metabolism 25/22
6. Molecular Transport, Inflammatory Response, Haematological System Development and Function 14/15
7. Metabolic Disease, Organismal Injury and Abnormalities, Respiratory Disease 12/14
8. Cellular Development, Cellular Growth and Proliferation, Cellular Movement 12/14
9. Cell Death and Survival, Cell Cycle, Cellular Assembly and Organization 12/14
10. Cell Death and Survival, Cardiovascular System Development and Function, Cell Morphology 12/14
Ingenuity pathway analysis was performed with the annotated UC-WBC- and placental DMP Ensembl gene lists in EOPE 
with focus on canonical pathways and networks. Enriched canonical pathways were calculated using the Fisher's Exact 
test and subjected to Benjamini-Hochberg procedure for controlling FDR (p<0.05). Networks were generated based on 
network eligible molecules, which were encoded by our DMP genes and also interact with other molecules in the Ingenuity 
Pathways Knowledge Base. A high score for a network indicates a more approximate fit between network eligible molecules 
and the molecules that constitute the network, calculated using the right-tailed Fisher's Exact Test. No significant EOPE 
placental canonical pathways were observed.
DMPs differentially methylated positions; HUVEC human umbilical vein endothelial cells; FDR, false discovery rate.
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 From our data it appears that oxidative stress may have more 
consequences for EOPE pregnancies, where placental and newborn tissues are 
indeed subjected to this adverse exposure from early pregnancy onwards. In 
EOPE, chorionic villi are exposed to oxidative stress at 8-9 weeks of  gestation 
through contact with maternal oxygenated blood due to early unplugging of  
spiral arteries, disturbing the formation of  the definitive placenta by restricted 
invasion and impaired remodelling of  spiral arteries 12. One might hypothesize 
that the epigenetic programming involved in this initial placental formation 
and differentiation is in fact already affected, perhaps inducing the further 
development of  EOPE, rather than being a consequence of  the disease. We 
suggest that perhaps the very initial process of  epigenetic reprogramming 
between fertilisation and formation of  the blastocyst is already affected in 
EOPE, explaining the observed extensive involvement of  placental DMPs 
and also suggesting a more causative epigenetic involvement. In general, 
impaired placentation seems to play a much larger role in the pathophysiology 
of  EOPE than LOPE, with more adverse consequences for the fetus, such 
as FGR, supporting the current results 11. Also the maternal and fetal pro-
inflammatory milieu is more pronounced in EOPE than in LOPE, with more 
potential consequences for UC-WBC epigenetic programming, as substantiated 
by our data 15.
 Although we would have expected to establish some degree of  
differential methylation in LOPE, the lack of  differential methylation is in 
accordance to previous literature 152, 153, 160-162. Only Zhu et al. identified DMRs in 
placental tissue of  severe LOPE pregnancies as compared to that of  gestational 
age- and parity-matched controls. They however used different techniques 
(DNA immunoprecipitation and deep sequencing) and included only severe 
cases of  LOPE, potentially explaining the discrepancy with our findings 156. 
 A possible reason for observing associations between EOPE and 
PTB only, is that these two groups are least affected by a larger gestational 
age range and additional comorbidity and hence easier to compare than the 
other control groups. The lack of  any significantly differential methylation in 
HUVEC obtained from EOPE pregnancies might be partly explained by the 
decreased power as a result of  the lower HUVEC sample size (n=8) and the 
larger variation, compared to (un)complicated controls.
 The majority of  DMPs in placental tissue was hypomethylated, 
which is substantiated by literature 153, 160-163, whereas the more prominent 
hypermethylation in UC-WBC is in contrast to previous studies 154, 164. These 
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studies did not adjust for potential confounders such as gestational age or 
leucocyte-count, which may explain the discrepancy of  the results. Compared to 
the total number of  DMPs, the relatively small shared set of  25 DMPs and 152 
corresponding genes suggests that UC-WBC and placenta are behaving rather 
differently in association to EOPE. This is substantiated by the fact that only 52% 
of  the shared DMPs and 36% of  the shared genes in UC-WBC and placental 
tissue are behaving in the same methylation direction relative to PTB, and by the 
opposite enrichment patterns described below. In certain overlapping genes it 
appears that different CpGs are affected in UC-WBC than in placental tissue.
CpG-density- and gene-centric enrichment of  EOPE UC-WBC- and 
placental DMPs. Enrichment analysis of  the identified EOPE DMPs showed 
opposite patterns for the positions of  UC-WBC- and placental DMPs relative to 
CpG-islands. EOPE was associated with strong differential methylation of  non-
CpG island regions in UC-WBC and depletion in CpG islands, whereas in placental 
tissue differential methylation was observed in CpG islands and depletion in non-
CpG islands, which is in line with previous studies 153, 154. Evidence emerges that 
CpG island methylation is mostly associated with long-term repression of  gene 
expression such as imprinting, which is an important process for normal placental 
development 22, 23. Indeed, a supporting role of  imprinting in the development of  
PE has been observed in previous studies 165. 
 UC-WBC- and placental DMPs display strong enrichment in gene 
bodies and evident depletion in intergenic regions. Previous studies describe 
enrichment of  EOPE DMPs in placental enhancer- and UC-WBC ‘open sea’-
regions, classified according to the Illumina gene-centric annotation which is 
not directly comparable to our UCSC gene-centric annotation results. Gene 
body regions seem to be more susceptible to variation in DNA methylation, and 
may therefore represent interesting genomic regions for future epidemiologic 
epigenetic association studies 23. Because methylation of  gene bodies is generally 
associated with stimulation of  transcription, the strong placental hypomethylation 
suggests mainly repression of  transcription and the contrary for UC-WBC 23. 
GO-term enrichment and IPA of  EOPE DMP genes. DMP GO functional 
annotations demonstrated that genes linked to UC-WBC DMPs were involved 
in many processes associated with the pathogenesis of  PE, such as regulation 
of  inflammatory responses and RAS-activity 3, 166. We and others have previously 
described decreased leucocytes and increased nucleated red blood cells in EOPE 
UC-WBC, indeed suggesting inflammatory response involvement and disturbed 
fetal haematopoiesis 53, 167. Therefore, of  particular interest is the enriched GO 
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term of  erythrocyte development. The observed enriched GO-term of  cellular 
death regulation might be related to flawing of  the endothelial vessel wall in PE, 
causing apoptosis of  endothelial cells, which has been related to the increased 
presence of  endothelial microparticles in PE 15. One of  the most enriched UC-
WBC GO terms covers a broad spectrum of  cell signalling processes involved 
in many general processes, which is likely a result of  general excessive oxidative 
stressors. The latter was confirmed by all highest significant canonical pathways 
from IPA. Placental DMP GO functions covered general functions such as cellular 
differentiation and cell death, embryogenesis and regulation of  gene expression, 
which is in agreement to the impaired placentation and compromised fetal growth 
in EOPE and substantiated by literature 153.
 The involvement of  DNA methylation differences in cardiovascular 
programming of  PE offspring was strongly suggested by many identified 
gene-ontology (GO) functional annotations and pathways associated with the 
DMP genes. Repeated enrichment of  IPA genetic networks associated with 
development of  cardiovascular and metabolic disease was observed. This is partly 
substantiated by previous PE EWAS, describing differential methylation in the 
fatty acid synthase pathway and in collagen-related genes 152, 154. There exists partial 
overlap between identified genes in association with EOPE in previous EWAS 
in both UC-WBC and placental DMP-genes, as depicted in Supplementary 
table 3. We believe these overlapping genes might represent interesting loci for 
further research and suggest a certain degree of  reproducibility of  our results. 
Yuen et al identified hypomethylation of  the TIMP3 gene in EOPE placentas, 
suggesting reduced angiogenesis and trophoblast invasiveness by use of  the 
Illumina GoldenGate Methylation assay 162. In other vascular-related candidate 
gene studies, altered DNA methylation in association with PE was found of  
LEP, VEGF, FLT-1, KDR-genes and collagen-metabolism genes 161, 163, 168, 
substantiating the role of  disturbed vascular programming in PE. All of  these 
previously identified candidate genes were also present among our DMPs in UC-
WBC and/or placental tissue.
 Several studies have demonstrated that epigenetic programming may 
indeed be involved in the development of  cardiovascular disease, as reviewed by 
Casanello et al. 21. One of  these studies showed increased DNA methylation of  
estrogen receptor beta promotors in endothelial cells of  atherosclerotic plaques 169. 
Alexander at al. showed that in smooth muscle cells epigenetic mechanisms were 
involved in the phenotypic switch to less contractility with vascular dysfunction 
as a result 170. 
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Strengths and limitations. The design of  our EWAS is unique in that it 
addresses tissue-specific methylation levels of  EOPE and LOPE and uses 
both uncomplicated and FGR- and PTB-complicated normotensive control 
pregnancies. The different tissues were obtained mostly from the same pregnancies 
and therefore the data provide novel insights in the tissue-specific epigenome-
wide DNA-methylation in PE-exposed newborn tissues. Moreover, we adjusted 
for gestational age and UC-WBC cell mixtures 36, 162, which has not often been 
done in previous studies 152, 154, 155. The UC-WBC cell populations were however 
partly estimated, based on our own and external populations. Our description 
of  the standardised tissue sampling is more extensive than in most other studies, 
and this is relevant because the method of  tissue sampling can be an important 
potential confounder or effect modifier of  DNA methylation 171, 172. 
 Inherent to the observational and case-control character of  the study, 
residual confounding cannot be fully excluded. The addition of  birthweight as 
potential confounder did not improve our statistical model and was discarded 
also because of  the limited sample size. Moreover, we had no expression data 
to validate our findings and the external validity is reduced by the relatively high 
presence of  comorbidities in uncomplicated controls in our tertiary hospital 
setting. Our findings could have improved with the use of  larger sample sizes 
and homogeneous cell types of  placental tissue (and UC-WBC), thereby avoiding 
potential confounding by cell mixture variation 134, 135.
Conclusion. We found a large number of  genome-wide DMPs in UC-WBC 
and placental tissue that were associated with EOPE. The enrichment in 
several cardiovascular system developmental pathways implies that epigenetic 
programming may be an underlying mechanism explaining the association with 
increased cardiovascular disease risks in EOPE offspring. Future follow-up 
studies in offspring should address whether these pathways represent potential 
targets for intervention or prevention of  the enhanced cardiovascular disease 
susceptibility.
EARLY- AND LATE-ONSET PREECLAMPSIA AND THE TISSUE-SPECIFIC EPIGENOME OF THE PLACENTA AND NEWBORN
128
SUPPLEMENTARY DATA
Appendix 1.
Data collection. Immediately after delivery of  the newborn, UC-WBC samples 
from the umbilical vein were collected in anticoagulant vacutainer tubes 
(Ethylenediaminetetraacetic acid) with the placenta still in situ. The complete 
umbilical cord was cut at the placental insertion and immediately stored in 
umbilical cord buffer (HBSS with 1 % penicillin/streptomycin) at 4 to 8 °C 
until further HUVEC isolation within 24 hours after delivery. Umbilical cord 
and placental samples were collected within 10 minutes after delivery of  the 
placenta. Placental samples of  0.5 cm3 were taken from the fetal side of  the villi 
at four different sites in a 3 cm radius around the umbilical cord insertion, after 
carefully removing the membranes and 2 mm of  the top placental layer. After 
washing in phosphate buffered saline-solution (PBS) to remove maternal blood, 
placental samples were snap frozen in liquid nitrogen and stored at -80 °C until 
DNA extraction. All samples were collected by trained researchers.
UC-WBC processing. UC-WBC vacutainer tubes were stored at 4 to 8 °C and 
processed within 48 hours after delivery. Total white blood cells were isolated 
after centrifugation of  the vacutainer tubes. The white blood cell-pellets were 
stored at -80 °C until DNA extraction. 
HUVEC isolation. The umbilical cord vein was connected to infusion tubes 
on both extremes and rinsed with cord buffer. Once all remaining umbilical 
cord blood was removed, the umbilical vein was filled with collagenase solution 
(1mg/ml) and incubated for 15 minutes in a PBS water bath at 37 °C. Detached 
HUVEC were obtained in suspension and further purified by magnetic 
activated cell separation (MACS) with CD146 MACS MicroBeads (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany). PBS washed HUVEC cell pellets 
were snap frozen in liquid nitrogen and stored at -80 °C until DNA extraction.
DNA extraction. Thawed WBC pellets were subjected to erythrocyte lysis 
by use of  an Erythrocyte Lysis Buffer (Qiagen, Hilden, Germany), following 
manufacturer’s protocols. Thirty mg frozen placental tissue was grinded 
manually on dry ice using a tissue grinder. The powder was immediately added 
to a cell lysis buffer and stored at -80 °C until further processing. Subsequently, 
genomic DNA was extracted from all tissues using the Allprep DNA/RNA 
isolation mini kit (Qiagen, Hilden, Germany), according to manufacturer’s 
instructions. 
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Appendix 2.
Data quality control and pre-processing. All data pre-processing and statistical 
analyses were performed in R software version 3.2.2 and Bioconductor version 
3.1 141. We checked performance of  built-in internal quality controls in the 
Control Dashboard using the methylation module of  GenomeStudio (Illumina 
Inc., San Diego, USA). It included a sample call rate check, colour balance check 
and control dashboard checks. Probes targeting a CpG with documented single-
nucleotide polymorphisms in the C or G nucleotides were removed (n=17,196) 
(Minor allele frequency > 0.05, European population, 1000 Genomes Project). 
Probes directed at the sex chromosomes (n=11,648) and with a detection P value 
>0.01 in more than 1% of  samples (n=2,773) were also excluded. Out of  all 
485,512 probes, a total of  454,892 were left for further analysis. Normalisation 
was performed for all samples together by the Dasen method, which consists of  
background adjustment and between-array normalization, applied to Type I and 
Type II probes separately (Bioconductor package watermelon version 1.80) 142. 
Appendix 3.  
CpG-density- and gene-centric enrichment analysis of  DMPs. DMPs were 
annotated according to their position relative to CpG-islands and relative to genes 
using UCSC-database. In relation to CpG islands, we identified CpG shores as 
the 2 kb CpG island flanking region and shelves as the 2 kb CpG shore flanking 
region. Remaining DMPs were annotated as non-CpG island regions 121. Relative 
to genes, DMPs were annotated as gene body (+500 basepairs (bp) to 3’ end 
of  the gene), distal promotor (> 10 to 1.5 kb from the nearest TSS), proximal 
promotor (-1.5 to +500 bp from the nearest TSS), intergenic (> 10kb from the 
nearest TSS), and downstream regions (3’ end to +5 kb from 3’ end). Human 
genome build 37 was used for all annotations. The DMP enrichment analyses 
were performed using the selected 43,488 UC-WBC probes and 134,700 placental 
probes, respectively.  
Gene Ontology (GO) term enrichment analysis and Ingenuity Pathway 
Analysis (IPA) of  DMP genes. UC-WBC- and placental DMPs were mapped 
to the nearest gene based on Ensemble annotations from UCSC, also when 
facing multiple genes. Assigned Ensembl genes were uploaded to the DAVID 
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tool to examine possible enrichment of  corresponding GO terms using the GO_
BP_FAT annotation category (DAVID Bioinformatics Resources 6.7, http://
david.abcc.ncifcrf.gov/) 149, 150. Fisher Exact was applied to measure the gene-
enrichment of  annotated GO terms of  the uploaded gene list, against the whole 
human genome list as a background. To focus on the biology of  the annotated 
GO terms, clusters of  similar annotations were examined from the DAVID 
Functional annotation Clustering table tool. The clustering algorithm is based on 
the hypothesis that similar annotations have similar gene members, resulting in a 
Group Enrichment Score to rank their biological significance.
 We additionally conducted IPA with the annotated DMP Ensembl gene 
lists to validate the DAVID enrichment and focussed on canonical pathways and 
networks. Associated canonical pathways were subjected to Benjamini-Hochberg 
procedure for controlling FDR (p<0.05). Networks were generated based on 
network eligible molecules, which were encoded by our DMP genes and also 
interact with other molecules in the Ingenuity Pathways Knowledge Base. A high 
score for a network indicates a more approximate fit between network eligible 
molecules and the molecules that constitute the network, calculated using the 
right-tailed Fisher's Exact Test.
 To check the reproducibility of  our DMPs we compared our results to 
three previous EWAS with available DMP datasets and similar study designs with 
respect to patients and tissues. We were able to compare our DMPs in UC-WBC 
to results of  Ching et al and our DMPs in placental tissue to Blair et al and Anton 
et al by using jvenn web application 148, 152-154. 
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The vast majority of  statistical significant CpGs were represented on the M-value scale with a linear correlation to 
the β-scale; that is between 0.2 and 0.8 methylation on the β-scale. This enabled using a single effect-size M-value 
cut-off  without introducing a bias based on the absence of  linearity between M- and β –values in the methylation 
extremities. UC-WBC umbilical cord white blood cells.
SUPPLEMENTARY FIGURE 1. Relation of  methylation β-value and M-value and vi-
sualisation of  genome-wide significantly differentially methylated CpGs (repre-
sented as red dots) and insignificant CpGs (represented as blue dots) in UC-WBC 
(A) and placenta (B).
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SUPPLEMENTARY FIGURE 2. Principal Component Analysis (PCA) of  EOPE, 
LOPE and (un)complicated control pregnancies. 
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PCA plots show the results of  the EWAS using all tissues (A), using only UC-WBC samples (B), using only placental samples 
(C) and using only HUVEC samples (D). Each dot represents a single patient sample. Red dots represent EOPE-, dark blue 
dots represent LOPE-, black dots represent uncomplicated control-, green dots represent FGR- and light blue dots represent 
PTB samples. Distinct clustering is observed between different tissues (A) and between EOPE and (un)complicated controls 
in UC-WBC samples (B). EOPE early-onset preeclampsia; LOPE late-onset preeclampsia; FGR fetal growth restriction; PTB 
preterm birth; UC-WBC umbilical cord white blood cells; HUVEC human umbilical vein endothelial cells. 
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SUPPLEMENTARY TABLE 1. UC-WBC cell leucocyte counts 
SUPPLEMENTARY TABLE 2. Number of  EOPE DMPs per comparison with different 
effect-size cut-off  values
Uncomplicated Complicated controls
EOPE LOPE controls Normotensive 
FGR
Normotensive 
PTB
(n=13) (n=16) (n=36) (n=27) (n=20)
Total leucocytes (x109/L) 
Missings of total group
6.39 (2.14)  
7 
12.41* (2.92)
7 
13.67* (3.57)
9 
12.38* (3.74)
9 
10.38 (5.40)
8 
Missings of group with UC-WBC 4 4 8 6 5
Imputed total leucocytes (x109/L) 6.43 (2.11) 11.98 (3.4) 13.22 (3.96) 12.96 (4.17) 9.61 (4.60)
Data are presented as mean (standard deviation).
UC-WBC umbilical cord white blood cells; EOPE early-onset preeclampsia; LOPE late-onset preeclampsia; FGR 
fetal growth restriction; PTB preterm birth.
Effect-size cut-off EOPE -  
unc. controls
placenta
EOPE -  
unc. controls
HUVEC
EOPE - 
FGR
placenta
EOPE -  
PTB
UC-WBC
EOPE -  
PTB
placenta
None 1 (7x10-6 %) 1 (2x10-5 %) 1 (7x10-6 %) 12,040 (28 %*) 5,668 (0.5 %*)
 Hypomethylated 1 1 1 3,457 (29 %) 4,684 (83 %)
 Hypermethylated 0 0 0 8,583 (71 %) 984 (17 %)
12.5 % β ~ 0.8 m-value 1 1 1 5,001 869 
 (Without duplicate DMPs) 3,444 697
 Hypomethylated 1,417 (28 %) 566 (65 %)
 (Hypomethylated without duplicate DMPs) 1,001 (29 %) 467 (67 %)
 Hypermethylated 3,584 (72 %) 303 (35 %)
 (Hypermethylated without duplicate DMPs) 2443 (71 %) 230 (33 %)
20 % β ~ 1.3 m-value 1 1 1 569 58
EOPE DMPs versus (un)complicated control groups per tissue. No LOPE DMPs were identified. The effect-size 
cut-off  value 12.5 % β ~ 0.8 m-value and corresponding DMPs depicted in bold were applied during final data 
analysis
EOPE early-onset preeclampsia; LOPE late-onset preeclampsia; FGR fetal growth restriction; PTB preterm birth; 
UC-WBC Umbilical Cord Blood; HUVEC Human Umbilical Vein Endothelial Cells; DMPs differentially meth-
ylated positions. 
* This % is calculated by dividing the number of  significant CpGs by the total number of  probes used per tissue: 
n=43,488 UC-WBC probes, n=134,700 placental probes.
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SUPPLEMENTARY TABLE 3. is available at the website of  the scientific journal in 
which this part of  the thesis  has been published.
SUPPLEMENTARY TABLE 4. EOPE DMP enrichment in the gene-centric and 
CpG-density annotation of  UC-WBC- and placental DMPs
EOPE-PTB  
UC-WBC
EOPE-PTB 
placenta
n (%) OR (95% CI) n (%) OR (95% CI)
DMP enrichment in the gene-centric annotation
Intergenic region 635 (13 %) 0.53* (0.49-0.58) 151 (17 %) 0.63* (0.53-0.75)
Distal promotor 306 (6 %) 1.08 (0.96-1.23) 63 (7 %) 1.22 (0.93-1.58)
Proximal promotor 1,071 (22 %) 0.76* (0.71-0.82) 231 (27 %) 0.98 (0.84-1.15)
Gene body 2,870 (57 %) 1.71* (1.61-1.82) 393 (45 %) 1.25* (1.09-1.44)
Downstream region 119 (2 %) 1.00 (0.82-1.22) 31 (4 %) 1.49* (1.01-2.14)
DMP enrichment in the CpG-density annotation
CpG island 213 (4 %) 0.23* (0.20-0.26) 263 (30 %) 1.33* (1.15-1.54)
CpG shore 1,043 (21 %) 0.77* (0.71-0.83) 233 (27 %) 1.15 (0.98-1.34)
CpG shelf 797 (16 %) 1.54* (1.41-1.67) 75 (9 %) 0.93 (0.73-1.18)
non-CpG island 2,948 (59 %) 1.61* (1.52-1.71) 298 (34 %) 0.72* (0.62-0.83)
UC-WBC Umbilical Cord Blood; HUVEC Human Umbilical Vein Endothelial Cells; OR Odds ratio; CI Confidence 
interval.  * p< 0.05.
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PE is one of  the major pregnancy disorders associated with maternal and fetal 
morbidity and mortality and an increased risk of  cardiovascular disease in later life 
for both mother and child. In this thesis we have investigated the cardiovascular 
development and epigenetic programming of  placental and newborn tissues 
after exposure to EOPE and LOPE, in order to provide novel insights into the 
association with later cardiovascular disease risk, and its underlying mechanisms. 
The following objectives have been studied:
1.  The development of  placental and newborn cardiovascular tissues in 
 association with EOPE and LOPE (a), and of  the maternal microcircu- 
 lation in association with PE (b) (Part I)
2.  The tissue-specific DNA methylation in placental and newborn cardio- 
 vascular tissues in association with EOPE and LOPE (Part II)
We have performed flow-cytometric, histological and (genome-wide) epigenetic 
analysis. The main findings, the clinical implications and directions for future 
research are discussed below.
MAIN FINDINGS
1a. The association between EOPE and LOPE and a disturbed development 
of  placental and newborn cardiovascular tissues
During embryonic and fetal development, haematopoiesis and vasculogenesis are 
closely related and influenced by environmental conditions, such as blood flow, 
oxygen tension, oxidative stress and epigenetic factors 52 21. We observed that 
EOPE exposure is associated with disturbed haematopoiesis by revealing a four 
to sevenfold decrease of  neutrophil count and fivefold increase of  NRBC count 
in UCB (chapter 2). Additionally, we found that PE exposure was associated 
with a smaller umbilical vein area and vein wall thickness and LOPE with a larger 
placental width (chapter 3). 
 These findings suggest that PE exposure results in poor intrauterine 
conditions that are related to a disturbed development of  both haematopoiesis 
and vasculogenesis. In PE pregnancies, early placental morphology is assumed to 
be characterised by superficial trophoblast invasion and insufficient remodelling 
of  spiral arteries in the myometrium, causing suboptimal placentation with 
episodes of  placental hypoxia and reperfusion 31. As a result,  the production 
of  inflammatory cytokines in the maternal and fetal circulation increases, which 
promotes the production of  reactive oxygen species (ROS) by up to 40% in 
comparison to normal placentas 31, 51. The developing embryo and fetus are thus 
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exposed to excessive levels of  oxidative stress, partly because the suboptimal 
placenta during PE also displays a reduced antioxidant capacity 31. Various important 
developmental processes are however dependent on tightly controlled oxidative 
stress exposure, such as cellular signalling, differentiation and proliferation 12, 195. 
Haematopoiesis and vasculogenesis are therefore believed to be highly affected 
by the excessive oxidative stress exposure during PE pregnancies. Especially the 
vascular endothelium is known to be extremely susceptible to oxidative damage, 
due to its low cytoprotective capacity, as demonstrated in rodents 31. 
 Not only the exposure of  tissues to excessive oxidative stress, but also 
to the dysbalance of  angiogenic and antiangiogenic factors of  placental origin 
could contribute to the disturbance of  several developmental processes, later in 
pregnancy. The antiangiogenic factors soluble fms-like tyrosine kinase-1, (sFlt-1, 
also known as soluble vascular growth factor (VEGF) receptor -1) and soluble 
endoglin (sEng) are increased in plasma of  PE patients. sFlt-1 and sEng promote 
vascular dysfunction, capillary permeability, liver dysfunction and neurological 
abnormalities via antagonisation of  proangiogenic factors such as VEGF and 
placental growth factor (PlGF) and are therefore potential underlying factors 
for especially the decreased umbilical vein wall thickness in PE 12, 31. In chapter 
8 of  this thesis we describe lower DNA methylation of  PlGF in EOPE exposed 
placental tissue, supporting the involvement of  these (anti)angiogenetic factors 
in our data.
 Furthermore, the exposure to excessive oxidative stress and (anti)
angiogenic factors results in a general enhanced inflammatory state of  the 
maternal and fetal circulation, inducing endothelial cell dysfunction. Because 
prenatal haematopoiesis originates from endothelial cells in the ventral aorta 
of  the developing embryo, fetal endothelial damage may therefore not only 
affect fetal vasculogenesis, but also the maturation and development of  fetal 
haematopoiesis. Another reason to suggest a close relationship between disturbed 
haematopoiesis and vasculogenesis in PE, is the known involvement of  placental 
over-expression of  protein HIF-1α, due to the early suboptimal placental perfusion 
and prolonged hypoxic placental state in EOPE pregnancies 59, 60. HIF-1α regulates 
several processes such as angiogenesis, glycolysis and erythropoiesis, through 
erythropoietin-release 59. Although we did not measure HIF-1α, placental over-
expression of  HIF-1α may explain both the enhanced NRBC counts in UCB in 
EOPE and the decreased umbilical vein wall thickness in PE. 
 Interestingly, the above findings from our clinical studies suggesting 
disturbed haematopoiesis and vasculogenesis are largely substantiated by 
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the results of  our epigenome-wide analysis in Part II of  this thesis, where 
we observed differential DNA methylation in association with EOPE in 
placental tissue and umbilical cord white blood cells (UC-WBC), in genes 
associated with inflammatory responses, haematological system development, 
erythrocyte differentiation in particular and regulation of  cell differentiation 
and cardiovascular development. 
EOPE and LOPE demonstrated pronounced differences in our data on UCB 
cell populations and morphology of  the placenta and umbilical cord, and 
have been proposed as two distinct disease entities 11. The difference is best 
understood by the placental involvement in both phenotypes, and is clearly 
illustrated by the opposite placental measurements in EOPE and LOPE in 
chapter 3. A negative association was demonstrated with placental weight, length 
and width in EOPE, dependent of  gestational and birth weight, in contrast to 
a positive association with placental width in LOPE. This discrepancy may be 
explained by the concept of  initial poor and restricted placental development in 
EOPE, whereas in LOPE, trophoblast dysfunction at the end of  gestation may 
be due to villous overcrowding in large, term placentas without prior pathology 
13. Additionally, in term placentas an increasing uterine contractility occurs, 
causing suboptimal intervillous perfusion and a potential degree of  hypoxia-
reperfusion injury thereby inducing ROS production 196. Both phenotypes 
are thus characterised by placental induced generation of  excessive oxidative 
stress, but this occurs much later in gestation in LOPE, explaining why the fully 
developed fetal haematopoiesis as well as the fully developed umbilical cord 
(vasculature) at term are less affected in LOPE than in EOPE (Figure 2A and 
B, association A1 and B1). 
 Although EOPE displayed more severe features of  disturbed 
vasculogenesis than LOPE, a higher dependency of  gestational age and birth 
weight was observed. Indeed, also FGR and PTB have been associated with 
increased cardiovascular risk factors in offspring 69, 70. However, as suggested 
by our data and that of  others, the intrauterine environment in PE complicated 
pregnancies seems to be unique and exacerbates or acts in synergy with any risks 
inferred by PTB or FGR 7, 197. The strong significant association with a smaller 
vein area and wall thickness in the total PE group, independent of  gestational 
age and birth weight, demonstrates that the EOPE and LOPE subgroups may 
in fact be underpowered. Moreover, the dependency of  comorbidities FGR 
and PTB suggests that the severity of  placental pathology is relevant in the 
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association between EOPE and umbilical vascular alterations. The low rate of  
FGR cases within the EOPE pregnancies however indicates that a relatively 
small number of  pregnancies complicated by severe placental dysfunction leading 
to FGR was included, which cannot exclude that the observed association is 
underestimated. 
The combination of  disturbed leucocyte and NRBC counts in UCB and a 
decreased umbilical vein wall thickness may actually represent very early features 
of  the increased cardiovascular risk profile in PE offspring in later life, based on 
the suggested involvement of  the following mechanisms. Firstly, the observed 
altered UCB populations in EOPE suggest the involvement of  systemic 
inflammation, which is known to play an important role in cardiovascular disease 
and metabolic syndrome development. Secondly, both observations clearly 
suggest impaired endothelial function, which is confirmed in PE offspring 
in childhood and adolescence and has been proposed as the mechanistic link 
between PE and later cardiovascular disease risk 198-201. Thirdly, the reduced 
umbilical vein wall thickness may in fact be a proxy for early fetal vascular 
alterations, explaining why EOPE children have an increased blood pressure 
or an increased carotid intima media thickness in young adulthood, which is 
considered a subclinical marker of  atherosclerosis 201. Concentric remodelling 
has also been observed by increased cardiac wall thickness measurements 
in offspring at adolescence. This may not seem in agreement with reduced 
umbilical vein wall measurements, but could be a compensatory mechanism to 
the exposure of  maternal hypertension in utero or the abnormal uteroplacental 
haemodynamic state in PE 202. Indeed, a high resistance in the umbilical artery 
has been associated with low cardiac mass in preschool offspring, substantiating 
the association between heamodynamics in utero and later structure and function 
of  the cardiovascular system 203. The observed trend of  elastin reduction in the 
umbilical cord vein in EOPE may be an early feature of  arterial stiffness, which is 
a key determinant of  increased blood pressure in adults 204. 
 Interestingly, the increased risk of  high blood pressure and stroke is 
higher in offspring exposed to EOPE than offspring exposed to LOPE, which is 
in line with our observations 197. The current discussion in the literature centers 
around the potential genetic, behavioural or intrauterine origin of  cardiovascular 
disease development in PE offspring. In response to this discussion, we propose 
that offspring exposed to EOPE develop a suboptimal cardiovascular phenotype 
during pregnancy, predisposing them to cardiovascular disease in a relatively 
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normal postnatal environment, whereas offspring exposed to LOPE develop a 
relatively normal cardiovascular phenotype during pregnancy, possibly developing 
cardiovascular disease merely as an effect of  behavioural and environmental risk 
factors postnatally 197, 205 (Figure 2A and B, new hypothesis 1). This is further 
substantiated by our PE EWAS findings, demonstrating an evident involvement of  
differential DNA methylation in genes related to cardiovascular, inflammatory and 
metabolic pathways, in UC-WBC and placental tissue of  EOPE pregnancies only 
(Part II).
1b. The association between PE and maternal microcirculation
In severe PE, maternal endothelial dysfunction can results in haemodynamic 
instability with possible consequences for microcirculatory functioning 3. The 
microcirculation consists of  vessels with a diameter < 100 μm and is essential 
for oxygen and nutrient exchange, especially at the level of  capillaries. Sublingual 
microcirculation measurements demonstrated that women with severe PE and 
HELLP syndrome showed a reduced perfused vessel density, a reduced flow 
velocity and increased heterogeneity of  flow in capillaries, compared with women 
with severe PE without HELLP syndrome. No statistically significant differences 
were observed in microcirculatory perfusion between severe PE and healthy 
controls (chapter 4).
 The reduced density and velocity of  capillary perfusion may be a 
reflection of  microvascular erythrocyte fragmentation and platelet adherence to 
the damaged endothelial surface of  narrowed capillaries, explaining the haemolytic 
aspect and platelet decrease of  HELLP syndrome. Heterogeneity of  flow is an 
important and harmful characteristic of  impaired microcirculation, suggesting 
that the number of  perfused capillaries is reduced which results in a disturbance 
of  tissue oxygenation. This may be related to the observed endothelial dysfunction 
five-eight years after delivery in mothers who experienced PE, accompanied by 
increased inflammatory and antiangiogenic maternal biomarkers such as sFlt-1 
and CRP 199. The lack of  differences in microvascular measurements between 
severe PE and healthy controls may be related to the fact that endothelial 
dysfunction is not equally manifested in all vascular beds during PE, and 
sublingual microcirculation may not be the most representative site of  disease. 
Sublingual microcirculation is believed to be informative in severe haemodynamic 
imbalanced conditions like sepsis, shock and cardiac disease, because it reflects 
the splanchnic circulation given their shared embryologic origin, and splanchnic 
hypoperfusion is an early indicator of  systemic hypoperfusion 78.
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 Evidence is emerging that not only macrocirculatory measures such 
as blood pressure, but also microcirculatory outcome measures are relevant 
in the light of  adult cardiovascular disease development. The risk of  maternal 
cardiovascular disease is particularly high after EOPE pregnancies, where various 
maternal cardiac and vascular characteristics are disturbed during pregnancy 
including the impaired uteroplacental blood flow, increased peripheral resistance 
and reduced cardiac output 197. Because impaired maternal microcirculation seems 
to be involved in the pathophysiology of  severe PE/HELLP syndrome 206, this 
may be an informative measure in light of  the cardiovascular disease risk in 
mothers who experienced PE. 
2. The association between EOPE and LOPE and tissue-specific DNA 
methylation in placental and newborn cardiovascular tissues
Altered programming of  the placental and newborn epigenome may be an 
underlying mechanism for the disturbed development of  fetal haematopoiesis 
and vasculogenesis (Part I) and as such, elucidate the association between 
prenatal PE exposure and cardiovascular disease risk in later life. Because 
epigenetic programming is essential for lineage differentiation, embryogenesis 
and placentation in early pregnancy, we aimed to optimize our epigenetic studies 
by initially addressing the tissue-specific characteristics of  DNA methylation 
in pregnancies without major pregnancy complications such as PE, gestational 
hypertension, FGR or PTB.
The tissue-specificity of  DNA methylation. Firstly we describe significant 
tissue-specific DNA methylation of  imprinted genes IGF2 in Wharton jelly and 
H19 in placental tissue and Wharton jelly, in comparison to UC-WBC methylation 
patterns. No statistically significant differences were observed between total mean 
IGF2/H19 methylation of  CD34+ and CD34- UC-MNC fractions (chapter 
5). Next on a genome-wide level, HUVEC and placental tissue displayed large 
tissue-specific differences versus UC-WBC in 43% and 73% of  the total number 
of  genome-wide measured CpGs respectively, but no differentially methylated 
regions were identified between UC-MNC and UC-WBC (chapter 6). 
 A comparison between the candidate gene- and genome-wide findings 
is difficult because we applied different laboratory- and statistical analysis and 
used different tissues in both studies. However, the similarities between CD34+ 
and CD34- UC-MNC and between UC-MNC and UC-WBC are in agreement 
and suggest that DNA methylation levels in different UC-WBC subsets in general 
seem rather comparable. 
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 The genome-wide analysis revealed the most prominent tissue-
specific observations in placental tissue, which is best explained by the time-
point of  placental-specific development. After fertilisation followed by the 
global demethylation of  the paternally and maternally derived genome, the very 
first de novo DNA methylation at the late morula-stage determines the initial 
differential developmental event: lineage separation of  the inner cell mass that 
will give rise to the embryo, and the trophectoderm that will evolve into most 
of  the placental tissue. Inner cell mass methylation is more pronounced than the 
relatively hypomethylated trophectoderm, resulting in an asymmetrical methylation 
status from this developmental stage onwards 117, 118, 125. HUVEC displayed another 
substantial genome-wide tissue-specific methylation pattern compared to UC-
WBC, but less extreme than placental tissue. This can be argued by the fact that 
HUVEC and the surrounding umbilical cord originate from the inner cell mass 
127, thus displays a more common background with UC-WBC 52. In line with the 
extensive amount of  identified genome-wide HUVEC and placental tDMRs in 
comparison to UC-WBC, we applied a tissue-specific approach in our EWAS in PE 
as well. 
The association between EOPE and LOPE and tissue-specific DNA 
methylation in newborns. EOPE demonstrated extensive genome-wide DNA 
methylation differences in UC-WBC and placental tissue in comparison to PTB 
pregnancies, whereas in LOPE no significant differential methylation was observed 
(chapter 7). In the candidate-gene study we observed an association between PE 
and hypomethylation of  the PlGF gene and lower levels of  the SAM:SAH ratio in 
placental tissue, more pronounced in EOPE than in LOPE (chapter 8). 
 The PE-related excessive oxidative stress exposure during pregnancy is 
suggested to be highly involved in the disturbance of  epigenetic programming 15. 
In response to various forms of  stress, cells increase the production of  important 
protective proteins while reducing the translation of  others that are temporarily 
less essential to conserve energy, aiming at restoring cellular homeostasis 12. We 
observed both hyper- and hypomethylation in association with EOPE in UC-
WBC and placenta, and enrichment of  both positive and negative regulation of  
transcription among the functional annotations of  DMP genes, in line with these 
cellular stress responses. Moreover, in case of  partial failure to restore cellular 
homeostasis or a sudden excessive stress event, cellular death might occur, 
through apoptosis or necrosis 13. Also this cellular death- and survival pathway 
was identified among the DMP gene functional annotations, underlining the 
potential involvement of  excessive oxidative stress. 
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 In our genome-wide and PlGF gene methylation studies, altered DNA 
methylation seems to be more pronounced in EOPE pregnancies, where 
placental and newborn tissues are indeed exposed to excessive oxidative stress 
very early in pregnancy, in contrast to the oxidative stress exposure later in 
pregnancy in LOPE 11, 12. If  early unplugging of  spiral arteries occurs already 
at eight-to-nine weeks of  gestation like in EOPE, chorionic villi are not 
mature enough to withstand the oxidative stress through contact with maternal 
oxygenated blood, disturbing the formation of  the definitive placenta by 
restricted invasion and impaired remodelling of  spiral arteries 12. One might 
hypothesize that the epigenetic programming involved in this initial placental 
formation and differentiation is in fact already affected, perhaps inducing 
the further development of  EOPE, rather than being a consequence of  the 
disease (Figure 2A, new hypothesis 2). Perhaps, even the essential process of  
epigenetic reprogramming at the late-morula stage (at 3-4 days after fertilisation) 
is already disturbed, also suggesting a more causative epigenetic involvement 
(Figure 2A, new hypothesis 2). Whether cause or consequence, the evident 
involvement of  impaired placentation in EOPE may explain the large extent 
of  differential DNA methylation in the placenta 11. Also the maternal and 
fetal pro-inflammatory milieu is more pronounced in EOPE than in LOPE, 
with more potential consequences for UC-WBC epigenetic programming, as 
substantiated by our data 15. The lack of  genome-wide differentially methylation 
in LOPE is in accordance to previous literature 152, 153, 160-162. A possible reason 
for only observing associations between EOPE and PTB is that these groups are 
least affected by a large gestational age range and additional comorbidities and 
hence easier to compare than the other control groups.
 The involvement of  DNA methylation differences in cardiovascular 
programming of  PE offspring was strongly suggested by many identified 
gene-ontology (GO) functional annotations and pathways associated with the 
DMP genes. Repeated enrichment of  genetic networks associated with the 
development of  cardiovascular and metabolic disease was observed. This is 
partly substantiated by previous PE EWAS, describing differential methylation 
in the fatty acid synthase pathway and in collagen-related genes 152, 154. Yuen et al 
identified hypomethylation of  the TIMP3 gene in EOPE placentas, suggesting 
reduced angiogenesis and trophoblast invasiveness by use of  the Illumina 
GoldenGate Methylation assay 162. Moreover, further evidence for cardiovascular 
programming involvement is available in our PlGF candidate-gene study. Here, 
hypomethylation of  the PlGF gene in placental tissue demonstrated that (anti)
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angiogenic factors are likely to be involved in the pathophysiology of  EOPE in 
particular. The additional lower placental SAM:SAH ratio represents a lower cellular 
methylation potential, which is in line with both the placental hypomethylation 
of  PlGF and the observed genome-wide predominant hypomethylated state of  
the placenta in EOPE. PlGF is considered as one of  the major proangiogenic 
factors, essential for controlling placental growth and maintaining normal 
endothelial structure and function. PE is associated with lower levels of  PlGF 
due to increased sFlt-1 levels in plasma and declined placental PlGF production 
12. Our results are in agreement with the candidate gene study by Sundrani et al., 
describing altered placental DNA methylation of  (anti)angiogenic factors VEGF 
and FLT-1 in association with PE 163. 
 Enrichment of  other relevant pathways involved in systemic inflammation, 
cell differentiation and development and erythropoiesis may specifically explain the 
decreased leucocytes and increased NRBC that we observed in UCB of  EOPE 
pregnancies and decreased umbilical vein wall thickness in PE. The respiratory 
development pathway enrichment may explain the suggested association of  PE with 
neonatal bronchopulmonary dysplasia development 207. Also the renin-angiotensin 
system (RAS) pathway was enriched and seems important in PE pathophysiology, 
underlining the generally suggested potential role of  DNA methylation in the 
process of  cardiovascular programming in PE offspring.
METHODOLOGICAL CONSIDERATIONS
The data used for this thesis were collected in The Rotterdam Periconceptional 
Cohort, a prospective tertiary hospital-based cohort study. Both the clinical and 
epigenetic studies are based on the same samples derived from the same nested 
case-control study. This enables us to correlate the epigenetic findings to the 
clinical findings. Inherent to the tertiary hospital setting is the limited external 
validity due to the proportion of  high-risk pregnancies. Case- and control 
pregnancies presented with a relatively high percentage of  concurrent comorbidity. 
In particular pregnancies included in the first trimester of  pregnancy that were 
afterwards enrolled as uncomplicated pregnancies (without PE, gestational 
hypertension, FGR and PTB) showed a high frequency of  relevant maternal 
chronic comorbidity, including endocrine-, metabolic-, auto-immune-, renal- or 
cardiovascular disease. Complicated EOPE, LOPE, FGR and PTB pregnancies 
were more often included in the second half  of  pregnancy and presented with a 
lower frequency of  additional maternal comorbidity.
 Although we initially intended to enrol FGR- and PTB complicated 
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control groups to avoid additional adjustment for gestational age and birth 
weight, unfortunately EOPE and LOPE still appeared to have a lower birth weight 
and shorter gestational age than FGR and PTB.  This turned out to be a significant 
limitation for our analysis, because we had to apply adjustments despite the small 
sample sizes in each subgroup. Due to the unmatched inclusion we were not able to 
conduct a matched analysis afterwards, nor was it possible to adjust for all potential 
confounders and therefore also inherent to the observational study design residual 
confounding cannot be excluded. Selection bias due to the relatively high percentage 
of  missing samples in (the most severe) EOPE and LOPE pregnancies may have 
occurred, which seemed a result of  random factors such as stressful deliveries, 
caesarean sections or night shifts, but did not seem systematic.
 A limitation of  the epigenetic studies is the absence of  expression 
data to validate our findings and the absence of  validation by alternative DNA 
methylation techniques. Secondly, the implications of  our findings would have 
been improved by using homogeneous cell types of  placental tissue and UC-
WBC, thereby avoiding any potential confounding of  methylation differences due 
to underlying cell mixture differences 134, 135. 
 In general, the studies discussed in this thesis cannot distinguish 
whether observed umbilical cord (blood) and placental characteristics are causes 
or consequences of  EOPE or LOPE. We did establish important associations 
in line with our hypothesis, but we therefore cannot draw conclusions on causal 
relationships between our findings and PE and the increased cardiovascular 
disease risk, as depicted in Figure 2. However, this generates new hypotheses 
and provides an important background for future studies. 
CLINICAL IMPLICATIONS AND RECOMMENDATIONS FOR 
FUTURE RESEARCH 
This thesis implies that newborns of  pregnancies complicated by especially 
EOPE, may possess a cardiovascular phenotype characterised by disturbed 
haematopoiesis, impaired endothelial function and early structural vascular 
alterations. Given the increased risk to develop hypertension and stroke in 
adulthood, these children might therefore benefit from clinical follow-up, 
aiming at life-style interventions to lower and possibly prevent the risk of  adult 
cardiovascular events. Not only postnatal risk-management is needed, but also 
prenatal or even periconceptional intervention programmes are warranted to 
optimise the environment for the developing placenta and cardiovascular system 
of  the embryo and fetus. This may be particularly beneficial for the maternal 
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metabolic- and cardiovascular risk profile in LOPE pregnancies, helping both 
mother and child throughout pregnancy and beyond. 
 The observed epigenetic involvement in EOPE pregnancies may 
be useful in this context. By measuring validated epigenetic marks in early 
pregnancy in cell-free fetal DNA obtained from maternal peripheral blood, or 
at delivery from placental tissue or umbilical cord (blood), a clinical predictive 
value may be available 18. Epigenetic marks could also serve as possible targets 
for intervention and prevention, given that epigenetic changes are potentially 
dynamic 208, 209. An example of  an epigenetic-driven preventive measure may be 
to optimise periconceptional maternal folic acid intake, thereby providing an 
important source of  methylgroups necessary for various cellular developmental 
processes, such as DNA methylation. The identified lower SAM:SAH ratio in 
PE pregnancies indeed suggests a lower cellular methylation potential, and 
folic acid supplementation has proven to decrease maternal homocysteine 
levels and thereby the risk of  PE 210.
New research questions to be addressed in future clinical and epigenetic 
association studies are provided by this thesis. The evident difference in EOPE 
and LOPE presented throughout this thesis, implies that the two phenotypes 
should be considered as different disease entities in future studies, also with 
respect to the associated cardiovascular disease risk in offspring. Control groups 
should preferably be matched for gestational age and birthweight to avoid 
extensive adjustment in small sample size association studies examining PE. 
 The use of  umbilical cord (vascular) tissue and DNA methylation 
measurements seems promising for studying associations between adverse 
antenatal environmental factors such as PE, FGR, PTB and disease-outcome 
within the DOHaD concept. The relationship between umbilical cord 
vasculature and newborn vasculature could be examined by (functional) studies 
addressing haemodynamic, hormonal and morphological (dis)agreements to 
establish the predictive value of  this tissue. Potential associations with early 
predictive umbilical cord ultrasound measures may also be useful to investigate 
in this context and the relation with upcoming (anti)angiogenic biomarkers sFlt-
1 and PlGF. Additionally, due to its non-invasive character, microcirculatory 
measurements may provide real-time information on cardiovascular features 
of  newborn vascular sites that would otherwise be inaccessible. 
 With respect to future EWAS, firstly, the observed heterogeneity of  
UCB cell populations in EOPE, LOPE, FGR and PTB implies that UC-WBC 
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mixtures should always be considered as potential confounder. The marginal 
genome-wide UC-MNC and UC-WBC methylation differences seem negligible, 
supporting the use of  easily accessible UC-WBC over UC-MNC. However, 
the observed (genome-wide) tissue-specific aspect of  DNA methylation calls 
into question whether certain representative tissues such as UC-WBC, can be 
generally used in epigenetic epidemiological studies examining placental and/
or vascular-related diseases of  pregnancy. HUVEC is suggested to serve as an 
accessible vascular tissue for human studies investigating associations between 
prenatal exposures and vascular-related pregnancy outcome and future diseases, 
with epigenetic programming as underlying mechanism. In order to optimise 
the benefits of  EWAS, we should apply a universal approach concerning study 
design and statistics, enhance the use of  functional and technical validation, 
and stimulate the collaboration between research groups to achieve larger 
sample sizes. Moreover, further research with repeated measurements is 
needed to cover the maintenance and stability of  (tissue-specific) methylation 
differences throughout pregnancy and postnatal life. Finally, gene-body regions 
appeared most susceptible to (tissue-specific) variation in DNA methylation, 
highlighting their potential significance in future EWAS. 
GENERAL CONCLUSION 
The associations demonstrated in this thesis support our hypothesis that 
the development and epigenetic programming of  placental and newborn 
cardiovascular tissues is disturbed in EOPE offspring, and as such suggest 
that this (partly) explains their increased susceptibility to cardiovascular disease 
in later life.  This seems to be less applicable for LOPE.  
 We emphasize that those newborns at increased cardiovascular risk 
should be identified in order to establish targeted therapeutic risk management 
to lower and possibly prevent cardiovascular events in adulthood. This 
should be incorporated in a larger sample set prospective cohort study with 
long-term cardiovascular follow-up in mothers and offspring. Prenatal and 
periconceptional interventions are needed to improve intrauterine conditions 
for placental, embryonic and fetal development, especially in mothers at risk 
to develop LOPE. Although (genome-wide) epigenetic studies are challenging 
and need to be optimised, they may provide novel genomic loci or pathways 
of  interest that could contribute to a better understanding of  cardiovascular 
disease development in PE, and perhaps methylation-based early prediction of  
cardiovascular risk in offspring.
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SUMMARY
Evidence is accumulating that mothers and offspring exposed to pregnancies 
complicated by preeclampsia (PE) have an enhanced risk to develop cardiovascular 
disease in later life. PE complicates 2-8% of  all pregnancies and is defined as 
gestational hypertension accompanied by significant proteinuria arising de novo at 
or after 20 weeks of  pregnancy. Pregnancies complicated by PE are characterised 
by high maternal and perinatal morbidity and mortality. According to the moment 
of  disease-onset, two main disease entities have been identified, with early-
onset PE (EOPE) as the more severe phenotype, diagnosed before 34 weeks of  
gestation and late-onset PE (LOPE) diagnosed at or after 34 weeks of  gestation. 
 Currently, the exact pathophysiology of  both phenotypes is not yet fully 
understood, but there is extensive evidence that EOPE originates from poor first 
trimester placentation, causing episodes of  placental hypoxia and reperfusion, 
often resulting in fetal growth restricted fetuses. LOPE however, is considered a 
more maternal disorder originating from underlying maternal cardiovascular- and 
metabolic risk factors and associated with typically well-grown fetuses. In both 
phenotypes, the developing embryo and fetus are exposed to excessive oxidative 
stress, although in LOPE this occurs more towards the end of  gestation. As a 
result, pro-inflammatory cytokines and (anti)angiogenic factors are released into 
the maternal circulation inducing maternal endothelial dysfunction, leading to the 
clinical symptoms of  PE. 
 The adverse prenatal PE environment may disturb the development 
and programming of  placental and newborn cardiovascular tissues, resulting in 
a cardiovascular phenotype of  the newborn that is more susceptible to develop 
future cardiovascular diseases. The process of  developmental programming is 
strongly mediated by various epigenetic mechanisms such as DNA methylation, 
which involves the attachment of  a methyl group on the DNA sequence, thereby 
regulating gene-expression. The aim of  the present thesis was to gain more insight 
into the following topics: 
1.  The development of  placental and newborn cardiovascular tissues in 
 association with EOPE and LOPE (a), and of  the maternal microcircu- 
 lation in association with PE (b) (Part I)
2.  The tissue-specific DNA methylation in placental and newborn cardio- 
 vascular tissues in association with EOPE and LOPE (Part II) (Figure 1, 
 page 12-13)
The majority of  data described in this thesis was obtained from a nested case-control 
study embedded in The Rotterdam Periconceptional Cohort, a prospective hospital-
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based cohort study conducted at the Department of  Obstetrics and Gynaecology 
of  the Erasmus MC, University Medical Centre Rotterdam, the Netherlands. 
 The association between EOPE and LOPE and the development of  
placental and newborn tissues was examined by flow-cytometry measurements 
of  UCB cell populations, revealing a four to sevenfold decreased neutrophil 
count and a fivefold increased nucleated red blood cell count in association with 
EOPE (chapter 2). Moreover, we investigated the relation between EOPE and 
LOPE and (histo-) morphologic measurements of  the placenta and umbilical 
cord (vasculature). This data demonstrated that PE exposure was associated 
with a smaller umbilical vein area and vein wall thickness and LOPE with a 
larger placental width. These findings suggest that the prenatal development of  
haematopoiesis and vasculogenesis is disturbed in especially EOPE (chapter 3) 
(Figure 2, association A1 and B1, page 156-157).
 To investigate if  the known maternal endothelial dysfunction during PE 
exposure may be associated with real-time maternal cardiovascular disturbances, 
maternal sublingual microcirculatory measurements were performed. We 
demonstrated that women with severe PE and HELLP syndrome showed a reduced 
perfused vessel density, a reduced flow velocity and increased heterogeneity of  flow 
in capillaries, compared with women with severe PE without HELLP syndrome. 
This suggests an involvement of  microcirculatory dysfunction in the development 
of  PE/HELLP syndrome, potentially related to endothelial dysfunction and the 
increased maternal cardiovascular disease risk after PE pregnancies (chapter 4).
 In order to examine whether epigenetic mechanisms may be underlying 
these findings and whether they are associated with PE, (genome-wide) tissue-
specific DNA methylation studies were performed. We initially demonstrated 
the tissue-specific aspect of  DNA methylation of  imprinted IGF2/H19 genes in 
Wharton jelly of  the umbilical cord and placental tissue, versus UC-MNC (chapter 
5). Next on a genome-wide level, HUVEC and placental tissue displayed large 
tissue-specific differences in 43% and 73% of  all measured CpGs respectively, 
versus UC-WBC. No differentially methylated regions were identified between 
UC-MNC and UC-WBC (chapter 6). 
 The relation between EOPE, LOPE and DNA methylation alterations 
was therefore investigated in a tissue-specific manner and demonstrated 
extensive genome-wide UCB- and placental DNA methylation differences in 
EOPE, in comparison to PTB pregnancies. Moreover, functional annotations of  
DMP genes revealed a strong enrichment of  pathways associated with cellular 
stress responses, cardiovascular- and metabolic system development, systemic 
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inflammation, cellular differentiation and erythropoiesis, the latter substantiating 
our findings in chapter 2 and 3. No significant differential methylation was observed 
in LOPE pregnancies (chapter 7) (Figure 2, association A2, page 156). Finally, 
we revealed that PE was associated with hypomethylation of  the PlGF gene and a lower 
placental SAM:SAH ratio, more pronounced in EOPE than LOPE (chapter 8).
 In conclusion, this thesis provides evidence for associations between 
prenatal exposure to particularly EOPE and a disturbed development and 
epigenetic programming of  placental and newborn cardiovascular tissues, as 
potentially underlying mechanism for the association with future cardiovascular 
risk in offspring. We therefore emphasize the need for periconceptional 
and prenatal intervention programmes to optimise the environment for the 
developing placenta and the cardiovascular system of  the embryo and fetus. 
These programmes should in particularly target future mothers with metabolic- 
and cardiovascular risk factors and an increased risk of  especially LOPE.
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In toenemende mate is aangetoond dat vrouwen en kinderen die blootgesteld 
werden aan een zwangerschap gecompliceerd door preeclampsie (PE) een verhoogd 
risico hebben op het ontwikkelen van cardiovasculaire ziekten op latere leeftijd. 
PE manifesteert zich in 2-8% van alle zwangerschappen en wordt gedefinieerd als 
een hoge bloeddruk in combinatie met eiwitverlies in de urine, optredend vanaf  
de 20e zwangerschapsweek. Zwangerschappen die gecompliceerd worden door 
PE hebben een hoge maternale en perinatale morbiditeit en mortaliteit. Naar 
gelang het moment waarop de ziekte ontstaat wordt onderscheid gemaakt tussen 
twee vormen van PE: vroege en late PE. De vroeg in de zwangerschap optredende 
vorm van PE laat vaak een ernstiger verloop zien en wordt gediagnosticeerd voor 
de 34e zwangerschapsweek; de later optredende vorm van PE wordt vanaf  34 
weken zwangerschapsduur gediagnosticeerd.  
 De exacte ontstaanswijze van PE is nog niet volledig bekend, maar 
er zijn sterke aanwijzingen dat vroege PE ontstaat door een verstoorde aanleg 
van de placenta in het eerste trimester van de zwangerschap, waardoor er een 
suboptimale zuurstoftoevoer in de placenta optreedt, en het ontwikkelende kind 
vaak groeivertraging vertoont. Late PE wordt meer gezien als een maternale ziekte, 
omdat de moeder zelf  vaak diverse predisponerende cardiovasculaire risicofactoren 
heeft en het kind tijdens de zwangerschap een normale groei vertoont. Bij beide 
vormen van PE wordt het ontwikkelende kind aan overmatige hoeveelheden 
oxidatieve stress blootgesteld, echter bij late PE in een veel later stadium van de 
zwangerschap dan bij vroege PE. Dit veroorzaakt een verhoogde ontstekingsreactie 
in de maternale circulatie, resulterend in het dysfunctioneren van het endotheel (de 
binnenbekleding van bloedvaten) en de klinische symptomen van PE. 
 Een zwangerschap die gecompliceerd wordt door PE staat dus 
onder invloed van diverse suboptimale intra-uteriene omgevingsfactoren, die 
zouden kunnen leiden tot een verstoorde ontwikkeling van de placenta en de 
cardiovasculaire weefsels van de pasgeborene, resulterend in een verhoogd risico 
op het ontwikkelen van cardiovasculaire ziekten op latere leeftijd. De ontwikkeling 
van deze weefsels wordt sterk gereguleerd door verschillende epigenetische 
mechanismen waaronder DNA methylering, een proces dat gen-expressie kan 
reguleren (zie voor een uitgebreide Nederlandse uitleg hiervan pagina 176-177). 
Het doel van dit proefschrift is om meer inzicht te krijgen in:  
1.  De ontwikkeling van de placenta en cardiovasculaire weefsels van de 
 pasgeborene in associatie met vroege en late PE (a), en de maternale 
 microcirculatie in associatie met PE (b) (Deel 1)
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2.  De weefsel-specifieke DNA methylering in de placenta en cardiovas- 
 culaire weefsels van de pasgeborene in associatie met vroege en 
 late PE (Deel II) (Figuur 1, pagina 12-13)
Het grootste deel van de data die gebruikt werden voor dit proefschrift 
is afkomstig van een case-control studie die werd uitgevoerd binnen het 
Rotterdam Periconceptie Cohort, een prospectieve cohort-studie gebaseerd op 
de ziekenhuispopulatie van de afdeling Verloskunde en Gynaecologie van het 
Erasmus MC in Rotterdam. 
 De associatie tussen vroege en late PE en de ontwikkeling van de placenta 
en de cardiovasculaire weefsels van de pasgeborene werd onderzocht middels 
flow-cytometrie op verschillende bloedcellen uit navelstrengbloed, waarbij een 4 
tot 7-maal lagere neutrofielen hoeveelheid en een 5-maal hogere kernhoudende 
erythrocyten hoeveelheid werd aangetoond in associatie met EOPE (hoofdstuk 
2). Vervolgens onderzochten we de relatie tussen vroege en late PE en (histo-) 
morphologische metingen van de placenta en navelstreng (vasculatuur). Er 
werd een associatie aangetoond tussen PE en een kleinere navelstrengvene- 
oppervlakte- en wanddikte en tussen late PE en een grotere placenta-breedte. 
Deze bevindingen suggereren dat de prenatale ontwikkeling van haematopoiese 
en vasculogenese (aanmaak van bloedcellen en bloedvaten) verstoord is bij vooral 
EOPE (hoofdstuk 3) (Figuur 2, association A1 and B1, pagina 156-157).
 Om te onderzoeken of  de maternale endotheel dysfunctie gedurende 
een zwangerschap die gecompliceerd wordt door PE gepaard gaat met maternale 
cardiovasculaire afwijkingen, hebben we maternale sublinguale microcirculatoire 
metingen uitgevoerd. Daarmee toonden we aan dat in het capillaire vaatbed 
(allerkleinste bloedvaatjes) van vrouwen met ernstige PE en HELLP syndroom 
een lagere dichtheid van goed doorstroomde capillairen bestaat, met een 
lagere stroomsnelheid van het bloed en een toegenomen heterogeniteit van de 
bloedstroom, i.c.m. vrouwen zonder HELLP syndroom. Dit suggereert dat 
het suboptimaal functioneren van het capillaire vaatbedsysteem betrokken zou 
kunnen zijn in de ontwikkeling van PE/HELLP en mogelijk gerelateerd is aan 
de maternale endotheel dysfunctie en het verhoogde cardiovasculaire risico van 
vrouwen na een zwangerschap gecompliceerd door PE (hoofdstuk 4). 
 Met als doel te onderzoeken of  epigenetische mechanismen aan 
deze bevindingen ten grondslag liggen en geassocieerd zijn met PE, hebben 
we (genoomwijde) weefselspecifieke studies naar DNA methylering verricht. 
Allereerst hebben we de weefselspecificiteit van DNA methylering aangetoond 
van geimprinte genen IGF2/H19 in DNA afkomstig van de Wharton jelly 
PART 3  CHAPTER 10
175
van de navelstreng (gelei-achtige substantie om de navelstrengvaten) en de 
placenta, in vergelijking met leucocyten in navelstrengbloed (hoofdstuk 5). 
Vervolgens observeerden we op genoom-wijde schaal, dat endotheelcellen van 
de navelstrengvene en placentaweefsel een grote hoeveelheid weefselspecifiek 
gemethyleerde regio’s vertonen ten opzichte van DNA uit navelstrengbloed 
leucocyten, respectievelijk in 43% en 73% van de totale hoeveelheid gemeten 
posities. Er werden geen verschillend gemethyleerde regio’s aangetoond tussen 
DNA uit navelstrengbloed leucocyten en navelstrengbloed mononucleaire cellen 
(hoofdstuk 6). 
 De relatie tussen vroege en late PE en veranderingen in DNA methylering 
werd daarom ook in verschillende weefsels onderzocht. We observeerden 
uitgebreide genoomwijde verschillen in DNA methylering in navelstrengbloed 
en placentaweefsel van zwangerschappen gecompliceerd door vroege PE, i.c.m. 
zwangerschappen die gecompliceerd werden door spontane vroeggeboorte. De 
verschillend gemethyleerde posities bleken onder meer in of  bij genen te liggen 
die cellulaire stress reguleren, evenals de ontwikkeling van het cardiovasculair-
metabole systeem, ontstekingsreacties, celdifferentiatie en de ontwikkeling van 
rode bloedcellen. Dit laatste komt overeen met de bevindingen uit hoofdstukken 
2 en 3. Er werden geen significante epigenetische bevindingen aangetoond in 
navelstrengbloed en placentaweefsel van zwangerschappen met late PE (hoofdstuk 
7) (Figuur 2, association A2, pagina 156). Tot slot beschrijven we de associatie 
tussen PE en lagere methylering van het PlGF-gen en een lagere SAM:SAH ratio in 
placentaweefsel, beide meer uitgesproken in vroege dan late PE (hoofdstuk 8).
 Concluderend toont dit proefschrift aan dat er een associatie bestaat 
tussen prenatale blootstelling aan vroege PE en een verstoring van de ontwikkeling 
en programmering van de placenta en cardiovasculaire weefsels van de 
pasgeborene. Deze verstoring zou een mogelijke verklaring kunnen vormen voor 
het verhoogde cardiovasculaire risicoprofiel van de pasgeborene op latere leeftijd. 
We benadrukken daarom het belang van lange-termijn cardiovasculaire screening 
in vrouwen en kinderen na blootstelling aan PE, om het risico op cardiovasculaire 
ziekten op volwassen leeftijd te kunnen verlagen of  voorkomen. Met behulp 
van periconceptionele en prenatale interventieprogramma’s zou gestreefd 
moeten worden naar een optimalisering van de intra-uteriene omgeving van de 
ontwikkelende placenta en het cardiovasculaire systeem van het ontwikkelende 
kind. Dit laatste zou zich vooral moeten richten op toekomstige moeders met 
predisponerende cardiovasculaire risicofactoren en een verhoogd risico op met 
name late PE.
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DE DANS VAN DNA: een aanvulling op de Nederlandse samenvatting
Omdat ik de afgelopen jaren heb gemerkt dat het voor geïnteresseerde 
buitenstaanders niet altijd makkelijk te begrijpen is waar ik me als promovendus 
nu eigenlijk mee bezig heb gehouden, heb ik hier geprobeerd de begrippen 
Epigenetica en DNA methylering zo eenvoudig mogelijk uit te leggen, als aanvulling 
op de Nederlandse samenvatting. Ik gebruik hierbij een analogie die volgens mij 
bijzonder mooi past: dans. 
Zoals we ons waarschijnlijk allemaal ongeveer kunnen voorstellen, 
zit in alle kernhoudende cellen van ons lichaam DNA. Het DNA is een lange 
opgevouwen slinger met daarop een uitgestrekte code waarin alle mogelijke 
processen en bestanddelen van ons lichaam zijn vastgelegd. De code bestaat uit 
een specifieke volgorde van verschillende letters die onze genen vormen. We 
zouden onze DNA code kunnen vergelijken met een choreografie, waarin alle 
dansbewegingen in plaats en tijd zijn vastgelegd. Wanneer we onze DNA code 
aflezen is het eindproduct een eiwit, en als we de choreografie opvolgen is het 
eindproduct een dans. 
Het DNA is in principe niet te veranderen en in alle cellen gelijk. Toch is 
het niet zo dat een cel de hele DNA code met alle genen nodig heeft. Afhankelijk 
van het type cel, het type weefsel en allerlei omgevingsfactoren, is er in een cel 
behoefte aan specifieke eiwitten, dus bepaalde stukjes van de DNA code. Ook 
een choreografie is in principe niet te veranderen, en toch bestaat er een grote 
variatie aan uitvoeringen, doordat een choreograaf  de artistieke vrijheid heeft 
om de choreografie te interpreteren naar zijn/haar wensen. Als we bijvoorbeeld 
op kerstavond naar een hedendaagse uitvoering van De Notenkraker gaan, is de 
choreografie van de oorspronkelijke choreografen Marius Petipa en Lev Ivanov 
onveranderd, maar de interpretatie van de choreograaf  van nu waarschijnlijk heel 
anders dan tijdens de premiere in 1892. 
Zoals een choreograaf  kan bepalen hoe hij/zij de choreografie tot 
expressie wil laten komen tot een dans, kunnen de cellen in ons lichaam iets 
vergelijkbaars. Het is namelijk mogelijk om bepaalde stukjes van de DNA-
code aan of  uit te zetten en meer of  minder tot expressie te laten komen (te 
programmeren), om zo alleen die eiwitten te produceren die nodig zijn. Dit proces 
van het programmeren van onze genen op de DNA code heet epigenetische 
programmering (epi is Grieks voor op, dus op onze genen).  
De epigenetische programmering en de interpretatie van een choreografie 
worden beide sterk beïnvloed door omgevingsfactoren. Omgevingsfactoren 
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die de epigenetische programmering kunnen beïnvloeden zijn bijvoorbeeld 
leeftijd, voeding, zwangerschap, lichamelijke activiteit, roken of  alcohol. Bij de 
interpretatie van een choreografie kunnen we bij omgevingsfactoren denken aan 
de theaterruimte, muziek, kostuums en ten slotte de kwaliteit van de dansers zelf. 
Als de omgevingsfactoren niet optimaal zijn - de muziek hapert of  de dansers 
weinig getraind of  gegeten hebben - dan is de dans niet optimaal. 
Tijdens een zwangerschap die gecompliceerd wordt door preeclampsie, 
zijn de ontwikkelende placenta en het kind blootgesteld aan diverse negatieve 
omgevingsfactoren, vooral gekenmerkt door een verstoorde zuurstoftoevoer in de 
placenta. In deel II van dit proefschrift heb ik daarom onderzocht of  blootstelling 
aan preeclampsie tijdens de zwangerschap geassocieerd is met veranderingen in 
de epigenetische programmering van het DNA. 
Er zijn diverse mechanismen die zorgen voor de epigenetische 
programmering van het DNA. Daarvan heb ik er in dit proefschrift één onderzocht: 
DNA methylering. Hierbij gaat het om een chemische verbinding (methylgroep) 
op de DNA code, die ervoor zorgt dat een bepaald gen meer of  minder makkelijk 
kan worden afgelezen en tot expressie kan komen. Ik heb onderzocht in hoeverre 
de aanwezigheid van deze methylgroepen tussen verschillende cellen en weefsels 
verschilt, en of  dit verschilt in zwangerschappen blootgesteld aan vroege en late 
PE en controle zwangerschappen.
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 Prof. dr. M. Abou-Dakn, ich fühle mich sehr dankbar, dass ich unter 
Ihrer begeisterten Leitung in einer so tonangebenden Klinik die Geburtshilfe und 
Gynäkologie lernen darf  und hoffe auf  eine noch lange weitere Zusammenarbeit.
 Prof. dr. E.A.P. Steegers, Eric, veel dank voor uw inbreng bij de opzet 
van de klinische studies uit mijn proefschrift. Een Berlijn-Rotterdam symposium 
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zouden we wellicht in de toekomst nog eens kunnen organiseren, want het is zoals 
u terecht zei bijzonder fascinerend en verrijkend om van elkaar te leren.
 De hulptroepen bij de epigenetica-projecten: Dr. J.F. Felix en Dr. R.C. 
Slieker. Janine en Roderick, ik ben jullie ongelooflijk dankbaar voor jullie onmisbare 
inbreng bij de opzet, de statistische analyse en het schrijven en reviseren van 
beide epigenetica-projecten (en de waardevolle skypegesprekken). Roderick, mijn 
naaste omgeving kent jou als mijn held, dat je dat even weet; veel dank voor de 
ontelbare momenten dat je iets schijnbaar onoplosbaars in een split-second hebt 
opgelost. Ik hoop dat dit niet onze laatste gezamenlijke projecten waren! 
 Dr. A.J.M. Roks, beste Anton, je hebt ervoor gezorgd dat ik mij als simpele 
dokter die niet kon pipetteren heel snel thuis ging voelen in jullie super gezellige 
laboratorium, en mij en Marcela bovendien heel veel geleerd. Ik vond het vaak jammer 
wanneer my precious endothelial cells weer gewonnen waren en ik terug moest kruipen 
achter mijn computer.
 Prof. dr. ing. P.H.C. Eilers en S.P. Willemsen, beste Paul en Sten, wat 
moeten wij als onderzoekers zonder statistici? Bedankt voor jullie beider hulp, 
en Sten natuurlijk in het bijzonder voor je zeer intensieve inzet tijdens de 
genoomwijde epigenetica analyses. 
 Dr. J.M.J. Cornette, Jerôme, je hebt een grote rol gespeeld in het ontstaan 
van mijn interesse in de verloskunde, gynaecologie en onderzoek doen in het 
bijzonder. Ik kijk met veel plezier terug op onze gezamenlijke PICO tijdens mijn 
coschap, het microcirculatie-project, en jouw uiterst heldere en eerlijke inzichten 
over de toekomst, zowel op privé als professioneel vlak. 
 Alle medewerkers van het pathologie-laboratorium in het Erasmuc MC, 
in het bijzonder prof. dr. R.R. de Krijger, Frieda Uijtdewilligen en Alex Nigg, voor 
jullie inzet tijdens de grote hoeveelheden navelstrengcoupes die Anniek en ik in 
korte tijd moesten produceren en analyseren en onze regen aan vragen over het 
snij-, plak-, kleur-, scan- en digitaal beoordeel-proces.
 Michael en Mila! Zonder jullie was deel II van mijn proefschrift er 
nooit geweest, en waren al die maanden DNA- en RNA- isolaties bovendien een 
heel stuk minder gezellig geweest. Bedankt voor al jullie hulp en geduld met die 
onhandige dokters in het lab. Lang leve Zwitsal!
 Prof. dr. I.K.M. Reiss, bedankt voor uw inbreng en bijzonder aanstekelijke 
enthousiasme tijdens de overleggen binnen ons gezamenlijk neonaten-project, 
weliswaar niet in dit proefschrift opgenomen, maar m.i. nog steeds spannend om 
nader te onderzoeken. Prof. dr. P.J. van der Spek and Dr. A.P. Stubbs, Andrew, 
many thanks for helping me to perform and interpret the extensive bioinformatic 
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analysis of  both epigenetic projects. Prof. dr. B.T. Heijmans, Dr. M. van der 
Zee, Martin, Dr. R. de Jonge, Dr. S.G. Heil, Sandra, Prof. dr. J.J. Cornelissen, Dr. 
L. Duinhouwer, Lucia, Dr. R.C.J. de Jonge, Rogier, veel dank voor het samen 
opzetten, uitwerken en meeschrijven aan verschillende onderzoeken binnen mijn 
proefschrift.
 De verloskundigen, verpleegkundigen, medisch studenten en artsen van 
de verloskamers in het Erasmus MC, die mij (meestal) keurig opbelden wanneer 
er bijna een Predict-placenta geboren zou worden zodat ik vaak halfslapend op 
de fiets moest springen. Gelukkig zijn die Predict-placenta’s vanaf  een zeker 
moment ook in zeer goede handen gekomen van het fantastische ‘Predictteam’, 
te herkennen aan de flitsende step met roze fietsmand, die bij tij en ontij met 
klotsende vloeibare stikstof  onderweg was. Ik geef  toe dit misschien iets 
romantischer klinkt dan het op sommige momenten was... Voor het slagen van 
dit logistiek zeer uitdagende project waren onze fijne researchverpleegkundigen 
Joke en Titia onmisbaar. 
 De groep wisselende bewoners op de 22e verdieping van de oude 
faculteitstoren van het Erasmus MC. Deze bewoners hebben een aantal bijzondere 
rituelen, zoals het drinken van overmatige hoeveelheden thee, het nuttigen 
van overmatige hoeveelheden Cake in de Week en gefrituurde kaasstengels en 
het zeer punctueel opvolgen van het lunchmoment, dat begint met een groot 
verzamelspectakel om 12:13u stipt. Ik heb o.a. van de volgende karakteristieke 
bewoners mogen genieten: strenge maar hele lieve Predict- en borrelqueen Eef, 
kleurrijke sprankelende Babsie, ballerina/mede-methylerings-nerd Kim, professor 
Twigt, Matthijs mijn secret-computer-helpdesk, my dear Eline en Jorine, cara 
Franceska, mijn veel te lieve kamergenootje Nic (bedankt voor alle mandarijnen, 
bezoekjes aan Dordrecht en discussies over waarom we nu eigenlijk promoveren), 
reisgenootje Caro (bedankt voor de vele gesprekken over waarom we nu eigenlijk 
in God moeten geloven en van de man moeten houden), en mede-dansfanaat 
Ireen (zo cool dat jij gewoon meedoet als ik voorstel mee te dansen in een gothic 
christmas-chick dansje op University College of  een flashmop tussen een zaal vol 
psychiaters!). Ik mis jullie!
 De fantastische medisch studenten, die van grote hulp waren bij een 
groot deel van deze projecten: Anniek, Martina en Jacky. Special thanks goes 
to Dr. J.M. Galvez, dear dear Marcela, it was so much fun working with you! I 
loved all our very first bloopers in the laboratory of  Anton and our desperate 
attempts to obtain those bloody endothelial cells.... I think you are a very 
talented researcher and wish we were still working together!
206
 Liebe liebe Oberärzte und Kollegen aus dem St. Joseph Krankenhaus, 
es ist mir sehr wichtig, mich bei euch für die sehr angenehme Zusammenarbeit, 
eure Unterstützung und die Freiheit zu bedanken, die ich sogar in einigen 
Nachtdiensten, versteckt hinter meinem Laptop, für dieses PhD Projekt 
gebraucht habe. Dr. T. Lehmann, unsere leitende Oberärztin, liebe Tina, ich bin 
sehr dankbar dass ich von dir lernen darf  und dass du zu meiner Verteidigung 
nach Rotterdam kommst! 
 Marleentje, mijn paranimf! Ik op mijn beurt, mis jou ook veel te vaak 
en te veel en verlang geregeld naar onze kookfestijnen, ons urenlange gezever 
over PhD perikelen onder het genot van jullie drankvoorraad, onze licht-
snobistische koffie-gesprekken, en vooral dat ik even snel op de fiets naar je toe 
kan komen voor een pizza al Michèle, en een Limoncello in de voortuin. Je bent 
een ontzettend waardevolle vriendin, ver weg of  niet. 
 Mijn hele fijne en bijzondere vrienden en vriendinnen: Geer en Oliver, 
Benno, Leo en Lisa (laten we de appelboor uit de microbiologie-les en de 
Bailey’s in laboratorium-ijs voor altijd blijven eren), Floor en Ro, Desiree en 
Roeland (met een speciaal kusje voor Felix), Frederique, RJ, Annelies, Wytse, 
Willemijn, Sjoerd, Stella, Robert (O&N op mijn dakterras?), Anna en Casper, 
Renée en Floris, Magdalena (waiting for your Placental Art exhibition...), en de 
veel te luidruchtige, rete-gezellige Familie Starrenburg-Herzog: ik ben blij dat ik 
hier nog een keer zwart op wit tegen jullie kan zeggen dat jullie van ontzettende 
waarde geweest zijn tijdens dit uitdagende project, Dankjulliewel! 
 Mijn lieve zusjes Adrienne en Marcella. Alle drie zijn we een beetje 
eigenwijs en vol met onze eigen dromen en ambities. Dat maakt onze levens 
soms heel verschillend, en ook nog zo ver uit elkaar... maar destemeer bewonder 
ik jullie doorzettingsvermogen, doelgerichtheid en vooral jullie enorme talent. 
Op naar het EK 2018! Veelzijdige Marcella’tje, ja zeker, voor altijd mijn kleine 
zusje, maar ook mijn paranimf. Ik ben inderdaad een zondagskind zoals je altijd 
zegt, dat jij bij de verdediging van dit celmembranen-proefschrift naast mij 
staat. Heb je wel even opgezocht wat een paranimf  precies is...?
 Lieve lieve pap en mam. Op vakantie zei een Zuid-Afrikaanse vrouw 
met drie kinderen die verspreid over de wereld woonden tegen mij: ‘Well, I 
guess we did something good in raising our children in such a way, that they are 
brave enough to discover the world’. Misschien helpt het een beetje om dit zo 
te zien, want zo is het echt! Ik ben jullie heel dankbaar voor alles dat jullie ons 
lieten zien, alles dat jullie voor ons mogelijk maakten, en hoe jullie ons vrij lieten 
in het langzaam ontdekken van onze dromen en talenten. Maar vooral ook dat 
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jullie dat stimuleerden en ons lieten geloven dat misschien wel alles mogelijk 
was... Als kind wilde ik soms dat we een wat normaler doorsnee Woudenbergs 
gezinnetje waren, maar het is juist helemaal goed zo. Ik kijk al uit naar de eerste 
avond met zijn allen voor de open haard in de boerderij...
 Allerliefste Frank. Ik vrees dat het een illusie is dat de geliefde van 
een promovendus voldoende bedankt kan worden in enkele regels van het 
dankwoord. Maar dit wat hier ligt is iets van ons samen, en het belichaamt vele 
lange uren, die overal te vinden waren, schrijvend op de meest uiteenlopende 
locaties: in de rook bij Wohnzimmer, op de trap aan het water langs de Donau, 
voor de open haard in Zuid-Duitsland en in de zon op het terras bij Kaffee A. 
Horn. Als ik eraan terug denk weet ik heel zeker, dat jij degene bent waardoor 
het lichter leek, waardoor we zo veel moesten lachen en ik de mooie dingen niet 
uit het oog verloor. Het is wel wat vreemd, maar ook goed dat het voorbij is voor 
mij, en bijna voor jou. Jouw proefschrift wordt tenminste een écht boek, coming up 
soon... Ik kijk uit naar alles dat nog komen gaat, met jou.

